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Neutrophils are a crucial component of the innate immune response and are
responsive to a wide range of pro-inflammatory signals. However, the response of a
neutrophil to a secretagogue agonist can be "primed" by pre-exposure to certain
agents, including platelet-activating factor (PAF), tumour necrosis factor-a (TNFa)
and lipopolysaccharide (LPS). Although priming refers specifically to the enhanced
responses observed when neutrophils are subsequently stimulated, other functional
responses are also associated with the primed state. These include cell polarization
and increased neutrophil adhesiveness, which promote their recruitment to sites of
inflammation. However, despite the undoubted beneficial and protective effects of
neutrophils, these cells are paradoxically involved in the pathogenesis of a variety of
inflammatory conditions. Furthermore, neutrophil priming has been shown to be an
important prerequisite for neutrophil-mediated host tissue damage. Since primed
neutrophils have been identified in the blood of patients with ARDS and
inflammatory bowel disease, and in the joints of people with active rheumatoid
arthritis, this functional upregulation of neutrophils is believed to contribute to the
pathology of these disease states.
The potential for neutrophils to recover from a primed state, i.e. to "de-prime",
remains largely unexplored. However, the priming of neutrophils under non-
physiological conditions, using hypotonic buffers, has been shown to reverse upon
the restoration of isotonicity. Having confirmed this finding, I demonstrated that the
priming of human neutrophils with PAF, a well-established, rapid-acting, receptor-
mediated priming agent, was transient with complete reversal to an un-primed state
within 2 hours. Furthermore, de-primed neutrophils retained their capacity to be re-
primed when subsequently challenged with either PAF or TNFa. The recovery of
neutrophils to an un-primed state was confirmed by the assessment of superoxide
anion release, cell polarization, and CD1 lb/CD18 function, and was shown to reflect
neither a reduction in neutrophil viability or cell responsiveness, nor the metabolism
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of PAF. These observations implied that neutrophil priming to a receptor-mediated
agent was fully reversible. Transient neutrophil priming was also observed with
inositol hexakisphosphate (InsP6), a ubiquitous inositol polyphosphate whose
minimal priming effects were found to occur independently of specific InsP6
receptors on the surface of human neutrophils. In contrast, the receptor-mediated
priming effects of TNFa were both slower to evolve and more sustained than those
of either PAF or InsP6. However, the primed responses elicited by PAF or TNFa
could be manipulated by specific receptor blockade.
It has been suggested that a prolonged state of neutrophil priming might be an
important component of the long-term inflammatory response observed with agents
such as endotoxin (LPS). Thus, the recognition of a novel process whereby
neutrophils have the potential to de-prime may represent a physiological and
potentially targetable mechanism, upstream of the final activation pathway, to
counteract the pro-inflammatory activity of neutrophils in vivo.
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1. CHAPTER 1: INTRODUCTION
1.1 The Neutrophil
Neutrophils are leukocytes that are the first cells to be recruited to a site of
inflammation (Schleimer et al., 1989): hence, they constitute a fundamental
component of the innate immune response. Their primary function is to phagocytose
and degrade cell debris and any material which is foreign to the host (e.g. bacteria).
The functional capacity of neutrophils depends upon several main processes: (i)
chemotaxis towards the inflammatory site; (ii) phagocytosis of the offending agent;
(iii) degranulation, with the release of pre-formed enzymes and proteins from
intracellular granules; (iv) the respiratory burst, with the generation of highly
microbicidal reactive oxygen species (ROS); and (v) the de novo generation of
inflammatory mediators.
The important role of the neutrophil in acute inflammation has been inferred from the
recurrent infections, especially with pyogenic bacteria, encountered by patients with
abnormal neutrophil function. This includes patients with reduced numbers of
circulating neutrophils (neutropaenia) (Bodey et al., 1966), as well as those with
isolated defects of neutrophil function, for example of adherence (e.g. leukocyte
adhesion deficiency, LAD (Anderson and Springer, 1987)), migration and
chemotaxis (e.g. Chediak-Higashi syndrome (Rausch et al., 1978)), microbicidal
activity (e.g. chronic granulomatous disease (Thrasher et al., 1994)) and
phagocytosis (e.g. diabetes mellitus). However, whilst neutrophils are essential for
host defence, their inappropriate or excessive activation may, paradoxically, also
contribute to the pathology of various inflammatory conditions (see 1.4). Indeed, the
regulation of neutrophil activation has been described as a "double-edged sword"
(Smith, 1994), defining a fine balance between the defence and damage of host
tissues.
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This Chapter will outline the primary role of the neutrophil as a professional
phagocyte. It will commence with the neutrophil's origin in the bone marrow and
subsequent release into the circulation; thereafter, it will consider the neutrophil in the
context of an acute inflammatory response, with its recruitment from the circulation
and priming/activation in the tissues, to its inevitable death. Although acute
inflammation also comprises various vascular events, including vasodilatation and
increased vascular permeability which increase the delivery of leukocytes and
mediators to the inflammatory site, these will be discussed only where relevant to
neutrophil function.
1.2 The Generation of Neutrophils
Neutrophils are produced from pluripotent stem cells within the bone marrow, under
the influence of granulocyte- and granulocyte-macrophage colony-stimulating factors
(G-CSF and GM-CSF, respectively). Mature neutrophils are released into the
circulation as terminally-differentiated cells, at a rate of 1011 cells per day (Cannistra
and Griffin, 1988), where they represent 50-60% of the total circulating leukocyte
pool. They have a lobular nucleus identifying them as polymorphonuclear leukocytes,
and are packed with cytosolic granules (Table 1.1) whose contents are essential for
microbicidal killing. However, the circulating neutrophil count reflects a dynamic
balance between three separate neutrophil pools residing in: (i) the bone marrow; (ii)
the vasculature (which includes a circulating and a marginated pool); and (iii) the
tissues. Indeed, neutrophils spend a relatively brief time within the circulation, with
an estimated vascular half-life of 6-7 hours (Mauer el al., 1960; Athens et al., 1961).
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Table 1.1 The Classification of Neutrophil Granules
(Borregaard el a/., 1993)
Granule Type Main Contents Main Functions of Contents
• Secretory vesicles CD lib/CD 18 (Mac-1) Endothelial Adhesion
fMLP-receptors Chemoattraction
FcyRIII Antibody recognition
Cytochrome bssg Respiratory burst activity







• Specific (secondary) Lactoferrin Microbicidal
Lysozyme Microbicidal
CD1 lb/CD18 Endothelial Adhesion
Collagenases Extravasation
fMLP-receptors Chemoattraction
Cytochrome b558 Respiratory Burst Activity
• Gelatinase (tertiary) Gelatinase Extravasation
CD 11 b/CD 18 Endothelial Adhesion
fMLP-receptors Chemoattraction
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1.3 The Role of the Neutrophil in Host Defence
The delivery of leukocytes to sites of inflammation (extravasation) is a critical
function of the acute inflammatory response. Neutrophil extravasation comprises a
sequence of events (Figure 1.1): (i) margination and rolling along the vascular
endothelium; (ii) firm adhesion to the endothelial surface; and (iii) trans-migration
across the endothelium.
1.3.1 Neutrophil Margination and Rolling
Under normal, laminar flow, leukocytes and erythrocytes travel in an axial stream
within the vasculature, leaving a boundary layer of plasma in contact with the
endothelium. Flowever, in the early stages of an inflammatory response, leukocytes
fall out of the axial stream and marginate towards the endothelial surface. This
margination is particularly important in the microvascular beds of the lung, spleen
and liver, where neutrophils are temporarily sequestered. The transient adherence of
neutrophils to the activated endothelium results in their rolling along the walls of the
microvasculature, especially the postcapillary venules (and small pulmonary
capillaries) (Schmid-Schonbein et al., 1980; Atherton and Born, 1973). Neutrophil
rolling is thought to involve low-affinity, transient interactions of L-selectin (CD62-
L), expressed on the tips of neutrophil microvilli (Borregaard et al., 1994; Picker et
al., 1991), with sulphated glycoproteins on the endothelial surface (Rosen, 1994).
There may also be contributions from P- and E-selectin, which are up-regulated on
the surface of activated endothelial cells, and interact with oligosaccharides (such as
Lewis antigen (Lex) and sialyl-Lex) on the neutrophil (Abbassi et al., 1993; Lawrence
and Springer, 1993; Bevilacqua and Nelson, 1993).
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Schematic Representation ofNeutrophil Extravasation.
Neutrophil recruitment to an inflamed site requires a series of adhesion and
morphological events mediated by both the neutrophil and the vascular
endothelium.
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1.3.2 Firm Adhesion to the Endothelium
The low-affinity adhesive events that initiate neutrophil rolling can slow, but not
stop, marginated neutrophils (McEver, 1993; Lasky, 1992). The complete arrest of
neutrophils requires their firm adhesion to the endothelium, and is controlled by
mediators generated during an acute inflammatory response. Chemotactic factors
signal the recruitment of neutrophils to the inflammatory site, and may originate
from various sources, including: (i) infectious agents at the inflammatory site (e.g.
fMLP, LPS); (ii) previously activated leukocytes and endothelial cells (e.g. TNFa,
GM-CSF, IL-8, PAF, LTB4); and (iii) activated plasma components (e.g. C5a).
Although the majority of these agents diffuse from their source to act as soluble
mediators, some may be sequestered (in solid phase) on the surface of activated cells.
For example, newly-synthesized PAF is co-expressed with P-selectin on the surface
of activated endothelial cells, where it may trap and stimulate rolling neutrophils
(Lorant et al., 1993; Lorant et al., 1991): this is an unusual example of juxtacrine
stimulation (Zimmerman et al., 1993) where a signalling molecule remains
associated with the surface of the signalling cell (Figure 1.2).
Upon stimulation, the rapid exocytosis of intracellular granules, especially secretory
vesicles (Borregaard et al., 1994; Sengelov et al., 1993), results in the fusion of
granule membrane with the neutrophil plasma membrane. This increases the surface
expression of (32-integrins (especially CD1 lb/CD 18) which are required for the firm
adhesion of neutrophils to the endothelial surface (Smith, 1990; Anderson et al.,
1985). Flowever, the increased surface expression of CDllb/CD18 alone does not
ensure neutrophil adherence to the endothelium (Hughes et al., 1992; Vedder and
Harlan, 1988). Indeed, CDllb/CD18 must be modified at the plasma membrane
before it becomes functional: this may be a result of phosphorylation (Buyon et al.,
1997), or increased expression of integrin-modulating factor-1 (Hermanowski-
Vosatka et al., 1992). The up-regulation of CDllb/CD18 avidity and expression on
stimulated neutrophils is accompanied by an increased expression of the
complementary intracellular adhesion molecule-1 (ICAM-1) on the surface of
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activated endothelial cells (Springer, 1990). The prolonged, high-affinity nature of
these neutrophil-endothelial interactions mediates the firm adhesion of neutrophils to
the endothelium (Calafat et al., 1993; Tonnesen, 1989). Neutrophil
priming/activation also results in the shedding of L-selectin from the neutrophil
surface (Stocks et al., 1995; Lasky, 1992) which is a further prerequisite for trans-
endothelial migration of these cells (Kuhns et al., 1995).
The progression of the inflammatory response leads to the increased synthesis and
expression of additional endothelial adhesion molecules, including E-selectin, that
promote neutrophil rolling, thereby facilitating further adhesion to the activated
endothelium (Bevilacqua and Nelson, 1993). Neutrophils may also adhere to the
endothelium via bridging molecules, such as fibronectin, fibrin, and complement
fragments (Marks et al., 1991).
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Figure 1.2
Mechanisms of Cellular Signalling by Bioactive Mediators.
In the juxtacrine mechanism, the signalling molecule remains associated
with the surface of the signalling cell, rather than being released to activate
the target cell in the fluid phase. This distinguishes juxtacrine interactions
from endocrine, paracrine, and autocrine signalling mechanisms. (After
Zimmerman et al., 1993).
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1.3.3 Neutrophil Shape Change
Quiescent neutrophils are spherical cells. Approximately 20-30% of their total actin
content is held as polymerized F-actin and contributes to the cytoskeletal network
that lies adjacent to the plasma membrane (Sheterline et al., 1984). Since this
intracellular cytoskeleton interacts with the plasma membrane through integral
membrane proteins, including integrins (Juliano and Haskill, 1993) and fMLP
receptors (Jesaitis and Allen, 1988), it has been proposed to stabilize the membrane
against external forces and have a role in the transduction of extracellular signals to
the cell interior (Hynes, 1992). However upon neutrophil stimulation, the
incorporation of secretory vesicle membrane into the neutrophil plasma membrane
(Sengelov et al., 1993) results in membrane ruffling (Hoffstein et al., 1982).
Furthermore, the rapid recruitment of monomeric G-actin from the cytosol into
cytoskeletal F-actin produces focal alterations in the sub-membranous cytoskeleton,
which are a prerequisite for the ensuing neutrophil stiffening, shape change and
motility responses (Pecsvarady et al., 1992; Worthen et al., 1989). These
morphological changes (particularly the reduced neutrophil deformability) facilitate
the margination of neutrophils in the microvasculature, particularly in the small
vessels of the lung (Schmid-Schonbein et al., 1980).
1.3.4 Trans-Endothelial Migration
In order to leave the vascular space, neutrophils must squeeze through the inter-
endothelial junctions of systemic post-capillary venules or pulmonary capillaries.
Thus, they adopt a polarized morphology, with an elongated cell body, a broad,
anterior lamellipodium and a small, uropod tail. Trans-endothelial migration is
dependent upon directional cues from chemotactic factors and involves little random
migration (chemokinesis) (Kitayama et al., 1997). Although this process has not
been fully characterized, it is known to require high-affinity interactions between
neutrophil (32-integrins and endothelial ICAM-1, and between glycosylated
aminoglycans on the neutrophil plasma membrane and PECAM-1 (platelet
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endothelial cell adhesion molecule), which is located in the inter-endothelial
junctions (Muller et al., 1993). After traversing the endothelial junctions, neutrophils
are retarded transiently by the basement membrane (which forms a contiguous barrier
beneath the vascular endothelium), but eventually pierce it, possibly aided by the
secretion of granule contents such as gelatinase (Weiss et al., 1986). Furthermore, it
has been suggested that the endothelium, itself, may play a major role in the local
degradation and reformation of the vascular basement membrane (Huber and Weiss,
1989).
1.3.5 Neutrophil Chemotaxis
In the tissues, neutrophils are guided towards an inflammatory focus by a gradient of
chemotactic factors. The accuracy of this orientation correlates with the number of
occupied receptors across the neutrophil surface (Zigmond et al., 1981). The binding
of chemotactic factors continues to promote the recruitment of secretory vesicles and
specific granules to the neutrophil plasma membrane, with the consequent up-
regulation of surface receptors, e.g. for fMLP (Fletcher and Gallin, 1983; Jesaitis et
al., 1982). This increased receptor expression occurs primarily at the leading edge of
the lamellipodium (Nunoi et al., 1985), whilst down-regulated receptors may be
cycled to the trailing uropod and shed (Devreotes and Zigmond, 1988). These events
are accompanied by dynamic morphological alterations in the lamellipodium,
mediated by cycles of actin-dependent protrusion and contraction (Cassimeris et al.,
1990; Zigmond, 1993). Furthermore, neutrophil integrins mediate transient
interactions with extracellular matrix proteins (Fuortes et al., 1993; Hendey et al.,
1992), providing the traction required for locomotion.
1.3.6 The Phagocytosis of Opsonized Particles
The neutrophil is a professional phagocyte, and therefore has a primary function to
recognize, phagocytose, and destroy any agent which is foreign to the host. The
continued exocytosis of secretory vesicles and specifc granules to the neutrophil
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surface, results in the up-regulation of CR1 and CR3 (CD1 lb/CDl 8), and FcyRIII
(Tosi and Zakem, 1992): these are receptors for the complement components C3b
and C3bi, and Fc fragments of immunoglobulin G (IgG), respectively, which act as
opsonins by binding to foreign particles and marking them for phagocytosis. Thus,
once the neutrophil has reached the inflammatory site it can identify particles that
have been opsonized or certain lectins on the surface of micro-organisms (via non¬
specific glycosylated receptors). This recognition process triggers the extrusion of
pseudopodia and engulfment of the target into a phagocytic vesicle (Figure 1.3).
1.3.7 The Respiratory Burst and Degranulation
The process of phagocytosis, together with the high, local concentrations of soluble
stimuli at the inflammatory focus, initiates the transmembrane assembly of the
NADPH oxidase enzyme system from its component parts (Babior, 1994). These
parts include resident plasma-membrane components (the cytochrome b558 subunits
p91ph°x an(j p21 i)hox) (phox =/?/2agocytic oxidase) and cytosolic factors (p47phox, p67phox
and p21rac) (Rotrosen et al., 1993). The functional NADPH oxidase then catalyzes
an electron transport chain, using NADPH (generated by the cytosolic, hexose
monophosphate shunt) as an electron donor (Babior et al., 1973), to reduce oxygen to
superoxide anions (O,"):
NADPH + H+ + 20, -> NADP+ + 2H+ + 20,"
This correlates with an intense consumption of oxygen by the cell, which is referred
to as the "respiratory burst" (Baldridge and Gerard, 1933). Superoxide anions are
pumped into the phagocytic vesicle, where they dismute in the presence of the
enzyme superoxide dismutase, producing hydrogen peroxide (H,0,):

















Schematic Representation of Phagocytosis and Microbial Killing.
(1) The recognition of opsonized agents by neutrophils at the
inflammatory site initiates the process of phagocytosis. (2) The release
of granule contents into the phagocytic vesicle together with the
activation of NADPH oxidase generates a highly microbicidal
environment (phagolysosome). (3) This results in the killing and
degradation of the ingested agent. SOD = superoxide dismutase, MPO
= myeloperoxidase. (After Smith, 1994).
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Even more reactive products, such as hydroxyl radicals (OH") and singlet oxygen
2-
(O ") may also be formed, but these products are very short-lived and are of unknown
importance (Rosen et al., 1995). The fusion of neutrophil granules with the
phagocytic vesicle represents the process of degranulation. This includes the
discharge of myeloperoxidase from azurophilic granules which promotes the
generation of highly microbicidal, chlorinated oxidants, such as hypochlorous acid
(HOC1) and chloramines (Bernofsky, 1991):
H202 + HC1 -» HOC1 + H20
The collective products of respiratory burst activity represent a pool of reactive
oxygen species, and together with the contents of neutrophil granules, represent a
potent, cytotoxic cocktail with which to ensure efficient killing and degradation of
the phagocytosed material.
1.3.8 The Synthesis of Inflammatory Mediators
Activated neutrophils also synthesize and release an important array of additional
inflammatory mediators, including PAF (De Nichilo et al., 1991; Camussi et al.,
1987), TNFa (Dubravek et al., 1990), IL-8 (Bazzoni et al., 1991), LTB4 (Bozza et
al., 1996) and PGE2 (Bozza et al., 1996). The release of these mediators, either
singly or in combination, from large numbers of activated neutrophils at an
inflammatory focus allows the fine tuning of inflammatory responses.
1.4 Neutrophil-Mediated Host Tissue Damage and its Prevention
Since activated neutrophils can generate such highly cytotoxic products, these must
be prevented from damaging normal host tissues. Endothelial cells generate
substances, including PGI2 (Zimmerman et al., 1985), which inhibit neutrophil
adhesion, and contain "ecto-enzymes" that can convert ATP and ADP into
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adenosine, which also inhibits various neutrophil functions (Firestein et al., 1995).
The intracellular hypochlorous acid of neutrophils can react with, and thus denature,
azurophilic granule enzymes and the NADPF1 oxidase, in the absence of other
substrates (Weiss, 1989). Products released from neutrophils (e.g. during
phagocytosis) can be inactivated by various anti-proteases (e.g. a[-anti-trypsin) and
anti-oxidants present in exudate fluids. The final line of host protection is another
professional phagocyte, the macrophage, which can recognize and ingest senescent
neutrophils prior to the onset of necrosis (see 1.5), thereby preventing extracellular
release of cytotoxic products (Savill et al., 1989).
However, if the host's anti-inflammatory control mechanisms are overwhelmed, the
microbicidal potential of neutrophils will be turned upon the host, eliciting
inadvertent host tissue damage. For example, the pathology of emphysema (Gadek,
1992) has been linked to the deficiency of aranti-trypsin. Host tissue damage will
also occur if the specific arms of the immune response (e.g. antibodies and other cells
with cytotoxic potential) fail to differentiate between foreign and self antigens, thus
marking host tissues for destruction. As a consequence of the above, neutrophils
have been implicated in the pathogenesis of a variety of clinical disorders, including
the adult respiratory distress syndrome (ARDS) (Wardle et al., 1992), ischaemia-
reperfusion injury (Williams, 1994), pulmonary fibrosis (Behr et al., 1991),
rheumatoid arthritis (Robinson et al., 1992) and vasculitic diseases (Thomas et al.,
1988; Savage and Rees, 1994).
1.5 Neutrophil Apoptosis
Senescent neutrophils die by the process of apoptosis (programmed cell death). This
involves cell shrinkage, nuclear condensation and the formation of cytoplasmic blebs
(Arends and Wyllie, 1991). Subsequently, the neutrophil undergoes fragmentation
into several membrane-bound, apoptotic bodies which are then rapidly removed by
mononuclear phagocytes (Savill et al., 1989), a process that fails to elicit an
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inflammatory response (Meagher et al., 1992): apoptosis thus represents a means of
terminating neutrophil-mediated inflammation.
1.6 Neutrophil Priming
The primary role of the immune system is to defend the host from injurious agents.
However, as discussed above, the enormous cytotoxic potential required for such a
function predisposes the host to inadvertent tissue damage. Thus, a system has
evolved whereby, under normal conditions, circulating immune cells remain in a
quiescent and functionally inactive state, until they receive a series of specific
activation (and often co-activation) signals. However, it has since been realized that
neutrophil behaviour is regulated in a far more complex manner and is highly
influenced by environmental factors. Indeed, previous in vitro studies have
demonstrated that if neutrophils are pre-exposed to certain agents, which themselves
fail to activate these cells, their subsequent microbicidal response to a subsequent
agonist challenge may be markedly enhanced. This functional up-regulation has
been termed priming. Neutrophil priming was originally demonstrated with LPS,
which did not elicit a respiratory burst alone, but greatly enhanced respiratory burst
activity (specifically superoxide anion release) to a subsequent (initially non-
activating) challenge with fMLP (Guthrie et al., 1984; Cohn and Morse, 1960). The
enhancement of fMLP-stimulated superoxide anion release has since been considered
as the "gold standard" in vitro rmeasure of neutrophil priming. Although, the
definition of neutrophil priming has evolved to include the enhancement of various
other functional responses, it still requires that the following criteria be fulfilled:
(i) the priming agent, at its designated concentration, does not initiate the effector
function
(ii) the priming agent must precede the activating stimulus.
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i.e. Quiescent neutrophil —> Stimulated neutrophil
(little response)
Quiescent neutrophil —» Primed neutrophil -» Primed-Stimulated neutrophil
(little response) (major response)
Although dedicated priming agents are unable to activate neutrophils directly,
irrespective of the concentration used (Hallett and Lloyds, 1995), it is now
recognised that other agents may prime neutrophils at low concentrations and
activate them at higher concentrations. For instance, low concentrations of fMLP
and PMA, both well-established neutrophil stimulants, have been reported to prime
responses to a second agonist (Bender and Van Epps, 1983; English et al., 1981;
Bellavite et al., 1993; Wymann et al., 1987). These observations imply that priming
and activation are closely linked events, which may occur sequentially in vivo when
neutrophils move along a chemotactic gradient. Furthermore, the demonstration that
individual pro-inflammatory mediators may prime one response (e.g. respiratory
burst activity) whilst simultaneously "activating" another (e.g. shape change (Flaslett
et al., 1985) or adhesion molecule up-regulation (Condliffe et al., 1996)), again
highlights the difficulty in defining the boundaries between neutrophil priming and
activation.
Nevertheless, the current weight of in vitro and in vivo data indicates that neutrophils
will not express their full microbicidal potential to patho-physiological activating
agents unless they have first been primed. For example, when neutrophils are
incubated with fMLP, the extent of superoxide anion release is directly proportional
to their level of priming. This problem has been a major confounding variable in
many in vitro neutrophil studies, due to the endogenous priming (by agents such as
LPS) that is inherent to many neutrophil isolation procedures (Haslett et al., 1985).
Thus, it is possible that neutrophils cannot produce a respiratory burst upon
activation unless they have first been primed (Pabst, 1994). However, it remains
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unclear whether priming represents an increased response of the whole neutrophil
population, or whether it symbolizes the recruitment of previously quiescent
neutrophils to a responsive state (Hallett and Lloyds, 1995) (see 1.6.3).
1.6.1 Indices ofNeutrophil Priming
Since individual agents can induce a range of functional responses in neutrophils, no
single test will provide an adequate screen for neutrophil priming. However, if
several functions are measured in parallel, this provides a global assessment of
neutrophil responses to a particular agent. The respiratory burst is a characteristic
property of the professional phagocyte. Thus, the enhancement of respiratory burst
activity to a subsequent stimulus remains the most conventional indicator of
neutrophil priming. As mentioned above, the gold standard for determining whether
neutrophils are primed is taken as the measurement of fMLP-stimulated superoxide
anion release, because it relates directly to the microbicidal potential of neutrophils,
whilst being a sensitive, objective assay. However, other secondary responses can
also be measured in primed neutrophils (Figure 1.4). For example, neutrophils can
be primed for degranulation (Fittschen et al., 1988) and enhanced release of various
inflammatory mediators, including LTB4, AA, PGE2 and PAF (Daniels et al., 1992;
Bozza et al., 1996; Doerfler et al., 1994; Doerfler et al., 1989).
The quantification of cellular shape change provides a direct measurement of the
chemotactic and chemokinetic potential of neutrophils (Haston and Shields, 1985).
Although the intracellular signalling pathways for chemotaxis are distinct from those
leading to superoxide anion production (Yasui et al., 1994; Reibman et al., 1991), the
degree of neutrophil shape change has been shown to correlate directly with the
priming of fMLP-stimulated superoxide anion release (Haslett et al., 1985). Thus,
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•No respiratory burst activity
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Schematic Representation of Neutrophil Priming.
Various pro-inflammatory mediators can prime neutrophils for an enhanced
respiratory burst to secretagogue agonists. Priming is associated with other
increased functional responses, including neutrophil shape change,
adhesiveness, and release of inflammatory mediators.
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Neutrophil shape change does not require adhesion (Anderson et al., 1986; Anderson
et al., 1985). However, the chemotactic response of neutrophils in vivo is intimately
associated with a sequence of adhesive events (Jutila et al., 1989; Arfors et al., 1987;
Wallis et al., 1986) mediated by changes in selectin and integrin molecule expression
and function. It has been reported that cross-linking of L-selectin molecules with
monoclonal antibodies, or cell adhesion to glass or plastic surfaces, leads to
neutrophil priming (Waddell et al., 1994). In addition, concentrations of stimuli that
prime respiratory burst activity have also been shown to alter the relative distribution
of neutrophil adhesion molecules, inducing the loss of L-selectin and the up-
regulation of CDllb/CD18 expression and avidity (Condliffe et al., 1996;
Borregaard et al., 1994; Griffin et al., 1990; Kishimoto et al., 1989). Thus,
neutrophil priming may be concerned with the recruitment of "rolling" neutrophils to
an inflammatory site.
*
The following model for the role of neutrophil priming in the inflammatory response
can therefore be proposed: during an acute inflammatory response in vivo, priming
may occur (in response to soluble or cell-associated priming agents) as neutrophils
marginate or roll along the endothelial surface. These neutrophils still express L-
selectin and are exposed to cytokines and low concentrations of chemotactic factors.
The subsequent exocytosis of secretory vesicles results in the incorporation of vesicle
membrane, rich in CDllb/CD18, but devoid of L-selectin (Borregaard et al., 1994),
into the plasma membrane, whilst inducing shape change. The up-regulation of p2-
integrins and shedding of L-selectin promotes the endothelial arrest of primed
neutrophils. During their ensuing trans-endothelial migration, increasing
concentrations of chemotactic factors provide increasing neutrophil stimulation,
leading to more pronounced cell polarization and granule exocytosis, with the
continuing up-regulation of plasma membrane components (e.g. receptors for fMLP
and the opsonins, and cytochrome b558). When these functionally up-regulated
neutrophils have reached the inflamed site, the high concentrations of soluble stimuli
and opsonised particles then triggers full activation, initiating phagocytosis,
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degranulation and respiratory burst activity. Thus, if neutrophils have been primed
for action en route, they will hopefully achieve their full microbicidal potential.
1.6.2 Neutrophil Priming Agents
Many conditions have been reported to prime neutrophils. Nevertheless, priming
agents can be broadly classified as physiological, physico-chemical, or
pharmacological. Although studies with physiological mediators have the most
relevance to in vivo events, much can be learned from the artificial manipulation of
priming with the latter two groups of agents. Indeed, the recognition that
venepuncture itself may (under certain circumstances) result in neutrophil priming,
illustrates the importance of maintaining neutrophil homeostasis at all times,
especially during ex vivo priming studies.
Physiological priming agents act through specific, cell-surface receptors, of which
there are at least three different classes. The classic, G-protein-linked receptors,
consisting of seven transmembrane domains, mediate the effects of the majority of
neutrophil chemoattractants: thus, fMLP, PAF, C5a, IL-8, and substance P all utilize
this family of receptors (Gerard and Gerard, 1991; Murphy and Tiffany, 1991;
Boulay et al., 1990). The cytokine/growth factor family of receptors comprise a
single transmembrane domain, and signal the effects of agents such as TNFa, GM-
CSF and G-CSF (Tartaglia and Goeddel, 1992). The third group of receptors also
exhibit a single transmembrane domain, but require immobilization or crosslinking
(rather than ligand occupancy) for activation: this group includes the integrins and
FcR family (Metzger, 1992; Ng-Sikorski et al., 1991). The structural heterogeneity
of these receptors reflects their different functional roles and may provide insight into
their downstream signalling targets. In addition, it may help to explain the variability
between the onset and duration of priming induced by different classes of agents.
The following section will introduce the main physiological priming agents
investigated in this thesis.
20
1.6.2.1 Platelet-Activating Factor
Since PAF can activate a wide variety of cell types (Chao and Olson, 1993), it is not
surprising that it may contribute to many physiological and patho-physiological
processes in vivo, including vasodilatation and hypotension (Sun et al., 1990),
allergic and inflammatory reactions (Braquet et al., 1987; Humphrey et al., 1982),
asthma and transplant rejection (Page, 1990; Foegh, 1988; Vargaftig, 1987;
Feuerstein and Hallenbeck, 1987; Braquet et al., 1987). Although platelet-activating
factor (PAF) was originally identified as l-0-alkyl-2-acetyl-.y«-glycero-3-
phosphocholine (Demopoulos et al., 1979; Benveniste et al., 1979), it is not a single
molecular species, but represents a family of molecules with an alkyl linkage at the
sn-1 position, an sn-2 short-chain acyl group, and a polar phosphocholine head
group. However, many cells that were originally thought to produce alkyl-PAF may
also produce acyl-PAF, a group of bioactive molecules with an sn-1 acyl linkage
(Pinckard and Prihoda, 1996; Triggiani et al., 1991; Alonso et al., 1986) that
confound the bioassay of PAF.
The majority of cell types produce PAF upon appropriate stimulation, including
vascular endothelial cells (Prescott et al., 1984), mast cells (Mencia-Huerta et al.,
1983), macrophages (Albert and Snyder, 1983), platelets (Chignard et al., 1980) and
neutrophils (Lynch et al., 1979): neutrophils have been reported to generate more
PAF than any other inflammatory cell, estimated at 10-100 pmol PAF per 106
neutrophils following calcium ionophore treatment (Oda et al., 1985; Jouvin-Marche
et al., 1984; Lynch and Henson, 1986). Cell stimulation initiates the remodelling
pathway for PAF synthesis, probably in a light membrane fraction such as the
endoplasmic reticulum (Riches et al., 1985; Ribbes et al., 1985; Saffitz et al., 1986;
Mollinedo et al., 1988). The rate-limiting step in PAF synthesis is the release of
arachidonic acid (AA) and lyso-PAF from membrane phospholipids, by the action of
phospholipase A2 (Chilton et al., 1984): lyso-PAF is both a precursor and metabolite
of PAF. The de novo synthesis of PAF also occurs (Snyder, 1987), but its
contribution to the overall levels ofPAF remains unclear.
21
PAF mediates its effects through a seven-transmembrane domain, G-protein-linked
receptor (Nakamura et al., 1991). There is some confusion in the literature regarding
the possible heterogeneity of these receptors, confounded by repeated attempts to
correlate the results of binding studies performed under many different assay
conditions. However, virtually all studies agree that: (i) neutrophils contain specific,
high affinity PAF receptors (with reported KD values of 0.1-16.3 nM); (ii) these
receptors are localized to the plasma membrane and are responsible for the bioactions
of PAF; and (iii) PAF receptor antagonists can inhibit neutrophil responses to PAF
(Casals-Stenzel et al., 1987; Shen et al., 1985; O'Flaherty et al., 1989; Dent et al.,
1989; O'Flaherty et al., 1986; Marquis et al., 1988; Hwang, 1988; O'Flaherty and
Nishihira, 1987). An "earmuffs" model has been proposed for the PAF binding site
(Godfroid et al., 1991), with a central hydrophobic pocket (for insertion of the sn-1
alkyl/acyl group) embedded below two, opposing zones of positive charge (for
interaction with the polar phosphocholine head group). In addition to the
extracellular PAF receptor(s), there have also been suggestions that neutrophils
contain intracellular PAF binding sites (De Kimpe et al., 1995; Svetlov and Nigam,
1993; Muller and Nigam, 1992), which may mediate some of the autocrine actions of
PAF retained within its cell of origin.
The effects of PAF on human neutrophils have been widely documented. In vitro,
PAF has been shown to induce a variety of functional responses, including
aggregation (Camussi et al., 1980), chemotaxis (Pinckard et al., 1992; Shaw et al.,
1981), and adherence to endothelial cells (Ingraham et al., 1982). However, PAF
does not directly stimulate respiratory burst activity unless neutrophils have been
pre-treated with cytochalasin B or propanolol, or PAF is present at high (>10 pM)
concentrations (Gay, 1993; Shaw et al., 1981; Pinckard et al., 1992). Instead, PAF is
a potent and rapid-acting neutrophil priming agent, enhancing the subsequent
respiratory burst induced by activating stimuli such as fMLP, PMA or C5a (Pinckard
et al., 1992; Dewald and Baggiolini, 1985; Gay et al., 1986; Ingraham et al., 1982).
PAF has also been shown to prime AA mobilization and eicosanoid formation
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(Bozza et al., 1996; Tanizawa and Tai, 1989), and (in the presence of cytochalasin B)
degranulation (Vercellotti et al., 1988; Shaw et al., 1981; Ingraham et al., 1982).
Although neutrophil priming in vitro has been most widely studied with PAF acting
in solution, PAF may also function in vivo as a cell-associated, pro-inflammatory
mediator. It has been proposed that when endothelial cells are stimulated by certain
agonists (including thrombin, LTC4, histamine, bradykinin and ATP) they synthesize
PAF rapidly (Mclntyre et al., 1985; Mclntyre et al., 1986; Prescott et al., 1984) and
express this molecule on the cell surface alongside the tethering molecule P-selectin
(Lorant et al., 1991). In this way, PAF has been proposed to contribute to the
juxtacrine stimulation of rolling neutrophils (Lorant et al., 1993; Lorant et al., 1991),
an event which requires the engagement of specific PAF receptors on the neutrophil
surface (Vercellotti et al., 1988; Flwang, 1988). According to this model, PAF
stimulates up-regulation of both the avidity and surface expression of CD1 lb/CD18,
the shedding of L-selectin, and the firm adherence of neutrophils to the activated
endothelium (Lorant et al., 1991; Ingraham et al., 1982). Concurrently, neutrophils
become polarized (Lorant et al., 1993) and primed for enhanced respiratory burst
activity and degranulation prior to their extravasation (Lorant et al., 1993; Vercellotti
etal., 1989).
1.6.2.2 Tumour Necrosis Factor-a
Tumour necrosis factor-a (TNFa) is a cytokine that was originally identified by its
cytotoxic activity against tumour cells (Carswell et al., 1975). It has also been
demonstrated that TNFa is a mediator of endotoxin-induced septic shock, cachexia
(hence its other name, cachectin) and inflammatory responses (Beutler and Cerami,
1989; Beutler and Cerami, 1988). TNFa is produced by activated cells of the
immune system, particularly by LPS-exposed macrophages (Aggarwal et al., 1985b).
Mature TNFa is cleaved proteolytically from the cell surface by the action of TNFa-
converting enzyme (TACE) (Black et al., 1997) and exists as a homotrimeric
molecule composed of 17 kDa subunits (Wingfield et al., 1987; Aggarwal et al.,
23
1985). It mediates its effects through two distinct TNF receptor subtypes of 55 and
75 kDa, of which the former is present on the majority of cell types whilst the latter
is present only on cells of haemopoeitic lineage (Brockhaus et al., 1990).
TNFa has various effects upon neutrophil function. It is chemotactic (Figari et al.,
1987; Ming et al., 1987) and can increase the surface expression of receptors,
including CDllb/CD18 (Ozaki et al., 1988; Berger et al., 1988). It can prime the
respiratory burst of neutrophils in suspension to agents such as fMLP and PMA
(Elbim et al., 1994; Tennenberg and Solomkin, 1990; Berkow et al., 1987) and is a
direct activator of superoxide anion generation in adherent neutrophils
(Schleiffenbaum and Fehr, 1990; Nathan, 1987).
1.6.2.3 Lipopolysaccharide
Lipoplysaccharide (LPS or bacterial endotoxin) is a major cell-membrane component
of Gram-negative bacteria, which is believed to contribute to the widespread patho¬
physiology of Gram-negative septicaemia and the pulmonary vascular injury
associated with ARDS (Parsons et al., 1989). The LPS molecule is composed of a
variable polysaccharide moiety which is expressed externally, linked to an
intramembranous lipid A component, comprising a highly-conserved,
diglucosamine-based phospholipid (Kulshin et al., 1992) which appears to contain
the bioactive portion of LPS (Galanos et al., 1985). LPS can elicit neutrophil shape
change, aggregation and adhesion molecule up-regulation (Dahinden et al., 1983). In
addition, LPS is a well-recognized neutrophil priming agent that has been reported to
enhance respiratory burst activity and LTB4 production in response to a second
stimulus such as fMLP, PMA or immune complexes (Aida and Pabst, 1990; Doerfler
et al., 1989; Guthrie et al., 1984).
Several studies have suggested that the effects of LPS on neutrophils are mediated by
CD14, a membrane glycoprotein (Shapira et al., 1995; Weingarten et al., 1993)
which is believed to function as its cell-surface receptor. However, it has been
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demonstrated that the response of neutrophils to LPS is greatly enhanced in the
presence of plasma (Aida and Pabst, 1990): an acute phase protein, named
lipopolysaccharide binding protein (LBP), was proposed to mediate this facilitation
(Vosbeck et al., 1990; Tobias et al., 1986). Thus, it is currently believed that LPS
forms a complex with LBP, and that this complex then primes neutrophils via CD14
(Shapira et al., 1995; Yasui et al., 1992; Vosbeck et al., 1990; Wright et al., 1991).
Other serum LPS-binding proteins, the septins, have also been identified (Wright et
al., 1992), but are not thought to contribute to the priming effects of LPS (Shapira et
al., 1995).
1.6.2.4 Inositol Hexakisphosphate
Inositol hexakisphosphate (InsP6) is the most abundant inositol phosphate found in
nature (Cosgrove, 1980), being found in mammalian cells at concentrations between
10 pM and 1 mM (Szwergold et al., 1987). It is an intriguing molecule whose true
physiological role has yet to be revealed. However, InsP6 has been proposed to have
various intracellular functions, for example, acting as a general antioxidant (Graf and
Eaton, 1990), Ca2+ chelator (Luttrell, 1993), inhibitor of iron-catalysed hydroxyl
radical formation (Hawkins et al., 1993) and phosphate store (Berridge and Irvine,
1989).
InsP6 may also have a number of extracellular actions: it has been reported to lower
blood pressure and heart rate when infused into specific regions of the rat brain-stem
(Vallejo et al., 1987). InsP6 can also suppress the development of colonic cancer in
animal models, probably by chelating metal ions and thereby limiting mitogenic,
iron-catalysed, redox reactions (Graf and Eaton, 1993). At a cellular level, InsP6 has
2+
also been shown to elicit Ca influx and catecholamine release in bovine adrenal
chromaffin cells (Regunathan et al., 1992) and to enhance Ca2+ influx in cultured
neuronal cells (Nicoletti et al., 1989).
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However, in addition to these diverse actions, it has also been suggested that InsP6
may have a pro-inflammatory role by acting as a neutrophil priming agent (Eggleton
et al., 1991), an action not observed with other inositol polyphosphates. It was
reported that the preincubation of human neutrophils with InsP6 led to an enhanced
superoxide anion generation to fMLP (Eggleton et al., 1991) and a rapid, yet
sustained, assembly of F-actin (Crawford and Eggleton, 1992). Thus it has been
proposed that effete cells present at an inflammatory focus might release InsP6,
which could then function to prime adjacent neutrophils and thereby augment the
inflammatory response.
1.6.2.5 Adenosine Triphosphate
Adenosine triphosphate (ATP) is released from a variety of cell types by a process of
exocytosis. The stimulated release of ATP has been particularly well studied in the
context of platelet aggregation, where it has been estimated that the local,
extracellular concentration of ATP may reach 12 pM (Ingerman et al., 1979). Such
elevated levels of ATP may be transient however because endothelial cells possess
ecto-nucleotidases that can rapidly hydrolyze ATP to adenosine, via ADP and AMP
(Pearson et al., 1980),
Extracellular ATP has been reported to activate a variety of cell types (Hallam and
Pearson, 1986) via P2 purinoceptors (Burnstock, 1978). Furthermore, ATP has been
shown to elicit rapid neutrophil priming for enhanced superoxide anion generation to
both fMLP and immune complexes (Naum et al., 1991; Ward et al., 1988; Kuhns et
2_j_
al., 1988): this priming effect was associated with an influx of Ca (Kuhns et al.,
1988). Thus, it was postulated that ATP released from stimulated platelets in vivo
might modulate the functions of nearby neutrophils (Kuhns et al., 1988).
Nevertheless, these pro-inflammatory effects of ATP might be limited by its
subsequent metabolism to adenosine, an inhibitor of various inflammatory responses
which signals through several distinct receptor subtypes (Walker et al., 1990;
Cronstein et al., 1983).
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1.6.3 Neutrophil Priming in Vivo
Neutrophil priming was initially described as an in vitro phenomenon. However,
since the majority of priming agents are established pro-inflammatory mediators
released during various patho-physiological states, it is hardly surprising that there
are numerous examples of priming occurring in vivo.
Primed neutrophils have been reported in the blood of patients with Hodgkin's
disease (Tullgren et al., 1991), psoriasis (Bloomfield and Young, 1988),
inflammatory bowel disease (Suematsu et al., 1987), ARDS (Chollet-Martin et al.,
1992), sarcoidosis (Barth et al., 1988), bacterial and fungal infections (Bass et al.,
1986), and essential hypertension (Pontremoli et al., 1989). In addition, neutrophil
priming is apparent in the blood of otherwise healthy individuals following blunt
trauma (Krause et al., 1988) and moderate exercise (Smith et al., 1990), and primed
neutrophils have been isolated from the joints of people with active rheumatoid
arthritis (Robinson et al., 1992). Evidence of neutrophil activation (as indicated by
an increased plasma concentration of neutrophil granule contents) has been observed
in septicaemia (Panyutich et al., 1993), bacterial meningitis (Panyutich et al., 1993)
and following strenuous exercise (Dufaux and Order, 1989; Pyne, 1994).
The mechanisms involved in neutrophil priming are unknown in the majority of
cases, because detectable levels of circulating cytokines are only found in extreme
circumstances. Nevertheless, the priming observed in septicaemia and ARDS have
been found to correlate with circulating levels of TNFa (Chollet-Martin et al., 1993;
Chollet-Martin et al., 1992; Trautinger et al., 1991). Indeed, persistently high levels
of TNFa and IL-6 have been linked to a poor outcome in septic shock (Pinsky et al.,
1993). Similarly, persistent endotoxaemia (circulating LPS) has been associated with
the development ofARDS (Parsons et al., 1989).
It is important to mention at this stage, that peripheral blood neutrophils are not a
homogeneous population; instead, they can be divided into sub-populations of
27
different age and morphology on the basis of cell-surface markers. Furthermore,
functional heterogeneity has been reported within the circulating neutrophil pool
(Daniels et al., 1994; Bass et al., 1986; Klempner and Gallin, 1978). Although the
physiological significance of functional heterogeneity is not fully understood, it may
indicate the previous history (e.g. margination) of circulating neutrophils. The
distribution of neutrophil sub-populations in peripheral blood is affected by various
patho-physiological states, including inflammatory disease, infection and exercise;
for example, patients with ARDS or acute bacterial infections have a sub-population
of peripheral blood neutrophils that show enhanced responses for respiratory burst
activity (Bass et al., 1986; Chollet-Martin et al., 1992) and antibody-mediated
phagocytosis (Simms et al., 1989). Although young neutrophils are released from
the bone marrow in response to infection (Simms et al., 1989), the number of
juvenile cells appears to be unrelated to the proportion of primed neutrophils and
their oxidative potential (Bass et al., 1986). Thus, the appearance of distinct
neutrophil sub-populations in response to priming stimuli, may indicate that priming
recruits previously non-responsive cells to a responsive state, rather than augmenting
the responses of all neutrophils (Daniels et al., 1994).
1.7 Potential Mechanisms ofNeutrophil Priming
Although the mechanisms underlying neutrophil activation have been widely studied,
the process ofpriming has received less attention. Progress in this area is hampered
by the complex, and divergent, intracellular signalling pathways utilized by different
neutrophil stimulants. However, the close links between the primed and activated
state suggest that many of the mechanisms described for neutrophil activation may
also be relevant to priming (Figure 1.5). Thus, the following section will outline
current knowledge regarding potential mechanisms that have been proposed to
mediate neutrophil priming. In broad terms, previous data have suggested that
piiming agents may up-regulate secretagogue-mediated responses at the receptor, G-
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protein or cytosolic second messenger level, but a universally applicable mechanistic
basis for neutrophil priming has yet to be established.
1.7.1 fMLP Receptors
The exposure of neutrophils to various priming agents, including PAF, TNFa and
LPS, and low concentrations of C5a and fMLP, has been associated with a Ca2+-
dependent up-regulation of fMLP receptor expression (Vosbeck et al., 1990;
Goldman et al., 1986; Tennenberg and Solomkin, 1990; Norgauer et al., 1991). This
has been proposed to result from the exocytosis of specific granules and secretory
vesicles, and occurs: (i) independently of alterations in receptor affinity (Tennenberg
and Solomkin, 1990) and (ii) in concert with CDllb/CD18 (CR3) up-regulation
(Norgauer et al., 1991). Thus, it was suggested that an increased expression of fMLP
receptors in primed neutrophils might explain the enhanced responses observed upon
subsequent exposure to fMLP. Flowever, it has been demonstrated that for both
TNFa-induced priming of degranulation (O'Flaherty et al., 1991) and calcium
ionophore-induced priming of respiratory burst activity (Andersson et al., 1987), the
enhanced functional response precedes the increase in fMLP binding. Furthermore,
the priming of respiratory burst activity elicited by IL-8 occurs at concentrations
below those that result in a detectable increase in fMLP receptor number (Roberts et
al., 1993). Thus, the up-regulation of fMLP receptors is unlikely to underlie the
priming of subsequent responses to fMLP.
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Schematic Diagram ofMultiple Signalling Pathways Triggered by Activation
ofG-protein-linked Receptors in Neutrophils.
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1.7.2 G-Proteins
Intracellular proteins (either cytosolic or membrane-associated) which bind GTP are
known as G-proteins. G-proteins are broadly classified as either heterotrimeric or
small molecular weight (approximately 20-25-kDa) monomeric G-proteins.
Heterotrimeric G-proteins are composed of a-and Py-subunits, and regulate cellular
events by a GTP hydrolysis cycle: the replacement of GDP (bound to the a-subunit)
with GTP results in the dissociation of a- and Py-subunits, and G-protein activation
(Neer and Clapham, 1988). Although the activated a-subunit is thought to be the
principal effector molecule in the majority of circumstances, free py-subunits can
also initiate certain responses (Lee and Rhee, 1995; Katz et al., 1992). The intrinsic
GTPase activity of the a-subunit subsequently hydrolyses GTP to GDP, whereby a
and Py recombine to end the activation cycle.
Heterotrimeric G-proteins couple the seven-transmembrane-domain family of
receptors utilized by the majority of neutrophil chemoattractrants (Neer, 1995) to
intracellular systems such as actin polymerization (Bengtsson, 1990) and the
phospholipases-C, -D and -A2 (Taylor, 1990). Although the identity of the Py-
subunits expressed in neutrophils are unknown, many different a-subunits have been
identified, including members of the Gsa, Gia, and Gqa classes (Thelen et al., 1993):
however, the major a-subunits in human neutrophils are Gia2 and Gia3 (Goldsmith et
al, 1987).
Both Gia2 and Gia3 are sensitive to pertussis toxin, which ADP-ribosylates and
inactivates them, thereby uncoupling these proteins from receptors. Since pertussis
toxin inhibits the superoxide response to fMLP (Snyderman et al., 1986; Lad et al.,
1985; Gay, 1993), other neutrophil stimulants which do not utilize G-protein-linked
receptors (e.g. PMA and calcium ionophores such as A23187) have been employed
to investigate the influence of pertussis toxin on neutrophil priming. However, the
literature regarding the pertussis toxin sensitivity of neutrophil priming is confusing.
For example, whilst it has been reported that pertussis toxin does not affect TNFa-
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induced (Berkow and Dodson, 1988) or PAF-induced (Gay, 1993) priming of the
superoxide response to PMA, nor the priming of A23187-induced AA release by
GM-CSF (Di Persio et al., 1988; Di Persio and Abbound, 1992), another study found
that pertussis toxin abolished GM-CSF priming of A23187-induced AA release
(McColl etal., 1989).
Nevertheless, there is preliminary evidence to suggest that priming agents, including
LPS (Yasui et al., 1992), GM-CSF (Durstin et al., 1993) and TNFa (Klein et al.,
1995), elicit the translocation of Giot2 to the neutrophil membrane. Since G-protein
translocation increases the pool size of relevant G-proteins available for
chemoattractant receptor-mediated signal transduction, this event may contribute to
the potentiation of chemoattractant-induced responses. Indeed, the time-courses for
the priming of fMLP-stimulated superoxide anion release by LPS, PAF and TNFa,
have been shown to correlate with the translocation of Gia2 to the plasma membrane
(Alison Condliffe, personal communication). This may also be the case with GM-
CSF, although the translocation of Gia2 to the plasma membrane was observed to be
more rapid (Durstin et al., 1993) than its superoxide-priming effect (Weisbart et al.,
1986). However, the exact role of G-proteins in GM-CSF signalling remains
somewhat controversial (Durstin and Sha'afi, 1996; Probst et al., 1992). Thus,
(certain) priming agents may promote the association of a-subunits with the plasma
membrane, which may contribute to their facilitation of subsequent responses.
1.7.3 Phospholipase C and Ins(l,4,5)P3
Human neutrophils contain phosphoinositide-specific phospholipase C (PLC), an
enzyme responsible for the cleavage of phosphatidylinositol 4,5-bisphosphate
(PtdIns(4,5)P2) to inositol 1,4,5-trisphosphate (Ins(l,4,5)P3) and 5nl,2-diacylglycerol
(DAG) (Thelen and Wirthmueller, 1994). Neutrophil stimulation, either with
chemotactic factors (e.g. fMLP, LTB4, C5a, PAF, IL-8) or via phagocytic receptors
(CR3, FcyR), results in the activation of the (3 and y isoforms of PLC, respectively.
This results in the rapid, but transient, accumulation of Ins(l,4,5)P3, and a similar
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2+
rapid elevation of DAG. Ins(l,4,5)P3 signals the release of Ca from intracellular
stores, and DAG is an activator of PKC. There has been limited study into a
potential role for Ins(l,4,5)P3 in neutrophil priming. In the few studies ofGM-CSF-
induced priming where this has been examined, it was reported that GM-CSF did not
affect (Bourgoin et al., 1990; Corey and Rosoff, 1989) basal or stimulated levels of
Ins(l,4,5)P3. This area of research requires further investigation.
1.7.4 Intracellular calcium
2+
The intracellular concentration of free calcium ([Ca ]j) is maintained at low levels
(approximately 100 nM) in resting neutrophils (Sklar et al., 1985). Neutrophil
2+ • • 2+
stimulation leads to a biphasic increase in [Ca ]j, with a rapid Ca spike resulting
2+
from the mobilization of intracellular Ca stores by Ins(l,4,5)P3, followed by a more
sustained phase of Ca2+ influx; the emptying of intracellular stores regulates the
2+ • 2+
permeability of the plasma membrane to Ca thereby increasing Ca influx
(Demaurex et al., 1994; Putney, 1986).
The elevation of [Ca2+]; contributes to neutrophil shape change, degranulation, and
superoxide anion generation (Morel et al., 1991; Richter et al., 1990; Pozzan et al.,
2+
1988). For example, it has been demonstrated that a threshold [Ca ]j of 250 nM is
required to elicit a respiratory burst (Flallett et al., 1990), and that depletion of
extracellular Ca2+ can prevent respiratory burst activation (Sha'afi et al., 1988;
2+
Dewald et al., 1988). However, Ca oscillations, rather than sustained elevation,
may control certain neutrophil functions, including those arising from [T-integrin
activation (Hendey et al., 1992; Jaconi et al., 1991), and Ca2+-independent pathways
of neutrophil activation may also exist (Gomez-Cambronero et al., 1989; Rossi et al.,
1988; Morel et al., 1991). It is important to note that neutrophil activation causes
2+
alterations in the concentration of other ions aside from Ca , including a transient
reduction in pHj, and a subsequent increase in [Na+]j resulting from activation of the
Na+/H+ antiport (Weisman et al., 1987).
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The role of [Ca ], in priming is unclear. Although certain priming agents such as
PAF (Ingraham et al., 1982), ATP (Kuhns et al., 1988) and calcium ionophores (e.g.
ionomycin) (Finkel et al., 1987) can elicit Ca2+ mobilization, in general the increased
2+
[Ca ]j has returned to baseline well before the addition of the second activating
agonist (Grynkiewicz et al., 1985; Ward et al., 1988; Vercellotti et al., 1988;
Ingraham et al., 1982). Furthermore, PAF has been shown to prime fMLP-
2+
stimulated superoxide anion release under [Ca" ]rbuffered conditions (Gay, 1993;
Walker et al., 1991; Koenderman et al., 1989). TNFa (Yuo et al., 1989; Klein et al.,
1990; Lloyds et al., 1995) and substance P (Lloyds et al., 1993) do not mobilize Ca2+
or augment the calcium transient elicited by other agonists, and the literature
regarding the actions of LPS (Klein et al., 1990; Yee and Christou, 1993; Doerfler et
al., 1989; Forehand et al., 1989) and GM-CSF (McColl et al., 1991; Sullivan et al.,
1987) is confusing. Thus, it would appear that an elevation in [Ca2+],, although
elicited by certain priming agents, is not an essential component of neutrophil
priming.
1.7.5 Phospholipase D and Phosphatidic Acid
Phospholipase D (PLD) mediates the cleavage of phosphatidylcholine (PC) to
generate phosphatidic acid (PA) and choline. Although the activation pathway for
PLD in neutrophils is not as well understood as that of PLC, a wide variety of agents
have been shown to activate PLD in neutrophils, including PAF, fMLP, ATP, LTB4,
C5a, C3b and C3bi (Fallman et al., 1993; Thompson et al., 1991).
PA may be involved in activaton of the NADPH oxidase (Bonser et al., 1989; Morel
et al., 1991) and actin polymerization (Ha and Exton, 1993), and has also been
proposed to play a role in neutrophil priming. For example, it has been shown that
fMLP-induced respiratory burst activity in neutrophils does not require PLD
activation unless the cells have first been primed (Watson et al., 1994). In addition,
although neutrophil priming with TNFa (Bauldry et al., 1991) or GM-CSF
(Bourgoin et al., 1990) has no significant effect upon basal levels of PA, it leads to
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an increased, sustained accumulation of PA following fMLP stimulation. Since the
subsequent conversion ofPA to DAG by phosphatidate phosphohydrolase is believed
to elicit the delayed secondary phase of DAG accumulation that is observed
following fMLP stimulation (Billah et al., 1989; Truett et al., 1988), this may also
contribute to neutrophil priming (see below).
1.7.6 Diacylglycerol and Protein kinase C
Neutrophils contain multiple isoforms of the protein kinase C (PKC) family of
2+
serine-threonine kinases, the most abundant being the Ca -dependent PKCp
(Majumdar et al., 1993; Majumdar et al., 1991). PKC has been shown to translocate
to the plasma membrane within seconds of neutrophil stimulation (Christiansen,
1988). Activation of PKCa or PKC(3 results from either an increase in intracellular
DAG alone, or the synergistic action of Ca2+ and DAG (Lee and Bell, 1991). In
addition, phorbol esters (e.g. PMA) can bind directly to, and thereby activate, PKC.
PKC activation induces the phosphorylation of various neutrophil proteins, including
G-actin, myosin light chain, profilin, and p47phox: this results in the stimulation of
many neutrophil responses such as superoxide anion generation, PLD activity and
specific granule exocytosis, and the inhibition of others, including chemotaxis and
Ca2+ mobilization (Faust et al., 1995; El Benna et al., 1994; Naccache, 1985).
The use of PMA and synthetic DAG has provided evidence that PKC may play a key
role in activation of the respiratory burst (Robinson et al., 1985). The ability of sub-
activating concentrations of PMA to prime neutrophils also suggests a possible role
for PKC in neutrophil priming. PAF stimulation has been reported to increase PKC
activity in the particulate fraction of human neutrophils (Gay and Stitt, 1988a) and to
enhance that induced by fMLP or PMA (Gay and Stitt, 1988b). In addition, PKC
inhibitors (sphinganine and staurosporine) have been shown to abolish PAF-induced
priming of superoxide anion generation (Gay, 1993). However, other studies have
shown that priming induced by TNFa (Berkow and Dodson, 1988), LPS (Forehand
et al., 1989) and GM-CSF (Sullivan et al., 1987) was not associated with prior
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translocation of PKC to the neutrophil plasma membrane, and that TNFa fails to
either elicit DAG formation directly or enhance that induced by fMLP (Bauldry et
al., 1991). In contrast, GM-CSF has been reported to augment the DAG response to
fMLP (Bourgoin et al., 1990; Tyagi et al., 1989). Therefore, the contribution of
DAG and PKC to neutrophil priming may be dependent upon the particular agent
used.
1.7.7 Phosphoinositide 3-OH kinase
Phosphoinositide 3-OH kinase (PI3K) is a ubiquitous enzyme that catalyses the
conversion of PtdIns(4,5)P2 to phosphatidylinositol 3,4,5-trisphosphate
(PtdIns(3,4,5)P3). Although the majority of cells express the pi 10-p85 heterodimeric
form of PI3K, there is evidence that neutrophils and platelets contain an additional
isoform of PI3K that is not associated with the 85-kDa subunit and is activated by
py-subunits of G-proteins (Stephens et al., 1997; Stephens et al., 1994). PI3K has
been implicated in various intracellular signalling pathways (Vlahos et al., 1995),
including cytoskeletal events such as membrane ruffling (Malarkey et al., 1995).
Furthermore, the demonstration that the fungal metabolite wortmannin (a specific
and irreversible inhibitor of PI3K when used at low concentrations) can abolish the
respiratory burst elicited by fMLP or opsonised particles (Ahmed et al., 1995; Arcaro
and Wymann, 1993; Dewald et al., 1988; Baggiolini et al., 1987), has implicated
PI3K as an obligate component of the signalling pathway for superoxide anion
generation (Stephens et al., 1993a; Traynor-Kaplan et al., 1989a).
Although many neutrophil agonists have been shown to activate PI3K (Traynor-
Kaplan et al., 1989), its role in priming remains uncertain. Several priming agents,
including GM-CSF (Corey et al., 1993), PAF and ATP (Stephens et al., 1993a;
Stephens et al., 1993a), have been reported to elicit the accumulation of
PtdIns(3,4,5)P3 in neutrophils. However, whilst TNFa alone does not affect
PtdIns(3,4,5)P3 accumulation (Corey et al., 1993), recently it has been shown to
enhance the accumulation induced by fMLP (Alison Condliffe, personal
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communication). Thus, augmentation of secretagogue-induced PI3K activation may
be important in the priming of human neutrophils. Since PI3K may signal through
the small G-proteins p21ras (Rodriguez-Viciana et al., 1994) and p21rac (Hawkins et
al., 1995) this also suggests a downstream link of PI3K with the MAP kinase
pathway.
1.7.8 Phospholipase A2
Mammalian cells express two main isoforms of phospholipase A2 (PLA2), namely
cytosolic PLA2 (cPLA2) (Sharp et al., 1991) and secretory PLA2 (sPLA2) (Kramer et
al., 1989): it is the former, cytosolic isoform which is involved in the generation of
arachidonic acid (AA) and PAF (Ramesha and Pickett, 1990; Suga et al., 1990; Lin
et al., 1992) from various integral membrane phospholipids, including PC,
phosphatidylethanolamine (PE), and phosphatidylinositol (PI) (Berridge, 1985;
Berridge, 1982). The activation of cPLA2 is dependent upon both phosphorylation
2+
by MAPK-dependent and -independent pathways, and Ca -dependent translocation
to the plasma membrane (Fouda et al., 1995; Lin et al., 1992). The sPLA2 is released
extracellularly where it may play a role in membrane homeostasis, through its non¬
selective cleavage of sn-2 fatty acyl groups of outer-leaflet membrane phospholipids
(Schalkwijk et al., 1990; Dennis, 1983).
Neutrophil priming agents, including LPS (Fouda et al., 1995; Doerfler et al., 1994),
GM-CSF (Durstin et al., 1994; Gomez-Cambronero et al., 1993), and TNFa (Bass et
al., 1994), have been shown to increase the mobilization and activity of both
isoforms of PLA2 and elicit a small, but significant release of AA. It has also been
demonsrated that TNFa can increase the activity of co-enzyme A-independent
transacylase (CoAIT) which maintains the phospholipid substrate levels for PLA2
(Winkler et al., 1994). Thus, it has been proposed that the enhanced availability of
AA may contribute to the priming of subsequent responses by these agents (Durstin
and Sha'afi, 1996; McDonald et al., 1993). However, this idea has been disputed by
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the demonstration that TNFa-induced priming of superoxide anion release occurs
independently ofAA release (Ely et al., 1994).
Although AA may function as an intracellular mediator in its own right, it also forms
the main precursor for the biosynthesis of eicosanoids (prostaglandins, leukotrienes
and thromboxanes, figure 1.6). LPS has been reported to prime LTB4 release in
response to PMA, opsonised zymosan and calcium ionophore, but not to fMLP
(Doerfler et al., 1989). However, the priming of fMLP-stimulated superoxide anion
release by TNFa and GM-CSF is unaffected by the inhibition of LTB4 synthesis
(Stewart et al., 1991); thus, although the contribution of PLA2 to lipid mediator
release is unequivocal, its role in neutrophil priming is doubtful.
Various priming agents, including LPS (Stewart and Harris, 1991; Worthen et al.,
1988), TNFa (Stewart et al., 1991), GM-CSF (De Nichilo et al., 1991; Wirthmueller
et al., 1989) and PAF itself (Doebber and Wu, 1987), can increase PAF synthesis
(and its release) in response to fMLP. It should be noted however that the majority
of newly-synthesized PAF is not released but is retained within the neutrophil (Lynch
and Henson, 1986). It has been suggested that PAF may act as an additional
2+
intracellular messenger for regulating [Ca ]j levels in human neutrophils during
phagocytosis (Tool et al., 1989), and that it may also contribute to the priming effects
of LPS (Worthen et al., 1988). However, since it has been demonstrated that the
priming of fMLP-stimulated superoxide anion release by TNFa and GM-CSF is not
affected by PAF receptor blockade (using WEB 2086, a specific antagonist of both
the extracellular and the putative intracellular PAF receptor) (Stewart et al., 1991), a
role for intracellular PAF in neutrophil priming remains to be established.
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Figure 1.6
Arachidonic Acid Metabolism through Cyclo-oxygenase and 5-
Lipoxygenase Pathways.
AA = arachidonic acid, CO = cyclo-oxygenase, PG = prostaglandin, TX
= thromboxane, 5-LO = 5-lipoxygenase, 5-HPETE = 5-
hydroperoxyeicosatetraenoic acid, LT = leukotriene.
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1.7.9 Tyrosine Phosphorylation
Protein phosphorylation is an important mechanism of intracellular signalling in
virtually all cells. Although the majority of phosphorylation reactions involve serine
and threonine residues, a critical role for tyrosine phosphorylation also exists in the
regulation of a diverse array of cellular functions, including neutrophil activation.
Neutrophils express receptors with intrinsic tyrosine kinase activity (e.g. for growth
factors) as well as numerous cytosolic tyrosine kinases (e.g. members of the src and
syk family) (Taniguchi et al., 1993; Akimaru et al., 1992; Bolen et al., 1992) that
mediate the effects of agents such as LPS (English et al., 1993) and opsonised
particles (Unkeless et al., 1992). Neutrophils also contain various tyrosine
phosphatases that are responsible for the removal of phosphate residues (Tsui et al.,
1993; Fialkow et al., 1993). In view of the central role of tyrosine phosphorylation
in regulating a large number of neutrophil functions, including migration, NADPH
oxidase activation, degranulation and phagocytosis (Fuortes et al., 1993; Unkeless et
al., 1992), there has been considerable interest in characterizing the precise repertoire
of tyrosine-phosphorylated proteins within the neutrophil and determining their exact
functional roles.
The majority of neutrophil stimulants, including fMLP, PAF, TNFa, G-CSF, GM-
CSF, PMA and substance P, have been shown to induce the tyrosine phosphorylation
of a number of intracellular proteins (McColl et al., 1991; Gomez-Cambronero et al.,
1989; Ohta et al., 1992; Lloyds et al., 1995; Akimaru et al., 1992; Gomez-
Cambronero et al., 1991; Nick et al., 1997; Rollet et al., 1994). The concentration-
dependency and time-course of tyrosine phosphorylation elicited by these agents
correlates closely with their capacity to induce priming, thereby suggesting a
mechanistic role. Furthermore, a marked similarity has been observed between the
pattern of tyrosine phosphorylation produced by different priming agents, with
proteins of 39-43 kDa, 72-76 kDa and 112-120 kDa consistently being detected
(Hallett and Lloyds, 1995; Richard et al., 1994). The demonstration that tyrosine
phosphatase inhibitors (by augmenting tyrosine phosphorylation) can enhance both
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respiratory burst activity and CD1 lb/CD 18 expression of human neutrophils, whilst
tyrosine kinase inhibitors prevent these responses (Naccache et al., 1994; Lloyds and
Hallett, 1994), further implicates a role for tyrosine phosphorylation in neutrophil
priming.
The precise tyrosine kinases and target proteins involved in these events have not yet
been identified. However, the demonstration that ligation and spatial clustering of
neutrophil adhesion molecules (e.g. L-selectin and p2-integrins) is linked to both
enhancement of respiratory burst activity and the tyrosine phosphorylation and
activation of p42/44 MAPK (Waddell et al., 1995; Waddell et al., 1994; Berton et
al., 1994), suggests a possible identity for the 39-43 kDa protein mentioned above
(Hallett and Lloyds, 1995). Tyrosine phosphorylation of MAPK has also been
reported following neutrophil priming with LPS (Fouda et al., 1995) and GM-CSF
(Gomez-Cambronero et al., 1992; Okuda et al., 1992), although not with TNFa
(Waterman and Sha'afI, 1995). The MAPK cascade is a series of serine/threonine
kinases whose activity depends upon phosphorylation of both tyrosine and threonine
residues (Anderson et al., 1990). Since both MAPK and a 72-kDa protein kinase
(which may represent the 72-76 kDa protein mentioned above) have been shown to
serine phosphorylate the terminal peptide sequence of the p47phox component of
NADPH oxidase (Grinstein et al., 1993), this may implicate their involvement in the
downstream signalling events of certain priming agents. Indeed, it has been
proposed that the tyrosine phosphorylation of both these proteins is required for
Ca2+-mobilizing agonists to fully activate p47phox (Hallett and Lloyds, 1995) and
hence the respiratory burst. However, as with many of the signalling events that
result from priming agonist exposure, the task of dissecting which events are critical
to priming and which are linked to other neutrophil functions is formidable.
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1.8 Neutrophil De-priming
The high rate of constitutive apoptosis observed in cultured neutrophils in vitro and
the short circulating half-life of these cells in vivo, explains in part why most in vitro
studies have focused on the short-term effects of priming agents and the cellular
mechanisms responsible for them. The few studies that have examined the long-term
priming effects of pro-inflammatory agents, such as LPS and G-CSF, have shown
that enhanced respiratory burst capacity can be maintained for at least 24 hours, both
in cultured human and sheep peripheral blood neutrophils (Carey et al., 1994;
Ichinose et al., 1990).
A similar, sustained priming effect has been demonstrated using agitated suspension
neutrophils, although these studies have been restricted to much shorter incubation
periods. For example, it has been shown that priming of fMLP-stimulated
superoxide anion release by LPS is maintained for at least 2 hours (Guthrie et al.,
1984), whereas GM-CSF and IFN-y can augment the intracellular respiratory burst
capacity of neutrophils for at least 4 hours (Roberts et al., 1993). In view of these
findings, it has been suggested that a sustianed neutrophil priming effect might be
important in vivo, as part of the long-term inflammatory response observed with
certain agents, including endotoxin (Carey et al., 1994). Thus, neutrophil priming
has been viewed as a permanent process, whereby neutrophils are maintained in a
functionally up-regulated state for the duration of their life-span, in order to allow
optimal resolution ofwidespread or prolonged inflammatory insults.
However, it has also been shown that intravascular priming of neutrophils can
increase the magnitude of vascular injury induced by immune complexes and various
chemotactic factors (Worthen et al., 1987; Warren et al., 1989). In fact, neutrophil
priming appears to be a prerequisite for neutrophil-mediated host tissue damage
(Smedly et al., 1986). Hence, a more flexible regulation of neutrophil priming would
appear to be in the host's best interest, in keeping with the fine tuning of other
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neutrophil responses. Thus, if neutrophils primed either within the circulation or at
the endothelial surface could revert in situ to an unprimed quiescent state, then this
might represent a means of host tissue protection in the midst of an acute
inflammatory response.
Despite the potential patho-physiological, and hence therapeutic, importance of being
able to rescue neutrophils from the primed state, this area of research remains
unexplored. This may reflect the practical difficulties encountered during neutrophil
isolation, when endogenous priming by LPS yields a population of basally-primed
neutrophils (Haslett et al., 1985). Even if a pure population of totally un-primed
neutrophils could ever be obtained ex-vivo, the ubiquitous nature of environmental
LPS and the short neutrophil life-span will always confound subsequent in vitro
investigations. Hence, very few studies have addressed the issue of whether
neutrophil priming is reversible.
The few published demonstrations of apparently "reversible" priming have used
physico-chemical stimuli to manipulate the primed responses of neutrophils. For
example, hypotonic shock (Edashige et al., 1993) and cell swelling (Miyahara et al.,
1993) have been reported to induce a temporary state of neutrophil priming that is
abolished upon the restoration of isotonicity and cell size, respectively. However,
these stimuli do not represent a physiological or ideal model of reversible priming,
not least because they also induce secondary non-specific effects upon plasma
membrane structures (resulting in the disorganization of intracellular microfilaments
and an increase in cell-surface net negative charge (Miyahara et al., 1993)). It is
unlikely therefore that the reversible priming effects of physico-chemical stimuli are
mediated through cell-surface receptors or give genuine insight into the potential for
this to occur following physiological challenge. Hence, these data should be
interpreted primarily as in vitro demonstrations that neutrophils can de-prime rather
than evidence of any such potential effect in vivo. However, if a receptor-mediated
biological agent that was part of the in vivo acute inflammatory response was shown
to evoke a range of reversible functional responses in vitro, including the gold
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standard of priming for superoxide anion generation, then this would represent a far
more substantial finding.
1.9 Aims
The research for this thesis was concerned primarily with the potential for human
neutrophils to revert from a primed to a quiescent state: this concept was referred to
as de-priming.
(1) Preliminary investigations were aimed at determining optimal priming conditions
for the selected agents, InsP6, PAF and TNFa, and the establishment of a protracted
(2 hour) in vitro incubation protocol that did not result in any loss in cell viability or
priming potential.
(2) Several indices of priming were chosen, in order to encompass the range of
neutrophil functions and ensure that neutrophil de-priming represented a global
reversal of neutrophil responses rather than the specific desensitization of individual
pathways.
(3) The potential for de-primed neutrophils to be re-primed, either with a
homologous or a heterologous agonist, was determined as an evaluation of the true
reversibility of neutrophil priming.
(4) A study of the potential mechanisms of neutrophil de-priming was undertaken,
which included the manipulation of inherent priming responses with specific receptor
antagonists.
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2. CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
All reagents, unless otherwise stated in the text, were purchased from Sigma
Chemical Company (Poole, Dorset, UK) and stored according to the manufacturer's
instructions. Dextran-500 (MW 500,000) was dissolved (6% w/v) in sterile 0.9%
saline and stored at 4 °C. PAF was dissolved (10 mM) in analar ethanol and stored at
-80 °C. LPS (E. Coli serotype 0111 :B4, y-irradiated) was dissolved (1 mg/ml) in
PBS, sonicated (ultrawave sonic bath, Belmont Instruments, Glasgow, UK) and
stored at -20 °C. fMLP was dissolved (70 mg/ml) in DMSO (dimethyl sulfoxide),
made up to 1 mM in PBS, and stored at -20 °C. PMA was dissolved (1 mg/ml) in
DMSO and stored at -20 °C. Superoxide dismutase was dissolved (7500 U/ml) in
PBS and stored at -20 °C.
Human recombinant TNFa was purchased (as a 1 ml solution in PBS) from
Genzyme (Cambridge, MA) and stored at -80 °C: immediately prior to use, it was
diluted in PBS according to the individual batch activity. Mouse monoclonal
antibodies (mAb) were from various sources: anti-CDllb (44) and anti-CDl lc (3.9)
mAbs were from Serotec (Oxford, UK); anti-L-selectin mAb (Leu-8) was from
Beckton Dickinson (Oxford, UK); anti-CDl la mAb (WAC 70) was donated by Dr. J.
Ross (Dept. of Surgery, Edinburgh University); anti-TNF-R55, anti-TNF-R75, and
anti-IL-2-R a-chain mAbs were from R&D Systems (UK); anti-phosphotyrosine
(4G10) mAb was from Upstate Biotechnology Inc. (New York). FITC (fluorescein
isothiocyanate)-conjugated F(ab)2 fragments of rabbit anti-mouse immunoglobulin
were from Dako (Buckinghamshire, UK), and peroxidase-conjugated, rabbit
polyclonal, anti-mouse secondary antibody was from Amersham (UK). Optimal
antibody binding concentrations were determined by titration.
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2.2 The Isolation of Human Neutrophils from Peripheral Blood
The activation status of neutrophils can be profoundly affected during their isolation
from peripheral blood (Norgauer et al., 1991; Fearon and Collins, 1983; Haslett et
al., 1985). Both the isolation procedure itself and contamination with trace amounts
of LPS can prime neutrophils, confounding their subsequent in vitro responses. It
was therefore critical to select a method that yielded a pure population of minimally
primed neutrophils ex vivo. Two preparative methods were investigated, and the
subsequent functional responses of the isolated neutrophils were compared. Both
methods yielded neutrophils with >99.5% viability (assessed by trypan blue
exclusion) and >95% purity (assessed by examination of May-Grunwald-Giemsa-
stained cytocentrifuge preparations) (Figure 2.1), with the <5% contamination
consisting of <0.5% monocytes, 1-2% erythrocytes and 3-5% eosinophils. If >5%
eosinophils were present the cells were discarded.
2.2.1 The Isolation of Human Neutrophils using Discontinuous Plasma-Percoll
Gradients
Human neutrophils were isolated exactly as previously detailed (Haslett et al., 1985),
using sterile, LPS-free (<0.1 ng/ml LPS by fhe Chromagenix Limulus amoebocyte
lysate assay) reagents and plastic-ware (Falcon, Oxford, UK). This method has been
shown to yield neutrophils that have minimal alterations in both their priming status
(with respect to fMLP-induced superoxide anion generation) (Haslett et al., 1985)
and their resting cell morphology (<8% shape change assessed by flow-cytometry)
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Figure 2.1
Representative Cytospin Preparation of Freshly-Isolated Human Neutrophils.
100 pi of freshly isolated human neutrophils (107 cells/ml in PBS with CaCl2 and
MgCl2) were spun onto a glass slide (300g, 3 min, cytocentrifuge) and stained with
May-Grunwald-Giemsa (x400).
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Peripheral venous blood was collected from healthy adult volunteers, into 50 ml
polyethylene tubes containing 4 ml of the anticoagulant sodium citrate (3.8%,
Phoenix Pharmaceuticals Ltd., Gloucester, UK), to a total volume of 40 ml. The
blood tubes were then centrifuged (300g) for 20 min. Each supernatant of platelet-
rich plasma was carefully aspirated and either centrifuged (2500g, 20 min) to
produce platelet-poor plasma (PPP), or used to prepare autologous serum at 37 °C,
by the addition of 20 pM CaCl2. 5 ml dextran-500 (6%) was added to the remaining
cell pellets, and 0.9 % saline was added to give a final volume of 50 ml. The
contents of each tube were mixed gently and thoroughly, and left for 30-40 min to
allow erythrocyte sedimentation to occur.
The overlying, leukocyte-rich, plasma layer was aspirated and centrifuged (300g, 6
min), and the mixed leukocyte cell pellet was resuspended in 2 ml PPP and
transferred to a 15 ml polystyrene tube. The leukocytes from two 50 ml tubes of
blood could be used for each gradient. A stock solution of 90 % v/v Percoll was
prepared in 0.9% saline, and was used to prepare fresh density gradients of 42% and
51% Percoll in PPP. The accurate preparation of the 51% Percoll step was critical
for the complete separation of neutrophils from erythrocytes. The resuspended cell
pellet was then underlayered sequentially with 2 ml of each of the 42% and 51%
Percoll gradients, and centrifuged (275g, 10 min). Polymorphonuclear cells were
harvested from a wide band at the interface of the 42% and 51% Percoll layers.
Mononuclear cells remained in a thinner band at the top, PPP/42% Percoll, interface
and erythrocytes pelleted at the bottom of the tube. The purified neutrophils were
washed sequentially in PPP (500g, 6 min), PBS without, and PBS with CaCl2 and
MgCl2 (endotoxin-free, pH 7.4, 300g, 6 min). Cell concentrations were adjusted
according to haemocytometer counts.
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2.2.2 The Isolation of Human Neutrophils using Discontinuous PBS-Percoll
Gradients
A second neutrophil isolation procedure, using PBS-Percoll gradients (Dooley et al.,
1982), was compared with the plasma-Percoll method. The initial part of the
separation procedures were identical, but diverged following aspiration of the
leukocyte-rich plasma layer. An isotonic stock solution of 90% v/v Percoll was
made with lOx PBS. The mixed leukocyte cell pellet was resuspended in 2.5 ml
55% Percoll in PBS, and transferred to a 15 ml polystyrene tube. Density gradients
of 70% and 81% Percoll in PBS were prepared, and 2.5 ml of each was used to
sequentially underlayer the resuspended cell pellet. The gradients were centrifuged
(700g, 20 min), and polymorphonuclear cells were collected from the 70%/81%
Percoll interface. Mononuclear cells remained at the top 55%/70% Percoll interface,
and erythrocytes pelleted at the bottom of the tube. The purified neutrophils were
washed sequentially in PBS without plus PPP, PBS without, and PBS with CaCl2 and
MgCl2 (300g, 6 min). Cell concentrations were adjusted as above, according to
haemocytometer counts.
2.2.3 The Comparison of Neutrophil Isolation Procedures
The activation status of neutrophils isolated by the two outlined methods was
compared, using parallel assays of respiratory burst activity (cytochrome C
reduction, lucigenin-dependent chemiluminescence, dihydrorhodamine 123
oxidation), shape change, and adhesion molecule expression (see below for
Methods). There was no significant difference between neutrophils isolated by the
two different methods (Figure 2.2), in: (i) the resting cell morphology; (ii) the basal
expression of L-selectin or CD lib; (iii) the basal or fMLP-induced intracellular
respiratory burst activity (measured by the oxidation of dihydrorhodamine 123).
However, superoxide anion release (measured by the reduction of cytochrome C or
lucigenin-dependent chemiluminescence) appeared to be a much more sensitive
indicator of neutrophil activation status. A significant increase in fMTP-stimulated
superoxide anion release, the "gold standard" indicator of neutrophil priming, was
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observed with neutrophils isolated by the PBS-Percoll method (Figure 2.3). Since
this indicated that a small degree of endogenous neutrophil priming had occurred
during this isolation procedure, the plasma-Percoll method was selected for all
further investigations.
2.3 The Assessment of Respiratory Burst Activity in Human Neutrophils
Neutrophil priming was originally defined as an enhancement of respiratory burst
activity. It can be quantified by measuring several different parameters of NADPPI
oxidase activity: (i) an increase in oxygen consumption; (ii) superoxide anion
generation; (iii) hydrogen peroxide production; and (iv) the overall, intracellular
respiratory burst activity. Of these, the enhancement of fMLP-stimulated superoxide
anion release has been viewed as the gold standard indicator of neutrophil priming.
The generation of superoxide anions is the initial step of the neutrophil respiratory
burst, where oxygen is converted to reactive oxygen species. During phagocytosis,
the bulk of these anions is released from neutrophils into the extracellular milieu.
Therefore, the measurement of extracellular superoxide anion release correlates
directly with the neutrophil's total microbicidal potential. Furthermore, it can be





Comparison of Freshly-Isolated Human Neutrophils Prepared by Discontinuous
Plasma-Percoll or PBS-Percoll Gradients.
Neutrophils (from the same donor) were isolated in parallel by either plasma-Percoll
or PBS-Percoll gradients and resuspended in PBS (107 cells/ml). Parallel assays of:
(a) shape change (EPICS flow cytometry, see 2.4.2); (b) expression of L-selectin and
CDllb (see 2.5.1); and (c) intracellular respiratory burst activity (DHR oxidation,






























































Comparison of Superoxide Responses of Freshly-Isolated Human Neutrophils
Prepared by Discontinuous Plasma-Percoll or PBS-Percoll Gradients.
Neutrophils (from the same donors as fig. 2.2) were isolated in parallel by either
plasma-Percoll or PBS-Percoll gradients and resuspended in PBS (107 cells/ml).
Superoxide anion responses of buffer-treated control neutrophils and neutrophils
stimulated with 100 nM fMLP were then assessed in parallel assays of: (a)
cytochrome C reduction (see 2.3.1, values represent mean ± SEM for triplicate
determinations from the 3 donors in figure 2.2); and (b) lucigenin-dependent
chemiluminescence (see 2.3.2, histograms from a single donor representative of 3).
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2.3.1 The Measurement of Superoxide Anion Generation using Cytochrome C
Cytochrome C is an electron-accepting compound that can be reduced by superoxide
anions, giving an increase in absorbance at 550 nm which can be detected with a
spectrophotometer. However, cytochrome C reduction is not specific for superoxide
anions, therefore superoxide dismutase (a superoxide-specific enzyme) must be
included in parallel samples to reveal the amount of residual oxidation by other
respiratory burst products. The superoxide dismutase-inhibitable reduction of
cytochrome C is a very sensitive and well established assay of cumulative superoxide
anion release from neutrophils (Haslett et al., 1985; Guthrie et al., 1984; Babior et
al., 1973).
Neutrophils, isolated by the plasma-Percoll method above, were resuspended
immediately in PBS with CaCl2 and MgCl2. Aliquots of 1 x 106 neutrophils (70-90
pi) were transferred to 2 ml sterile, polypropylene Eppendorf tubes, and allowed to
equilibrate at 37°C, upon gentle shaking (110 cycles/min) in a water-bath (Haake) for
approximately 5 min. Neutrophil priming was initiated by adding a 10 pi aliquot of
the appropriate priming agent or buffer control and incubating the neutrophils for the
specified time period. A volume of 800 pi pre-warmed cytochrome C (horse heart
preparation, final concentration 1 mg/ml in PBS with CaCl2 and MgCl2) was then
added, followed immediately by 100 pi fMLP (final concentration lOOnM), PMA
(final concentration 100 ng/ml) or buffer control, to give a final incubation volume of
1.0 ml. One of each set of quadruplicate samples included 375 U superoxide
dismutase. Incubations were continued in the shaking water-bath for a further 10
min (fMLP) or 60 min (PMA), whereupon samples were placed on ice to terminate
the reaction.
The cells were removed by centrifugation (12,000g, 2 min, 4°C) and supernatants
were transferred to 1.5 ml spectrophotometer cuvettes with a standard light path of 1
cm. The optical density of each supernatant was quantified at a wavelength of 550
nm (OD550) using a Pye-Unicam 8700 spectrophotometer that scanned between 535-
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565 nM, with the baseline provided by 1 mg/ml cytochrome C. The reduction of
cytochrome C was determined for each sample, using the extinction coefficient AE550
= 21.0 x 10 /M/cm (Massey, 1959), for the absorption of reduced minus oxidized
cytochrome C. For a sample volume of 1 ml and a light path of 1 cm, the observed
OD550 was multiplied by 47.6, as 1 mol superoxide anions reduces 1 mol cytochrome
C: upon subtraction of corresponding superoxide dismutase-inhibited samples, this
yielded the nmols superoxide anions generated per 106 neutrophils.
2.3.2 The Measurement of Superoxide Anion Generation using Lucigenin-
Dependent Chemiluminescence (LDCL)
Chemiluminescence (CL) allows kinetic analysis of the respiratory burst activity of
neutrophils. Oxygen radicals that are produced during the respiratory burst can react
with, and thus excite, biological substrates, which then relax to their ground state by
photon emission. This energy release is in the form of light, which can be amplified
by chemiluminescent probes (Allen and Loose, 1976) and measured in a
luminometer. Lucigenin is such a chemiluminescent probe, being an acridinium salt
which reacts specifically with superoxide anions (Williams and Cole, 1981) to
produce electronically-excited N-methylacridone. Lucigenin-dependent CL (LDCL)
therefore provides a rapid and convenient assay of the kinetics of superoxide anion
generation, whilst, at the same time, allowing a quantification of the cumulative
superoxide anion response that can be compared with that obtained by cytochrome C
reduction.
Freshly prepared lucigenin (bis-7V-methylacridinium nitrate, 0.25 mM in 100 pi PBS
containing 1 mg/ml BSA) was added to individual wells of white polystyrene
microtitre plates (Dynatech Laboratories, Billinghurst, U.K.) and allowed to
thermally equilibrate for approximately 30 min at 37°C. It has previously been
shown that both the rate of onset and the peak height of the neutrophil CL response is
dependent upon the cell concentration (Blair et al., 1988), with 1 x 106 neutrophils
per 250 pi well (of a 96-well plate) being sufficient for rapid kinetic analysis of
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superoxide anion release. Therefore, 1 x 106 neutrophils (70 pi in PBS with CaCl2
and MgCl2) were transferred into 2 ml sterile Eppendorf tubes and equilibrated at
37°C in a shaking water-bath. Quadruplicate samples were incubated for the
required time-period with a 10 pi volume of priming agent or buffer control.
Neutrophils were then transferred into the pre-warmed, lucigenin-containing
microtitre plates, with control wells of lucigenin alone or lucigenin plus neutrophils
(made up to 180 pi with PBS). Neutrophils were immediately treated with 20 pi
fMLP (final concentration 100 nM) or buffer, and loaded into a shaking, ML 3000
luminometer (Dynatech Laboratories Ltd., Billinghurst, UK) pre-heated to 37°C.
Chemiluminescence activity (relative light units, RLU) was recorded at 17 s
intervals, and subsequent analysis (Cellular Chemiluminescence, Dynatech
Laboratories Ltd.) allowed the peak height and cumulative CL activity (area under
the curve) to be determined from individual wells (Figure 2.4a).
2.3.3 The Correlation of Chemiluminescence Values: Peak Height versus Area
Under Curve
Previous reports have used several, different parameters to describe the CL response,
including (i) the maximum rate of increase in CL, (ii) the time to peak, (iii) the peak
height, and (ii) the integrated area under the curve. Since the area under the curve
provides a measure of the cumulative CL activity whilst encompassing both the rate
of increase in CL and the peak height, it is considered the most useful parameter for
inter-assay comparisons (Blair et al., 1988). However, the CL responses of
neutrophils treated under different conditions have been shown to differ markedly,
ranging from a rapid, well-defined peak (e.g. with fMLP (Bender and Van Epps,
1983; Stocks et al., 1995)) to a sustained plateau (e.g. with PMA (Schult et al.,
1985)). Therefore, we compared the peak height and integrated area values for
neutrophils treated under a variety of assay conditions (Figure 2.4b): a direct
correlation (y = 40.24x + 0.78, r = 0.78) was found between these two parameters, in



















Assessment of Superoxide Anion Generation by Lucigenin-dependent
Chemiluminescence.
Neutrophils were incubated with PAF (1 pM, 10 min) or buffer, prior to treatment
with fMLP (100 nM) or buffer in the presence of lucigenin (25 mM plus 1 mg/ml
BSA). Kinetic chemiluminescence activity (relative light units, RLU) was then
assessed, (a) Representative chemiluminescence data for neutrophils treated with
100 nM fMLP. (b) Correlation of peak height and area under curve values for
cumulative data.
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2.3.4 The Measurement of Intracellular Respiratory Burst Activity using
Dihydrorhodamine 123 (DHR)
The chemiluminescence and cytochrome C reduction assays both provide a measure
of the cumulative respiratory burst activity of the total neutrophil population.
However, these assays give no quantitative information about the actual responses of
individual cells. Since neutrophils are not a homogeneous cell population, but exist
as functionally distinct sub-populations (Daniels et al., 1994; Klempner and Gallin,
1978), one cannot assume that all cells are behaving identically. Even within a
homogeneous sub-population, a sub-optimal concentration of a stimulus could cause
a graded response, with partial activation of all cells, or cause an "all-or-nothing"
response, with activation of some cells and no effect on others (Daniels et al., 1994;
Bass et al., 1983). Dihydrorhodamine 123 (DHR) is a non-fluorescent, membrane-
permeable, cytometric probe (Kinsey et al., 1987), that is taken up by phagocytes,
and oxidized during the respiratory burst into the green-fluorescent, rhodamine 123
(Emmendorffer et al., 1990). It has thus been used as a sensitive measure of
intracellular respiratory burst activity (Rothe et al., 1991; Royall and Ischiropoulos,
1993; Emmendorffer et al., 1990). Flow-cytometric analysis allows the
quantification of respiratory burst activity at the single cell level, as well as the
percentage of neutrophils within each subpopulation.
Since DHR can be rapidly oxidized in air, preliminary experiments assessed the
intra-assay stability of DHR. Neutrophils (1 x 106 in PBS with CaCl2 and MgCl2)
were transferred in duplicate 90 pi aliquots to sterile 2 ml Eppendorf tubes, and
allowed to thermally equilibrate in a shaking water-bath at 37°C. A stock solution of
DHR (final assay concentration 1 pM) was freshly prepared in PBS, and warmed to
37 °C. A 700 pi volume of PBS with either 50 pi DHR or buffer control was then
added to the neutrophils, followed immediately by 10 pi priming agent or buffer for
the appropriate time period. A 50 pi aliquot of DHR was then added to those
samples that had been incubating with buffer alone, with the same volume of buffer
added to those already containing DHR. Neutrophils were incubated with 100 pi
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fMLP (final concentration 100 nM) or buffer for 10 min, whereupon the reaction was
stopped by placing the cells on ice.
The cell-associated green fluorescence of 5000 neutrophils per sample was analyzed
immediately, using an EPICS Profile II flow cytometer (Coulter Electronics, Luton,
UK). The log fluorescence intensity (LFL) was plotted against neutrophil number,
allowing the percentage of neutrophils within each sub-population to be determined
(Figure 2.5). However, in the vast majority of samples, a single neutrophil
population was observed and, therefore, the mean LFL was taken as a direct
measurement ofDHR oxidation and, hence, of the mean respiratory burst activity per
neutrophil.
Preliminary investigations demonstrated a direct relationship between the duration of
the DHR incubation with neutrophils and the LFL value (Figure 2.6). Thus, in order




Assessment of Intracellular Respiratory Burst Activity by Dihydrorhodamine
123.
Representative flow-cytometry (EPICS Profile II) histogram showing distinct
neutrophil sub-populations (gated as A, B and C) following treatment with TNFa
(200 U/ml, 30 min) then fMLP (50 nM, 10 min), in the presence of 1 pM DHR (x-





Dependence of Log Fluorescence Values on the Dihydrorhodamine 123
Incubation Time with Human Neutrophils.
Neutrophils were incubated with PBS alone or PBS containing DHR (final
concentration 1 pM, black outlines), followed immediately by buffer (A and C) or
PAF (1 pM, B and D) for 10 min. DHR was then added to the remaining samples
(light grey outlines) prior to a 10 min treatment with buffer (A and B) or 100 nM
fMLP (C and D). Samples were analyzed by flow cytometry (x-axis shows
logarithmic scale green fluorescence (LFL) and y-axis shows relative cell number).
Representative flow-cytometry (EPICS Profile II) histograms (n = 3 in triplicate).
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2.3.5 The Correlation Between Assays of Neutrophil Respiratory Burst Activity
Although LDCL, cytochrome C reduction, and DHR oxidation have been used to
measure respiratory burst activity, the inter-relationships between these assays have
not been established. Thus, parallel experiments were performed with human
neutrophils under a variety of incubation conditions (106 neutrophils/ml treated with
PAF (1 pM, 10 min), TNFa (200 U/ml, 30 min) or appropriate buffer controls,
followed by incubation with fMLP (100 nM, 10 min), PMA (100 ng/ml, 60 min), or
buffer), and respiratory burst activity was assessed by the three different methods
detailed above. Although a direct, linear relationship (y = 0.57x + 0.34, r = 0.62)
was shown between the LDCL (area under curve) and cytochrome C reduction
methods of assessment, which have both been used to specifically measure
superoxide anion generation (Haslett et al., 1985; Babior et al., 1973; Williams and
Cole, 1981), this association was relatively weak (Figure 2.7a) and did not appear to
depend on the stimulus used (individual data not shown). Since the cytochrome C
reduction assay was able to detect lower levels of neutrophil priming than LDCL, it
was used for all further experiments.
A direct, non-linear, correlation (y = 0.57x140) was demonstrated between the
measurement of cytochrome C reduction and the oxidation of DHR (Figure 2.7b), as
reported previously for opsonized zymosan-stimulated neutrophils (Smith and
Weidemann, 1993). Since DHR is a measure of intracellular oxidant production,
including H202 (Royall and Ischiropoulos, 1993; Rothe et al., 1991), it was used








Correlation of Assays for Neutrophil Respiratory Burst Activity.
(a) Correlation between chemiluminescence (area under curve) and cytochrome C
reduction values for parallel samples, (b) Correlation between DHR oxidation (log
fluorescence, LFL) and cytochrome C reduction values for parallel samples.
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2.4 The Assessment ofNeutrophil Shape Change
Although the enhancement of respiratory burst activity has been viewed as the gold
standard indicator of neutrophil priming, it may be accompanied by changes in other
important neutrophil responses. Thus, a biological mediator may act as a priming
agent, having no effect alone, but being able to enhance a subsequent response to a
secretagogue agonist (e.g. respiratory burst activity), whilst simultaneously acting to
directly activate other responses (e.g. shape change, aggregation, adhesion molecule
up-regulation). One of the earliest responses that can be observed when a neutrophil
is primed is the extrusion of pseudopodia from an otherwise spherical cell: this shape
change has been shown to be a very sensitive indicator of priming (Haslett et al.,
1985).
Freshly-isolated neutrophils (1 x 106 in 90 pi PBS with CaCl2 and MgCl2) were
allowed to equilibrate in 2 ml Eppendorf tubes, in a shaking water-bath at 37°C.
Agonists or corresponding buffer controls were added in a 10 pi volume to duplicate
samples, and incubated with neutrophils for the appropriate time-periods.
Neutrophils were subsequently fixed by the addition of 1 ml glutaraldehyde (final
concentration 2.5% in PBS) and assessed by either light microscopy or flow
cytometry.
2.4.1 The Light-Microscopic Evaluation of Neutrophil Shape Change
Microscopic quantification of shape change has been shown to correlate with
chemotaxis measured using Boyden chambers (Haston and Shields, 1985).
Glutaraldehyde-fixed neutrophils were assessed visually by phase-contrast light
microscopy (Figure 2.8). Shape change was defined as the percentage of neutrophils
that extruded more than one pseudopodia, and was calculated for a minimum of 300


























Assessment ofNeutrophil Shape Change by Polarizing Light-Microscopy.
Representative photographs of neutrophils incubated for 10 min with (A) buffer or
(B) 100 nM fMLP, as seen by polarizing light microscopy (courtesy of Dr. Jiamin
Qu, Babraham Institute, Cambridge).
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2.4.2 The Flow-Cytometric Evaluation of Neutrophil Shape Change
Neutrophils that are defined as shape-changed by light microscopy have been shown
to cause a greater scatter of oncoming light than spherical cells (Keller et al., 1995;
Cole et al., 1995). This increased forward light scatter is the basis of a rapid and
objective assay of shape change, which avoids the potential observer bias of light
microscopy.
The mean forward light scatter (FS) of 5000 cells per sample was determined using
an EPICS Profile II flow cytometer. The non-shape changed (spherical) neutrophil
population was determined from control samples and was gated out as previously
detailed (Cole et al., 1995), allowing the remaining, shape-changed neutrophils to be
quantified as a percentage of the total neutrophil population (Figure 2.9a).
2.4.3 The Correlation Between Assays of Shape Change
The values obtained by flow-cytometric assessment of neutrophil morphology (%
shape change) showed a direct, but non-linear, correlation (y = 6.79x° ~8) with those
derived by light-microscopic evaluation (Figure 2.9b). However, the flow-
cytometric method tended to slightly overestimate (by approximately 6%) the extent
of basal shape change, and slightly underestimate (by 3%) the maximal shape
change, when compared with the microscopic assessment of cell morphology. These
findings are similar to a previous report, where flow-cytometric quantification of the
shape change induced by various chemotactic factors tended to overestimate basal
shape change by 8%, and underestimate maximal shape change by 5% (Cole et al..
1995). Despite these small differences of quantification at the two extremes of
neutrophil shape change, the flow-cytometric method of analysis provided a more
convenient and objective measure of shape change than light microscopy, and was
thus preferred when large numbers of samples were generated.
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2.5 The Assessment of Neutrophil Adhesion Molecule Expression and
Activation
Neutrophil priming agents can regulate the expression of a variety of plasma
membrane glycoproteins, including the leukocyte adhesion molecules CDllb/CD18
and L-selectin (Borregaard et al., 1994). However, CDllb/CD18 can exist in an
inactive form at the cell surface, therefore its expression may not necessarily
correlate with its functional activity. Indeed, priming agents can differentially
regulate the expression and function of neutrophil adhesion molecules (Condliffe et
al., 1996). Therefore, both the expression of neutrophil adhesion molecules and the
functional capacity ofCD1 lb/CD 18 were taken as further indices of priming.
2.5.1 The Analysis of Adhesion Molecule Expression by Flow Cytometry
The surface expression of neutrophil adhesion molecules was quantified by indirect
immunofluorescence, as previously detailed (Dransfield et al., 1992). Purified
neutrophils (4 x 106 in 900 pi PBS with CaCh and MgCh plus 25 mM HEPES) were
incubated at 37 °C in 2 ml Eppendorf tubes, with 100 pi priming agent or buffer






Assessment of Neutrophil Shape Change by Flow-Cytometry.
(a) Representative flow-cytometry (EPICS Profile II) histogram showing neutrophils
incubated with TNFa (50 U/ml. 30 min. black outline) and control neutrophils (light
grey outline) (x-axis shows mean forward light scatter (FS) and y-axis shows relative
cell number). Percent shape change was calculated by gating out the population of
non-shape changed neutrophils determined from control samples, (b) Correlation
between the light-microscopic and flow-cytometric evaluation of percentage shape
change for parallel samples.
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A 50 jul aliquot of these neutrophils (2 x 103) was resuspended in 25 pi saturating
concentrations of the specified monoclonal antibody, in respective wells of a 96-
flexiwell plate, and incubated for 30 min (4 °C). The neutrophils were subsequently
washed three times (lOOOg, 60 s, 4 °C) in PBS containing 0.2 % BSA and 0.1 %
sodium azide, prior to a further 30 min incubation (4°C) with 25 pi FITC-conjugated,
goat, anti-mouse immunoglobulin (diluted 1:25 in PBS/BSA/azide), and washed
again. Neutrophils (5000 cells per sample) were analyzed immediately using an
EPICS Profile II flow cytometer, with fluorescence values recorded on a logarithmic
scale (LFL). The mean LFL value was used as a direct measurement of adhesion
molecule expression.
2.5.2 The Analysis of CDllb Activation by Albumin-Coated Latex Bead
(ACLB) Binding
The functional capacity of plasma-membrane CD1 lb/CD 18 was determined by flow
cytometry, upon the binding of fluorescent, albumin-coated latex beads (ACLB)
(Stocks et al., 1995). Fluorescent latex beads (2.5% v/v stock solution, Polysciences
Inc, Warrington, PA) were washed three times in PBS, resuspended (2.5% v/v) in
human serum albumin (10 mg/ml in PBS) for 10 min at 25°C, then washed (3x) prior
to resuspension (0.75% v/v) in PBS.
Aliquots of freshly isolated neutrophils (1.75 x 106 in 175 pi PBS with CaCl2 and
MgCl2) were thermally equilibrated in sterile 2 ml Eppendorf tubes in a shaking
water-bath at 37°C, then incubated with 25 pi priming agent or buffer control for the
specified time period. Fifteen minutes before the termination of each reaction, a 25
pi aliquot ofACLB (0.75% v/v solution) was added to each tube; for time-points less
than 15 min, the beads were added before the agonist. Reactions were stopped by the
addition of 0.5 ml glutaraldehyde fixative (0.5%), then neutrophils were
subsequently left for 30 min at 25 °C. Non-adherent ACLB were removed by three
washes in PBS.
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The log green fluorescence (LFL) of neutrophils (5000 cells per sample) was
determined using an EPICS Profile II flow cytometer. Since the LFL value is
directly proportional to the number of ACLB bound, distinct neutrophil sub-
populations could be distinguished with increasing numbers ofACLB: the number of
neutrophils with one or more attached ACLB was calculated as a percentage of the




Assessment ofCDllb Activation by Albumin-coated Latex Bead Binding.
Representative flow-cytometry (EPICS Profile II) histogram showing ACLB binding
to neutrophils following treatment with PAF (1 pM, 10 min, black outline) or buffer
control (light grey outline) (x-axis shows logarithmic scale green fluorescence (LFL)
and y-axis shows relative cell number). The percentage of neutrophils with attached
ACLB was calculated by gating out the far left peak determined from control
samples.
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2.6 Immunoblotting of Phosphorvlated Tyrosine Residues in Human
Neutrophils
2.6.1 Extraction of Proteins from Human Neutrophils using TCA
Freshly-isolated neutrophils were resuspended in PBS with CaCl2 and MgCl2.
Aliquots of 4 x 106 neutrophils (360 pi) were transferred to 2 ml sterile,
polypropylene Eppendorf tubes, and allowed to equilibrate at 37°C, upon gentle
shaking (110 cycles/min) in a water-bath (Haake, Sweden) for approximately 5 min.
Neutrophils were then treated with a 40 pi aliquot of PAF (1 pM, 10 min or 120
min), TNFa (100 U/ml, 30 min or 120 min) or buffer control (10 min, 30 min or 120
min). Reactions were stopped at the appropriate times by the addition of 1.6 ml ice-
cold FIEPES (20 mM)-buffered saline containing protease inhibitors (50 pg/ml
leupeptin, 20 pg/ml aprotinin, and 1 mM AEBSF) (HBSI), and neutrophils were
collected by centrifugation (7,500g, 1 min, 4 °C).
Cell pellets were then immediately resuspended in 0.5 ml HBSI plus 0.5ml 20%
TCA, vortexed, and incubated at 4 °C for 10 min. TCA extracts were sedimented
(10,000g, 10 min, 4 °C), and lipids were extracted by resuspension in 1 ml ice-cold
ethanol. Following sedimentation (10,000g, 10 min, 4 °C), protein extracts were
washed in 1 ml d.d. H20 (10,000g, 10 min, 4 °C), taken up in 10 pi d.d. H20,
resuspended in 190 pi boiling (2x)-Laemmli sample buffer (LSB: 0.125 M TRIS-
HC1, 4% SDS, 20% glycerol, 2.5 mM dithiothreitol, 0.01% bromophenol blue, 50
pg/ml leupeptin, 20 pg/ml aprotinin, and 1 mM AEBSF, pH 6.8) and boiled for 5
min in a heated water-bath (Grant, UK). Cooled samples were then incubated with
10 mM iodoacetamide for 20 min (25 °C), centrifuged (14,000g, 5 min, 25 °C), and
supernatants were stored at 4 °C prior to analysis.
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2.6.2 Extraction of Proteins from Human Neutrophils using Laemmli Sample
Buffer
As an alternative method of protein extraction, the cell pellets (obtained after
termination of the priming incubation and centrifugation in HBSI) were taken up in
25 pi HBSI, immediately resuspended in 175 pi boiling LSB, vortexed, and boiled
for 20 min. Following centrifugation (14,000g, 5 min, 25 °C), supernatants were
again stored at 4 °C.
2.6.3 Separation of Protein Extracts by Polyacrylamide Gel Electrophoresis
(PAGE) and Electroblotting onto Nitrocellulose Membranes
20 pi of each sample and 20 pi pre-boiled (5 min, 100 °C) molecular weight markers
(Rainbow markers, Biorad, CA) were loaded into individual lanes of a pre-cast 4-
20% TRIS-glycine polyacrylamide gel (Biorad, CA). PAGE was then conducted
(Mini Protean II apparatus, Biorad, CA) in Running Buffer (1.5 M TRIS base, 0.5%
SDS, pH 8.8) at 30 mA constant current for approximately 2 hours. Parallel gels
were either: (i) stained for total protein content with Coomassie Brilliant Blue
(0.25% plus 10% glacial acetic acid) for 4 hours, followed by 4x 4 hour washes in
40% methanol/10% glacial acetic acid; or (ii) used for protein transfer onto
nitrocellulose membranes (Hybond C, Amersham, UK) (400 mA, 4 hours), using
Mini Protean II transfer apparatus, Biorad, CA) filled with Transfer Buffer (5 mM
TRIS base, 5 mM glycine, 0.01% SDS).
Comparison of Coomassie-stained gels showed that TCA-extracted samples
contained greater numbers of prominent protein bands than samples extracted by the
boiling LSB method (Figure 2.11). Therefore, the TCA extraction protocol was
selected for all further studies.
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Figure 2.11
Comparison of TCA and SDS Methods ofNeutrophil Protein Extraction.
Human neutrophils were incubated with buffer for 10 min. Reactions were stopped
at the appropriate times with 20% TCA or boiling LSB (see text). Representative
Coomassie Brilliant Blue-stained PAGE gel (n = 3). Biorad Rainbow markers.
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2.6.4 Detection ofTyrosine Phosphorylated Proteins
Following protein transfer to nitrocellulose membranes, non-specific sites were
blocked overnight in 50 ml Blocking Buffer (150 mM NaCl, 20 mM TRIS-HC1,
0.02% Tween-20, 5% powdered fat-free milk (Marvel), pH 7.4), on a rocking
platform at 4 °C. Membranes were then incubated at 25 °C for 2 hours, in 50 ml
Blocking Buffer containing mouse monoclonal, anti-phosphotyrosine antibody
(4G10 1:5000, Upstate Biotechnology Inc., New York). This was followed by three
sequential washes (30 min, 25 °C) in Blocking Buffer, incubation for 2 hours with a
peroxidase-conjugated, rabbit polyclonal, anti-mouse, secondary antibody (1:5000,
Amersham, UK) in Blocking Buffer, and a further three washes in Blocking Buffer
alone. Immuno-labelled tyrosine-phosphorylated proteins were then detected by
enhanced chemiluminescence (ECU, Amersham, UK) and exposure to photographic
film (20 sec, Kodak XAR).
2.7 Statistical Analysis of Data
All values are expressed as means ± S.E.M. of (n) separate experiments. Values,
where applicable, were compared by ANOVA or two-tailed Students' t-test for
paired data, with p<0.05 considered to be significant. Significant differences
between experimental conditions were determined by the Newman-Keuls procedure.
Where relationships between different assays were found to be linear, the squares of
the Pearson correlation coefficient (r) are given: for non-linear correlations,
mathematical models were generated (Cricket Graph III, Computer Associates Inc.,
USA).
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3. CHAPTER 3: CHARACTERIZATION OF THE FUNCTIONAL
EFFECTS AND BINDING PROPERTIES OF INOSITOL
HEXAKISPHOSPHATE IN HUMAN NEUTROPHILS
3.1 Introduction
Inositol hexakisphosphate (InsP6) (Figure 3.1) is a ubiquitous, cytosolic molecule,
which has been reported to have effects upon human neutrophils in vitro that are not
seen with other inositol polyphosphates (Eggleton et al., 1991). This study showed
that InsP6 (250 pM) had no effect on basal respiratory burst activity, but could prime
the fMLP-induced superoxide anion response after an optimal 30 s pre-incubation
period: this priming effect was transient, being diminished by approximately 40%
after 5 min. In a subsequent study, InsP6 (100 pM) was shown to increase the
assembly of cytoskeletal F-actin after an optimal 5 min incubation period (Crawford
and Eggleton, 1992), an effect which also underwent a significant reduction by 10
min.
Since InsP6 is abundant in mammalian cells, being present at concentrations of up to
1 mM (Szwergold et al., 1987), it was postulated that InsP6 might play an important
proinflammatory role in vivo upon its release from necrotic cells within an
inflammatory focus (Eggleton et al., 1991). This role as an extracellular mediator
would require specific cell-surface receptors, through which InsP6 could mediate its
functional effects. Specific [3H]-InsP6 binding sites have been identified in
membranes derived from various mammalian tissues, including: rat cerebellum
(Hawkins et al., 1990); rat heart (Rowley et al., 1996); bovine adrenal chromaffin
cells (Regunathan et al., 1992); rat anterior pituitary and cerebral cortex (Nicoletti et
al., 1990). Furthermore, the InsP6 receptor from rat cerebellum has been identified as








The Molecular Structure of InsP6.
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The primary aim of the work in this chapter was to re-examine the transient nature of
InsP6-mediated priming effects in human neutrophils, in an attempt to initially
confirm the findings of Eggleton and colleagues and, thereafter, establish a model
with which to investigate the potential reversibility of neutrophil priming. The
receptor-dependence of the InsP6-mediated priming effect was also addressed.
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3.2 Methods
3.2.1 The Buffering of InsP6 Solutions
InsP6 possesses six, negatively-charged, phosphate groups (figure 3.1), making it
both a powerful Ca2+-chelator (Cosgrove, 1980), and an acid when in solution (InsP6
is also known as phytic acid). Therefore, it was essential to select a buffer that could
prevent pH fluctuations in vitro. Of the 5 buffers tested (Figure 3.2), PBS with Ca2+
and Mg2+ plus 25 mM HEPES was chosen because: (i) it produced a stable
physiological pEl for InsP6 concentrations <100 pM; (ii) it contains Ca2+ and Mg2+,
which are required for respiratory burst activation and shape change of neutrophils;
and (iii) it is colourless and therefore does not interfere with the spectrophotometric
cytochrome C reduction assay for superoxide anion generation.
3.2.2 The Priming of Neutrophils by Hypotonic Shock
To examine the priming effects of a hypotonic challenge, neutrophils (1 x 106 in 250
pi PBS with CaCl2 and MgCl2) were equilibrated at 37 °C and incubated for 19 min
in 730 pi PBS containing cytochrome C (1 mg/ml), with either 150 mM NaCl
(isotonic incubations) or 50 mM NaCl (hypotonic incubations). Neutrophils were
then treated for 1 min with 20 pi of 5 M NaCl (to reverse hypotonicity to isotonicity)
or PBS (to retain hypotonicity or isotonicity), prior to stimulation with 10 pi fMLP
(final concentration 100 nM). One sample of each set of triplicates included 375 U
superoxide dismutase. At the end of the incubation, samples were placed on ice, and
the cells removed by centrifugation (12,000g, 2 min, 4 °C). Supernatants were then
transferred to 1.5 ml spectrophotometer cuvettes and superoxide anion generation
was calculated as detailed in the Methods Chapter (2.3.1).
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Figure 3.2
pH Profiles of Buffers containing InsP6.
InsP6 (0.1 nM-1 mM) was dissolved in the following buffers: (a) HBSS plus Ca2" and
Mg2+ (closed diamonds); NKET buffer (light squares); HBSS with Ca2+ and Mg2+
plus 25 mM HEPES (open diamonds); (b) PBS with Ca2^ and Mg2+ plus 25 mM
HEPES (closed circles); PBS with Ca2" and Mg2+ plus 25 mM MOPS (open circles).
The pH of each solution was determined using an Orion pH meter (Boston, USA)
(n = 3).
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3.2.3 [3H]InsP6 Binding to Cell Membranes
[3H]InsP6 binding to human neutrophil and rat cerebellar membranes was performed
as previously described (Hawkins et al., 1990). All procedures were carried out at 4
°C, unless otherwise stated. Briefly, freshly isolated rat cerebella or human
neutrophils (15 x 106/ml) were resuspended in 20 volumes of 20 mM NaCl, 100 mM
KC1, 5 mM EDTA, 20 mM TRIS pH 7.7 (NKET buffer), and homogenized (3x 10s
bursts in a Polytron homogenizer, set on maximum). The membrane suspensions
were centrifuged (35,000g, 30 min) and the resulting membrane pellets washed twice
in NKET buffer before use. Protein concentrations were determined for each pellet
using the Pierce-BCA protein assay (with BSA as standard), and the membranes
were finally resuspended at 0.1 mg protein/ml in NKET buffer.
Duplicate incubations, using freshly-prepared membranes, were performed with 0-10
nM [1H]InsP6 (specific activity 15-24 Ci/mmol, DuPont-New England Nuclear,
Stevenage, UK) for the specified time period, in a final volume of 1 ml. Non¬
specific binding (NSB) was determined in parallel incubations, in the presence of 100
pM unlabelled InsP6. In competition assays, displacing agents (unlabelled InsP6,
Ins(l,3,4,5,6)P5 (Calbiochem, Nottingham, UK), and Ins(l,4,5)P3 (Research
Biochemicals International, St Albans, UK)) were added in 100 pi volumes.
Incubations were terminated by centrifugation (13,000g, 6 min, 4 °C) to separate
bound from free radioligand, and membrane pellets were washed rapidly (x2) in
NKET buffer. Pellets were dissolved overnight in Soluene, taken up in 1 ml
scintillation fluid (Packard Fluoroscint 4, Pangbourne, UK) and analyzed for
membrane-bound radioactivity by liquid scintillation counting (Packard Emulsafe,
Pangbourne, UK). Values were expressed as a percentage of maximal specific
[3H]InsP6 binding, where specific binding represented the total amount of membrane-
associated [3H]InsP6 minus the non-specific binding.
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3.2.4 [3H]InsP6 Binding to Intact Neutrophils
Two techniques were used to investigate [3H]InsP6 binding to intact human
neutrophils. All procedures were carried out at 4 °C, unless otherwise stated.
The first method was a modification of the cell membrane binding protocol, suitable
for use with intact cells. Freshly isolated neutrophils (3 x 106/ml, equivalent to 0.1
mg protein/ml) were incubated for 90 min with 0-10 nM [3H]InsP6, in a final volume
of 1 ml of either 25 mM HEPES-buffered PBS (pH 7.5) or NKET buffer (pH 7.7).
NSB was determined in parallel incubations containing 100 pM unlabelled InsP6.
Bound and free radioligand were separated by centrifugation (3000g, 2 min)
followed by two washes in the appropriate buffer. Neutrophils were dissolved
overnight in Soluene, and membrane-bound radioactivity was determined by liquid
scintillation counting.
The second method included the use of an inert oil cushion to facilitate the separation
of bound from free radioligand (O'Flaherty et al., 1990). Neutrophils (3 x 106) were
layered over 400 pi silicone oil (F-50, Croylek Ltd., Surrey, UK) in 2 ml Eppendorf
tubes, incubated as detailed above for 90 min, and then centrifuged through the oil
cushion (13,000g, 1 min). Parallel incubations were also performed using 10 pM
[,H]LTB4 (approximately 45,000 dpm ± 100 nM unlabelled LTB4 (NSB)) as a
positive control, since intact neutrophils are known to bind LTB4 (O'Flaherty et al.,
1990). The cell pellets and 200 pi samples of supernatants were isolated separately,
dissolved in 0.5 ml methanol for 10 min, taken up in 2 ml scintillation fluid, and
assessed for radioactivity by liquid scintillation counting.
3.2.5 Analysis of [3H]InsP6
In order to assess whether there was any metabolism of [3H]InsP6 during the 90 min
incubation with neutrophil membranes, pre- and post-incubation supernatants were
analyzed by anion-exchange H.P.L.C. (Hawkins et al., 1990). A 5-SAX H.P.L.C.
column (Partisphere 250 x 4.6 mm, Whatman Chromatography, Maidstone, UK)
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fitted with a Whatman guard cartridge, was eluted at a flow rate of 1.25 ml/min with
the following gradient: A (H20), B (3.5 M ammonium formate pH-adjusted to 3.7
with orthophosphoric acid): 0-5 min 0% B; 10-12 min 21.4% B; 18-23 min 28.5% B;
30 min 40.0% B; 40 min 42.0% B; 60-65 min 100% B. Fractions, collected every




3.3.1 Functional Studies with InsP6
3.3.1.1 Neutrophil Priming by Hypotonic Shock
Before pursuing the priming characteristics of InsP6, we required verification of the
ability of neutrophils to undergo transient priming in our system. The only
previously documented protocol for inducing reversible priming of superoxide anion
generation in human neutrophils was the use of hypotonic shock (Edashige et al.,
1993), and we therefore selected this model for re-examination. Using a
modification of the published hypotonic challenge protocol, fMLP (100 nM) alone
elicited little superoxide anion release under isotonic conditions, but this effect was
primed (approximately 2-fold) by a previous 20 min hypotonic challenge (Figure
3.3). This modest, but significant, priming effect was completely reversed when
isotonicity was restored 1 min prior to fMLP stimulation. Thus, in agreement with
Edashige et al. (1993), we were also able to observe the phenomenon of reversible
priming. We proceeded, therefore, to investigate the potential for neutrophils to de-
prime under more physiological conditions (i.e. following receptor-mediated










































Priming of Human Neutrophils with a Hypotonic Challenge.
Neutrophils were incubated for 19 min in isotonic PBS (150 mM NaCl) or hypotonic
PBS (50 mM NaCl), then treated for 1 min with 5M NaCl (hypotonic reversal) or
PBS (to retain iso-or hypotonicity), prior to a 10 min stimulation with 100 nM fMLP
or buffer (unstimulated controls) in the presence of 1 mg/ml cytochrome C.
Superoxide anion release was assessed spectrophotometrically. Values represent
mean ± SEM above unstimulated control values (nmol superoxide anion release/10"
cells: isotonic 3.25 ± 0.54, hypotonic shock 5.30 ± 0.38; hypotonic reversal 2.97 ±
0.67) (n = 3 in triplicate). *P<0.05, significantly different from isotonic conditions
(ANOVA).
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3.3.1.2 InsP6 Priming of fMLP-Stimulated Neutrophil Shape Change
The effect of InsP6 on basal and fMLP-induced shape change was used as a sensitive
indicator of potential chemotactic (Haston and Shields, 1985) and priming (Haslett et
al., 1985) activity. A 60 s exposure of neutrophils to InsP6 (100 nM-lmM) had no
effect on resting cellular morphology, but caused a concentration-dependent
enhancement of 0.1 nM fMLP-induced shape change, that reached a plateau at 100
pM InsP6 (Figure 3.4a): this agrees with the reported priming effect of InsP6 on
fMLP-stimulated superoxide anion release (Eggleton et al., 1991). The optimal
preincubation time for priming of fMLP-induced shape change was subsequently
determined. InsP6 (100 pM) caused a small, but significant, enhancement of fMLP
(0.1 nM)-induced shape change in un-primed neutrophils that was maximal after a
30-120 s pre-incubation and spontaneously declined to control levels after 10 min
(Figure 3.4b).
A concentration of 0.1 nM fMLP was selected for quantification of the priming effect
of InsP6 as this was shown to induce a sub-maximal degree of shape change
(approximately 60%) (Figure 3.5), and was therefore potentially amenable to
modulation. A 30 s preincubation of neutrophils with 100 pM InsP6 caused a small,
but significant, leftwards shift in the concentration-response curve for fMLP-induced
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Figure 3.4
Effect of InsP6 on fMLP-Stimulated Neutrophil Shape Change.
(a) Concentration-response for InsP6 priming of fMLP-induced neutrophil shape
change. Neutrophils were incubated with InsP6 (0 raM-1 mM, 60 s) prior to
stimulation with fMLP (0.1 nM, 10 min, light grey bars) or buffer (dark grey bars).
Samples were analyzed by light microscopy, (b) Effect of InsP6 preincubation time
on fMLP-induced neutrophil shape change. Neutrophils were pre-incubated for 0.5-
30 min with either InsP6 (100 pM, closed symbols) or 25 mM HEPES PBS buffer
(pH 7.3, open symbols), prior to treatment with fMLP (0.1 nM, 10 min, circles) or
buffer (squares) (mean ± SEM, n = 3 in duplicate). */><0.05, significantly different




Effect of InsP6 on fMLP Concentration-Response Curve for Neutrophil Shape
Change.
Neutrophils were incubated with InsP6 (100 pM, 30 s, closed symbols) or 25 mM
HEPES PBS buffer (pH 7.3, open symbols), prior to stimulation with fMLP (0-
lOOnM, 10 min). Reactions were terminated at the appropriate times by the addition
of 1 ml 2.5% glutaraldehyde and samples were analyzed by light microscopy. (Mean
± SEM of triplicate determination of representative experiment from 5. Where not
shown, SEM values fall within symbols).
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3.3.1.3 InsP6 Priming of fMLP-Stimulated Superoxide Anion Generation
An optimal InsP6 preincubation time of 30 s was selected for investigation into the
priming of fMLP-stimulated superoxide anion release, as the above time-course for
priming of the shape change response was similar to that previously reported for
priming of respiratory burst activity (Eggleton et al., 1991). The ability of InsP6 to
enhance fMLP-stimulated superoxide anion release was compared to that of the well-
established neutrophil priming agent LPS (100 ng/ml plus 1% heat-inactivated
autologous serum, 60 min) (Condliffe et al., 1996). InsP6 alone (100 pM, 30 s) did
not elicit superoxide anion release but significantly enhanced the superoxide anion
response induced by fMLP: however, the degree of priming induced by InsP6 was
small (1.8 ± 0.3 fold) in comparison to LPS (6.8 ± 0.6 fold) (Figure 3.6), although it
agreed with a previous report where InsP6 (250 pM, 5 min) caused a 100-200%
priming of the respiratory burst activity induced by fMLP, PMA and opsonised
zymosan (Eggleton et al., 1991).
3.3.1.4 Effects of InsP6 on Neutrophil Adhesion Molecule Expression
The shedding of L-selectin and up-regulation of the P2-integrins have been shown to
be a very sensitive indicator of neutrophil priming (Condliffe et al., 1996).
Furthermore, InsP6 has been reported to inhibit L-selectin-mediated adherence of
neutrophils to activated endothelial cells (Cecconi et al., 1994). Therefore, we
investigated the ability of InsP6 to modulate the expression of L-selectin and the P2-
integrins CDlla and CDllb. InsP6 (100 pM, 30 s) did not cause any significant
changes in the surface expression of L-selectin, CDlla or CDllb (Figure 3.7),
despite fMLP eliciting the down-regulation of L-selectin and the up-regulation of




























Effects of InsP6 and LPS on fMLP-Stimulated Superoxide Anion Release in
Human Neutrophils.
Neutrophils were incubated with InsP6 (100 pM, 30 s), LPS (100 ng/ml plus 1%
heat-inactivated autologous serum, 60 min) or buffer control, prior to treatment with
fMLP (100 nM, 10 min, light grey bars) or buffer control (dark grey bars) in the
presence of 1 mg/ml cytochrome C. Superoxide anion release was assessed
spectrophotometrically (mean ± SEM, n = 10 in triplicate). *P<0.05, significantly
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Figure 3.7
Effects of InsP6 on Neutrophil Adhesion Molecule Expression.
Neutrophils were incubated with InsP6 (100 pM, 30 s, black bars), fMLP (100 nM,
10 min, grey bars) or buffer (10 min, white bars). Reactions were stopped at the
appropriate times by placing the cells on ice. Neutrophils were then incubated (30
min, 4 °C) with mouse monoclonal antibody to L-selectin, CDlla or CD lib. and
subsequently with FITC-conjugated rabbit anti-mouse immunoglobulin. Mean
fluorescence was measured by flow cytometry. (Mean ± SEM, n = 4 in duplicate.
Where not shown S.E.M. values <2% mean and fall within symbols).
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3.3.1.5 Summary of The Functional Effects of InsP6 in Human Neutrophils
(i) InsP6 acts as a neutrophil priming agent in vitro, enhancing both the superoxide
anion and shape change responses to fMLP. However, these priming effects are
small in comparison to the well-established pro-inflammatory mediator, LPS.
(ii) InsP6 alone has no effect on resting neutrophil morphology or adhesion molecule
expression, in contrast to more conventional priming agents (see Chapter 4).
(iii) The priming of fMLP-induced shape change is maximal after a 30 s pre¬
incubation with InsP6, with a subsequent spontaneous reversal that is complete within
10 min. This reversibility is similar to that reported for priming of the fMLP-
stimulated superoxide anion response and assembly of cortical F-actin by InsP6, and
thus may represent de-priming of a range of functional responses.
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3.3.2 [3H]InsP6Binding to Human Neutrophil Membranes
Owing to the small and unusual nature of the priming effects of InsP6, it was
important to ascertain their receptor-dependence. Specific InsP6 binding sites have
been identified in a number of mammalian tissues, and the InsP6 receptor from rat
cerebellum has now been characterized in some detail (Hawkins et al., 1990;
Voglmaier et al., 1992). However, it remains unknown whether human neutrophils
possess a similar InsP6 receptor through which to mediate the priming effects of
InsP6.
3.3.2.1 Verification of [3H)InsP6 Binding Sites in Rat Cerebellar Membranes
In order to verify the protocol of Hawkins et al. (1990), we repeated the examination
of [3H]InsP6 binding to rat cerebellar membranes. We observed specific ['HjlnsPg
binding as previously reported, that was inhibited in the presence of excess (100 pM)
unlabelled InsP6 (Figure 3.8). The IC50 for competition with unlabelled InsP6 was 6
nM, but analysis of the curve gave a Hill coefficient significantly less than unity (nH
= 0.62), suggesting the presence of multiple [H]InsP6 recognition sites. Resolution
of the curve into two components, showed that 82% of the [3H]InsP6 bound to a site
with a Kj of 4 nM, whilst the remainder bound with lower affinity (Kj = 1 pM).
These data agree with previous reports of multiple, although slightly lower-affinity
[3H]InsP6 binding sites in rat cerebellum, where 88% of the f",H]InsP6 bound to a site




Displacement of [3H]InsP6 Binding to Rat Cerebellar Membranes by InsP6.
Assays were performed with 2.5 nM [3H]InsP6, 0.1 mg rat cerebellar membrane
protein and increasing concentrations of InsP6 in NKET buffer. Incubations were
performed for 90 min at 4 °C, with separation of bound from free radioligand by
centrifugation. Non-specific binding was determined in the presence of 100 pM
unlabelled InsP6 (mean ± S.E.M., n = 4 in duplicate).
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3.3.2.2 Kinetics of [3H]InsP6Binding to Human Neutrophil Membranes
Having verified the presence of [3H]InsP6 binding sites in rat cerebellar membranes,
we proceeded with the examination of [3H]InsP6 binding to human neutrophil
membranes. The total binding of [3H]InsP6 (2.5 nM, approximately 90,000 d.p.m.) to
human neutrophil membranes containing 0.1 mg protein/ml, was approximately
3,500 d.p.m. (200 fmol/mg protein) and reached equilibrium by 90 min (Figure 3.9).
Corresponding incubations in the presence of excess (100 pM) unlabelled InsP6
yielded NSB values of approximately 300 d.p.m. (i.e. <10% of total [3H]InsP6
binding). [3H]InsP6 binding to neutrophil membranes was reversible after 90 min,
with addition of 100 pM unlabelled InsP6 causing a rapid displacement (within 2
min) of>80% of the bound radioactivity (Figure 3.9).
3.3.2.3 Saturation of [3H]InsP6Binding to Neutrophil Membranes
[3H]InsP6 binding failed to saturate up to a radioligand concentration of 10 nM.
Owing to both the expense of radiolabelled compounds and the knowledge of the
calculated Kj values (150 nM and 5 pM) for [3H]InsP6 binding to neutrophil
membranes, attempts to fully saturate ['H]InsP6 binding were not taken further.
3.3.2.4 Competition of [3H]InsP6 Binding to Neutrophil Membranes
Analysis of the competition for [JH]InsP6 binding by unlabelled InsP6 (Figure 3.10a)
gave a Hill coefficient significantly less than unity (nH = 0.55). This value, together
with the demonstration of a curvilinear Bound versus Bound x Inhibitor plot (Figure
3.10b), suggested the presence of at least two [3H]InsP6 binding sites in human
neutrophil membranes. Resolution of the InsP6 competition curve into two
components, gave 53% of the [3H]InsP6 binding to a site of Kj 150 nM and 47% to a
lower affinity site of Kj 5 pM. This differs from the [3H]InsP6 binding we observed,
under identical assay conditions, in rat cerebellar membranes, where the majority of
['H]InsP6 bound to a higher affinity site of K; 4 nM and the remainder bound with a
Kj of 1 pM. For comparison, the previously reported [JH]InsP6 binding in
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membranes from rat cerebellum, rat cerebral hemispheres, rat anterior pituitaries, rat
heart, and bovine adrenal chromaffin cells has respective KD values of 61 nM
(Hawkins et al., 1990), 33 nM (Nicoletti et ah, 1990), 91 nM (Nicoletti et al., 1990),
30 nM (Rowley et al., 1996) and 90 nM (Regunathan et al., 1992); the purified rat
cerebellar receptor is of higher affinity, with a KD of 14 nM (Theibert et al., 1992).
3.3.2.5 Specificity of [3H]InsP6Binding to Neutrophil Membranes
In order to establish the specificity of [3H]InsP6 binding to human neutrophil
membranes, competition experiments were performed using unlabelled
Ins(l,3,4,5,6)P5 and Ins(l,4,5)P3 (Figure 3.11), which have previously been found to
displace InsP6 from its receptors in other tissue preparations (Nicoletti et al., 1990;
Hawkins et al., 1990). As the inhibition curve for Ins(l,3,4,5,6)P5 had a Hill
coefficient significantly less than unity, it was best resolved into two components,
where 40% of sites had an IC50 of 423 nM and the rest an IC50 of 18 pM, whilst
Ins(l,4,5)P3 bound with even lower affinity (IC50 3 0 pM). Thus, [3H]InsP6 binding in
human neutrophil membranes displays only a 3-fold selectivity for InsP6 over
Ins(l,3,4,5,6)P5. This specificity for InsP6 is less than that observed in other
mammalian tissues, where lower inositol phosphates bind to InsP6 receptors with a
reduced affinity of at least one order ofmagnitude (Nicoletti et al., 1990; Hawkins et
al., 1990). However, the purified InsP6 receptor from rat cerebellum displays only a
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Figure 3.9
Kinetics of [3H]InsP6 Binding to Human Neutrophil Membranes.
Incubations were performed for 0-90 min with 2.5 nM [3H]InsP6 and 0.1 mg human
neutrophil membrane protein in NKET buffer (4 °C). 100 pM unlabelled InsP6 was
added after 90 min, and incubations continued for a further 40 min. Bound and free
radioligand were separated by centrifugation (mean of duplicate determination from
representative experiment of 4).
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Figure 3.10
(a) Displacement of [3H]InsP6 Binding to Human Neutrophil Membranes by
InsP6.
(b) Bound versus Bound x Inhibitor Plot for Competition of [3H]InsP6 Binding
by InsP6.
Assays were performed with 2.5 nM [JH]InsP6, 0.1 mg human neutrophil membrane
protein, and increasing concentrations of InsP6 in NKET buffer. Incubations were
performed for 90 min at 4 °C, with separation of bound from free radioligand by
centrifugation. Non-specific binding was determined in the presence of 100 pM
unlabelled InsP6. (Mean ± S.E.M., n = 8 in duplicate. Where not shown, S.E.M.
<2% mean and fall within symbols).
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Figure 3.11
Displacement of [3H|InsP6 Binding to Human Neutrophil Membranes by InsP6,
Ins(l,3?4,5,6)P5 and Ins(l,4,5)P3.
Assays were performed with 2.5 nM [JH]InsP6, 0.1 mg human neutrophil membrane
protein, and increasing concentrations of InsP6 (white circles), Ins(l,3,4,5,6)P5 (black
squares), and Ins(l,4,5)P3 (black diamonds) in NKET buffer. Incubations were
performed for 90 min at 4 °C, with separation of bound from free radioligand by
centrifugation. Non-specific binding was determined in the presence of 100 pM
unlabelled InsP6. (Mean ± S.E.M., n = 8 in duplicate. Where not shown, S.E.M.
<2% mean and fall within symbols).
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3.3.2.6 Metabolism of [3H]InsP6
We have demonstrated that inositol phosphates other than InsP6 are able to associate,
albeit with lower affinity, to the [3H]InsP6 binding sites in human neutrophil
membranes. Therefore, the possibility arose that [3H]InsP6 metabolites generated
during the 90 min incubation period may have confounded the measurement of
[3H]InsP6 binding, and contributed to its apparent multi-site nature (see figure 3.10b).
H.P.L.C. analysis of post-incubation supernatants demonstrated a start radioligand
purity of >99.9%, with no detectable [3H]InsP6 metabolism ([3H]InsP,_5) during the
90 min incubation period (Figure 3.12). This agrees with the metabolic stability of
[3H]InsP6 previously reported under identical assay conditions, using rat cerebellar
membranes (Hawkins et al., 1990).
3.3.2.7 Protein Dependence of [3H]InsP6 Binding to Neutrophil Membranes
[3H]InsP6 binding was directly proportional to the protein content of the membranes
up to 0.2 mg protein/ml, until saturation was achieved at 0.5 mg protein/ml (Figure
3.13). This contrasts with the failure to saturate ['H]InsP6 binding in both rat cerebral
hemisphere (Nicoletti et al., 1990) and rat cerebellar membranes (Hawkins et al.,
1990), at protein concentrations < 2 mg/ml. In a separate series of experiments, the
effect of protein denaturation on [3H]InsP6 binding was assessed by boiling the
membranes for 90 min prior to use. This caused a >90% reduction in specific
['H]InsP6 binding (data not shown), as previously observed in membranes derived
from rat cerebral hemispheres (Nicoletti et al., 1990). This suggests that the majority
of [3H]InsP6 binds to a protein component of the membrane: the remainder could
represent a non-protein interaction, including an increase in the NSB to membranes
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Figure 3.12
HPLC Profile of [3H]InsP6.
[3H]InsP6 (specific activity 15-24 Ci/mmol) was analyzed by HPLC (eluted with an





Protein Dependence of [3H]InsP6 Binding to Human Neutrophil Membranes.
Assays were performed with 0-0.5 mg human neutrophil membrane protein and 2.5
nM ['H]InsP6 in NKET buffer (black cicles). Incubations were performed for 90 min
at 4 °C with separation of bound from free radioligand by centrifugation. Non¬
specific binding (white circles) was determined in the presence of 100 pM unlabelled
InsP6. (Mean ± S.E.M., n = 4 in duplicate. Where not shown, S.E.M. <2% mean and
fall within symbols).
100
3.3.2.8 Modulation of [3H]InsP6 Binding to Neutrophil Membranes by Mono-
and Divalent Cations
It has previously been shown that micromolar quantities of various di- and tri-valent
cations (e.g. Mg2+, Ca2+, Cu2+, Al3+, Fe3+), but not mono-valent cations (e.g. Na+), can
increase specific [3H]InsP6 binding to membranes prepared from rat cerebellum
(Poyner et al., 1993; Cooke et al., 1991), rat cerebral hemispheres and cultured
cerebellar neurones (Nicoletti et al., 1990). Therefore, we examined the influence of
various mono- and di-valent cations upon [3H]InsP6 binding to human neutrophil
membranes. For each buffer condition, total [H]InsP6 binding was compared to that
obtained in NKET buffer, with this value referred to as 100% binding (Figure 3.14).
Omission of 5 mM EDTA (a chelator of both Ca2+ and Mg2+) increased total binding
by 158 ± 20%. Replacement of EDTA with 5 mM EGTA (a Ca2+ chelator) caused a
76 ± 25% increase in binding, with a further increase of 89 ± 3% seen upon addition
of 1 mM Mg2+. [3H]InsP6 binding was also affected by variations in Na+ and K+
concentration: an increase of 79 ± 18%, and a decrease of 61 ± 6%, was observed in
KCl-free and NaCl-free buffer, respectively. Thus, the cations Ca2+, Mg2+ and Na+
enhance, whereas K+ inhibits, [3H]InsP6 binding to human neutrophil membranes.
NSB was similar under all conditions studied (7.3 ± 0.8% of total binding), except in
the presence of 5 mM EGTA plus 1 mM MgCl, when there was a dramatic increase
in membrane pellet-associated [3H]InsP6 (52,014 ± 4,362 d.p.m. i.e. approximately
70% of the total [3H]InsP6 added). This would suggest the formation of insoluble
[3H]InsP6-Mg2+ precipitates, as previously observed with 1 mM Ca2+ (Nicoletti et al.,












Effects of Mg2+, Ca2+, Na% and K+ on [3H]InsP6 Binding to Human Neutrophil
Membranes.
Neutrophils were resuspended in a series of 20 mM Tris/HCl buffers (pH 7.7)
containing: 5 mM EDTA, 100 mM KC1, 20 mM NaCl (column 1); 5 mM EDTA, 20
mM NaCl (column 2); 5 mM EDTA, 100 mM KC1 (column 3); 5 mM EDTA
(column 4); 100 mM KC1, 20 mM NaCl (column 5); 5 mM EGTA, 100 mM KC1, 20
mM NaCl (column 6); 5 mM EGTA, 100 mM KC1, 20 mM NaCl, 1 mM MgCl2
(column 7). Neutrophils were then homogenized, pelleted, and resuspended in the
same series of buffers at 0.1 mg membrane protein/ml. [1H]InsP6 binding to the
membranes was determined using 2.5 nM [JH]InsP6 for 90 min at 4 °C (in the
absence, light grey bars, or presence of 100 pM unlabelled InsP6, NSB, dark grey
bars). (Mean ± S.E.M., n = 3 in duplicate. Where not shown, S.E.M. <2% mean and
fall within symbols). 100% binding represents 4,958 ± 197 d.p.m., and NSB in
buffer 7 was >70% total [3H]InsP6 added.
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3.3.2.9 pH-dependence of [3H]InsP6Binding to Neutrophil Membranes
Characterization of the purified InsP6 receptor from rat cerebellum revealed that
[3H]InsP6 binding had a symmetrical pH-dependence curve, with maximal binding at
pH 6.0-7.0 (Theibert et al., 1992; Theibert et al., 1991). This pH-dependence was
also observed with membranes derived from rat cerebral hemispheres (Nicoletti et
al., 1990). Therefore, we investigated whether [3H]InsP6 binding to human
neutrophil membranes displayed a similar pH-dependence. In contrast to
observations in rat brain, specific [3H]InsP6 binding was markedly enhanced under
alkaline conditions, with a peak of maximal binding at pH 8.0 (750 fmol/mg protein)
(Figure 3.15). Below pH 7.0 [3H]InsP6 binding remained low. NSB was similar at
all pH values studied (313 ± 24 d.p.m.).
To verify that alterations in pH were not causing [3H]InsP6 binding to the Eppendorf
tubes, the experiment was repeated in the absence of membranes. The total ['H]InsP6
binding recorded to non-membrane components, at all pH values, was equivalent to
the NSB determined in the presence of membranes (data not shown).
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Figure 3.15
pH-Dependence of Specific [3H]InsP6 Binding to Human Neutrophil
Membranes.
[3H]InsP6 binding to human neutrophil membranes was determined using 2.5 nM
[3H]InsP6 and 0.1 mg human neutrophil membrane protein in a range of 25 mM Tris
(pH 7.5-9.0) and Tris-maleate (pH 5.5-7.0) buffers. Incubations were performed at 4
°C for 90 min, and non-specific binding was determined in the presence of 100 pM
unlabelled InsP6 (mean of maximal specific [3H]lnsP6 binding (13,355 ± 743 d.p.m),
n = 2 in triplicate).
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3.3.2.10 Heparin Inhibition of [3H]InsP6Binding to Neutrophil Membranes
Heparin is a highly-charged glycosaminoglycan whose pyranose ring structures (six
carbon saccharide residues) show similarity to the chair conformation of inositol.
Heparin has the potential to sterically block and inhibit the binding of inositol
derivatives, as seen with the InsP6 and InsP4 receptors in rat cerebellum (Theibert et
al., 1992). Vice versa, inositol derivatives may inhibit heparin binding, as observed
when InsP6 blocks heparin binding to fibroblast growth factor (Morrison et al.,
1994). This led us to investigate whether heparin could inhibit [3H]InsP6 binding to
human neutrophil membranes. As demonstrated in Figure 3.16, heparin inhibited the
binding of [3H]InsP6 in a concentration-dependent manner, with >80% inhibition at a
heparin concentration of 1 mg/ml. However, an IC50 value of 25 pg/ml suggests that
heparin is a less potent inhibitor of [3H]InsP6 binding to human neutrophil
membranes than to rat cerebellar membranes, where an IC50 of 0.6 pg/ml has been
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Figure 3.16
Displacement of [3H]InsP6 Binding to Human Neutrophil Membranes by
Heparin.
Assays were performed with 2.5 nM [3H]InsP6, 0.1 mg human neutrophil membrane
protein and increasing concentrations of heparin (0.1 pg/ml-1 mg/ml) in NKET
buffer. Incubations were performed for 90 min at 4 °C, with separation of bound
from free radioligand by centrifugation. Non-specific binding was determined in the
presence of 100 pM unlabelled InsPb (mean ± S.E.M., n = 3 in duplicate).
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3.3.3 [JH]InsP6Binding Sites on Intact Human Neutrophils
Although we had demonstrated the presence of InsP6 binding sites in human
neutrophil membrane preparations, the above characterization studies suggested they
were somewhat atypical when compared to InsP6 receptors identified in other tissues.
Thus, if InsP6 was to mediate its priming effects through these binding sites, their
location on the extracellular surface of neutrophil plasma membranes was essential.
Therefore, the binding of [3H]InsP6to intact human neutrophils was quantified.
3.3.3.1 Separation of Bound from Free [3H]InsP6 by Simple Centrifugation
The specific binding of [3H]InsP6 to freshly-prepared neutrophils, incubated in either
NKET (pH 7.7) or HEPES (25 mM)-buffered PBS (pH 7.5), was markedly reduced
(by 78.9 ± 4.2% and 75.7 ± 2.6%, respectively) in comparison to that observed in
neutrophil membrane preparations (Figure 3.17a). However, assessment of
neutrophil viability, measured by the ability of cells to exclude trypan blue dye,
revealed that approximately 10% of the pelleted neutrophils were permeable at the
end of the assay.As this method contained three, consecutive centrifugation steps (all
at 25 °C, 3,000g, 2 min) to separate bound from free radioligand, an alternative
separation method was selected using a one-step centrifugation (4 °C, 13,000#, 1
min) through an inert silicone oil cushion.
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Figure 3.17
[3H]InsP6 Binding to Intact Human Neutrophils.
Assays were performed using intact human neutrophils (3 x 106/ml) or human
neutrophil membrane protein (0.1 mg/ml) in NKET buffer (ph 7.7, light bars) or
HEPES (25 mM)-buffered PBS (pH 7.5, dark bars). Incubations were performed
with 2.5 nM [3H]InsP6 or 10 pM LTB4 (b only) for 90 min at 4 °C. Bound and free
radioligand were separated by: (a) centrifugation (3000g, 2 min); or (b)
centrifugation through a silicone oil cushion (13000g,l min). Non-specific binding
was determined in the presence of 100 pM unlabelled InsP6 or 100 nM LTB4 (mean
± S.E.M. for (a) n = 4, or (b) n = 3, each performed in duplicate).
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3.3.3.2 Separation of Bound from Free [3H]InsP6 by Centrifugation through an
Inert Oil Cushion
This protocol maintained neutrophils at a cell viability of >99.5% throughout the
assay period. A negligible amount (<0.03%) of the [3H]InsP6 added was associated
with the whole cell pellet, irrespective of the incubation buffer used (Figure 3.17b).
This implies that InsP6 does not bind to the extracellular surface of neutrophils. As
human neutrophils are known to possess extracellular LTB4 receptors (OFlaherty et
al., 1990), this was used as a comparative positive control: >15% of the [3FI]LTB4
added to the incubations bound specifically to the surface of neutrophils (Figure
3.17b).
3.3.3.3 Summary of [3H]InsP6 Binding in Human Neutrophils
(i) [3H]InsP6 binding was observed in human neutrophil membranes, that equilibrated
after 90 min and dissociated rapidly (2 min). Analysis of the InsP6 displacement data
suggested the presence of at least two [3H]InsP6 binding sites: 53% of the sites had a
K, of 150 nM and the remainder were of lower affinity (Kj 5 pM).
(ii) In competition experiments, [3H]InsP6 binding displayed a modest selectivity for
InsP6 over Ins(l,3,4,5,6)P5 and InsP(l,4,5)P3.
(iii) [3H]InsP6 binding was optimal at pH 8.0, was enhanced by Ca2+, Mg2+ and Na+,
and was inhibited by K+, heparin, and by pre-boiling the membranes.
(iv) However, [3H]InsP6 binding could not be identified in intact neutrophils.
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3.4 Discussion
Having confirmed that the priming of human neutrophils following hypotonic
challenge is reversible upon restoration of buffer tonicity, we sought a
physiologically-credible mediator that might exhibit reversible, receptor-mediated
priming. InsP6 is an abundant, cytosolic inositol polyphosphate (Stuart et al., 1994;
Bunce et al., 1993) that has been proposed as a novel neutrophil priming agent, upon
its release from necrotic cells within an inflammatory focus (Crawford and Eggleton,
1992; Eggleton et al., 1991). Owing to its ubiquity and potentially transient pro¬
inflammatory effects, we selected InsP6 for our investigations of reversible priming.
Initial experiments sought to define the capacity of InsP6 to modulate neutrophil
functions. Pre-incubation of neutrophils with InsP6 (100 p.M) did not affect resting
cell morphology, adhesion molecule expression, nor basal NADPH oxidase activity,
but caused a small, yet significant, enhancement of both the superoxide anion
response (1.8-fold) and polarization response (1.3-fold) to fMLP (100 nM and 0.1
nM, respectively). However, this potentiation of fMLP-induced superoxide anion
generation by InsP6 was minor when compared to LPS (6.8 fold), and other
established neutrophil priming agents (see Chapter 4). It has previously been
reported that InsP6 can prime the respiratory burst activity induced by fMLP, PMA
and opsonised zymosan by 100-200% (Eggleton et al., 1991): although we agree
quantitatively with respect to fMLP, our 1.8-fold potentiation of the superoxide
response by InsP6 sounds far less impressive.
Assessment of the optimal time required for InsP6 to affect neutrophil function,
revealed a rapid (maximal at 30-120 s) and transient (terminated by 10 min)
enhancement of shape change to fMLP. This correlates well with InsP6-primed
superoxide anion generation (Eggleton et al., 1991) and cortical F-actin assembly
(Crawford and Eggleton, 1992), which have been reported to have optimal InsP6 pre¬
incubation times of 30 s and 5 min, with a subsequent 30% reduction by 5 min and
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10 min, respectively. However, the lack of a direct effect of InsP6 on resting cell
morphology is not in keeping with other etablished priming agents (e.g. PAF and
TNFa, see Chapter 4). Therefore, although InsP6 can elicit a rapid and transient
priming of certain neutrophil functional responses, these effects are modest and
somewhat atypical when compared to more conventional priming agents.
Further studies examined whether the small and transient priming effect of InsP6 was
receptor-mediated in the neutrophil. Analysis of [3H]InsP6 binding identified the
presence of at least two binding sites in human neutrophil membrane preparations,
where InsP6 bound in approximately equal proportions to a site of K; 150 nM and a
lower-affinity site of Kj 5 pM. This was unlike the [H]InsP6 binding we observed in
rat cerebellar membranes, where the majority of [JH]InsP6 bound to a higher affinity
site of K; 4 nM. However, the affinity of this [3H]InsP6 binding was at least one log
order ofmagnitude higher than that previously reported in rat cerebellum (K; 61 nM),
where an identical protocol was followed (Hawkins et al., 1990). The reason for this
discrepancy is unknown, but since the purified InsP6 receptor from rat cerebellum has
a reported KD of 14 nM (Theibert et al., 1992), both values obtained from crude
membrane preparations lie within the expected range. The InsP6 binding reported in
all other membrane preparations has been to a single population of high affinity sites,
for example in: rat cerebral hemispheres (KD 33 nM) (Nicoletti et al., 1990); rat heart
(Kd 30 nM) (Rowley et al., 1996); rat anterior pituitaries (KD 91 nM) (Nicoletti et al.,
1990); and bovine adrenal chromaffin cells (KD 90 nM) (Regunathan et al., 1992).
InsP6 binding to these sites was reported to equilibrate faster and dissociate more
slowly than in human neutrophil membranes, possibly due to their greater affinity for
InsP6. Therefore, as InsP6 binds to several sites in human neutrophil membranes,
with lower affinity than that reported in other tissues, the nature of this binding
appears different and more complex than in other mammalian cells.
['HJInsPj, binding to human neutrophil membranes displays a 3-fold selectivity for
InsP6 over Ins(l,3,4,5,6)P5. Although this relatively low specificity is virtually
identical to that reported for the purified rat cerebellar InsP6 receptor (Theibert et al.,
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1992), it contrasts with the greater specificity of InsP6 binding sites reported in rat
brain, and bovine adrenal chromaffin cell membrane preparations, where lower
inositol phosphates bind with an affinity at least one log order ofmagnitude less than
InsP6 (Regunathan et al., 1992; Nicoletti et al., 1990; Hawkins et al., 1990).
However, all the reported binding sites have one thing in common: the more
phosphorylated the inositol compound, the higher its affinity for the InsP6 binding
site, with a rank order of potency: InsP6 > Ins(l,3,4,5,6)Ps > Ins(l,3,4,5)P4 >
Ins(l,4,5)P3 (Hawkins et al., 1990; Regunathan et al., 1992; Theibert et al., 1992).
A pH optimum of 8.0 was observed for [3H]InsP6 binding to human neutrophil
membranes, with a marked inhibition at more alkaline values, making a simple
charge-based membrane interaction unlikely. This pH-dependency differs from that
obtained in rat cerebral cortex (Nicoletti et al., 1990), and rat cerebellum (Theibert et
al., 1992), where maximal [3H]InsP6 binding occurred at pH 6 and 7, respectively.
Thus, in view of the pH-dependency, specificity, affinity, and heterogeneity of InsP6
binding to human neutrophil membranes, it is unlikely that neutrophil [3H]InsP6
binding sites represent any of those currently identified, including the IGF-II receptor
(Kar et al., 1994), the G-protein regulator, arrestin (Palczewski et al., 1991), the
Golgi coatomer K+ channel (Fleischer et al., 1994), or the clathrin assembly proteins,
AP-2 (Voglmaier et al., 1992) and AP-3 (Norris et al., 1995). These latter molecules
have been identified as potential InsP6 receptors in the rat brain, where they bind to
the plasma membrane with clathrin, to form clathrin-coated vesicles (Keen et al.,
1979): thus, they may have a role in the internalization of ligand-bound membrane
receptors by endocytosis. The AP-2 molecule has been characterized as a complex of
four proteins (Theibert et al., 1992), with two doublets of 115 kDa and 105 kDa that
bind InsP6 (KD 14 nM) and two non-binding singlets of 50 and 17 kDa. The high
affinity of InsP6 binding to AP-2 implies a physiological role, and InsP6 has been
shown to inhibit clathrin-coated vesicle formation (Beck and Keen, 1991).
The ability of cations (Mg2+, Ca2+ and Na+) to potentiate [3H]InsP6 binding in human
neutrophil membranes is qualitatively similar to observations (with Mg2+, Fe3+ and
112
Al3+) in rat tissues (Nicoletti et al., 1990; Cooke et al., 1991; Poyner et al., 1993),
although no effect of Na+ was reported. Since cation-potentiated InsP6 binding had
been found to be non-saturable and ubiquitous in membranes from rat tissues, it had
been suggested that highly-abundant membrane components, such as negatively-
charged phospholipid phosphate groups, are more likely to be the site of this binding
than a specific membrane protein (Poyner et al., 1993). We also observed this high
capacity for InsP6 binding in human neutrophil membranes if 1 mM Mg2+ was added
with an excess of unlabelled InsP6, as found previously with 1 mM Ca2+ (Nicoletti et
al., 1990). Thus, multi-valent cations may anchor InsP6 to intracellular membranes,
where it may function as: (i) a phosphate store (Berridge and Irvine, 1989); (ii) a
cation chelator, by chelating Ca2+ and hence regulating intracellular [Ca2+] (Luttrell,
1993), or by chelating Fe3+ and acting as an antioxidant (Hawkins et al., 1993); or
(iii) an inhibitor of enzymes, including alkaline phosphatase (Martin, 1995), and the
Ins(l,4,5)P3/Ins(l,3,4,5)P4 5- and Ins(l,3,4,5)P4 3-phosphatases (Hughes and Shears,
1990; Hoer and Oberdisse, 1991).
In contrast, the powerful cation-chelating properties of InsP6 raise the possibility that,
in the presence of excess InsP6, insoluble InsP6-cation complexes may form and
subsequently precipitate in membranes, as seen with Fe3+ concentrations up to 10 pM
(Poyner et al., 1993). This precipitation could also explain the "ubiquitous and non¬
saturable" binding previously reported in rat tissues (Poyner et al., 1993). In vivo
however, the high intracellular [K+] might competitively inhibit InsP6-cation complex
formation and thus protect against precipitation, as K+ was found to inhibit InsP6
membrane binding. Also, since >90% of the [3H]InsP6 binding was abolished by pre-
boiling the membranes, as shown previously (Nicoletti et al., 1990), binding should
represent an association between ['H-InsP6 and specific membrane proteins (if InsP6
is not present in excess). The multi-site nature of InsP6 binding to neutrophil
membranes could represent several, discrete binding sites with different affinities for
InsP6, or a single population of binding sites capable of exhibiting multiple,
interconvertible binding states. It is impossible to predict which of these is correct
(with the available data) because the binding characteristics of InsP6 are so complex.
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Nevertheless, InsP6 binding to at least one of these sites is affected by alterations in
pH and/or cation concentration. These specific InsP6 binding sites in human
neutrophil membranes could have a functional role, possibly in the control of
endocytosis, akin to InsP6 receptors in rat cerebellum.
In contrast to human neutrophil membrane preparations, [3H]InsP6 binding was not
detected in intact neutrophils. Therefore, the transient priming effects of InsP6 are
unlikely to be mediated by an InsP6-specific, cell-surface receptor. A variety of non¬
receptor mechanisms may underly the unusual priming ability of InsP6. The fact that
hypotonic shock (Edashige et al., 1993), cell swelling and various negatively-charged
agents (Miyahara et al., 1993), can prime the superoxide anion response in
neutrophils, whilst lipophilic and positively-charged agents (Miyahara et al., 1993)
inhibit superoxide anion generation, implies that an increase in either cell size or the
net negative charge across the plasma membrane can prime neutrophils. Thus, the
six, negatively-charged phosphate groups of InsP6 may underlie its neutrophil
priming effect. However, other inositol polyphosphates do not prime neutrophils
(Eggleton et al., 1991), rendering a simple charge-based effect unlikely. InsP6 has
been shown to be capable of chelating physiological levels of Ca2+, between the basal
intracellular and free extracellular [Ca2+] (Luttrell, 1993). Thus, it would be more
plausible to postulate that InsP6 has a non-specific extracellular effect (possibly by
acting as a cation chelator), that leads to secondary membrane perturbations, and thus
promotes the assembly and subsequent secretagogue stimulation of the membrane-
bound NADPH oxidase. These secondary membrane effects could also underlie the
priming of superoxide anion generation seen with hypotonic shock and cell swelling.
In conclusion, although human neutrophils possess specific, low affinity [3H]InsP6
binding sites, they are located only on intracellular membranes. This implies that
InsP6 may have a functional, intracellular role in neutrophils, possibly as a
membrane-bound cation chelator, phosphate store or modulator of endocytosis. In
contrast, an extracellular role for InsP6 in modulating neutrophil function is unlikely.
Thus, although InsP6 can elicit a rapid and transient priming of human neutrophils,
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this relatively small effect does not appear to be mediated by a specific, cell-surface
receptor. These findings must, therefore, question the biological significance of
InsP6 as a priming agent in vivo.
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4. CHAPTER 4: DEMONSTRATION OF REVERSIBLE
PRIMING OF HUMAN NEUTROPHILS BY PLATELET-
ACTIVATING FACTOR
4.1 Introduction
Since the small, yet transient, neutrophil priming effects of InsP6 were not mediated
by cell-surface receptors (Chapter 3), and hence may have constituted a non-specific
effect, we sought a receptor-mediated priming agent with which to investigate the
potential reversibility of neutrophil priming. Allowing for the relative paucity of
available literature regarding the kinetics of the priming response, several of the most
prominent candidates were discounted in view of their prolonged priming effects in
neutrophils, including LPS (Carey et al., 1994; Guthrie et al., 1984; Ichinose et al.,
1990), G-CSF (Ichinose et al., 1990), GM-CSF and IFN-y (Roberts et al., 1993).
The remaining pro-inflammatory mediators were graded, depending upon their
fulfilment of the following criteria.
The selected agent should primarily:
(i) be an established pro-inflammatory mediator in vivo;
(ii) produce a range of effector responses associated with neutrophil priming,
including the gold standard priming of agonist-induced superoxide anion
generation;
(iii) mediate these effects at physiological concentrations through receptors
on the neutrophil surface;
(iv) have previously been reported to induce responses that may be transient.
The three agents that best fitted the above criteria were IL-8, IL-1, and PAF. IL-1
has been reported to enhance the respiratory burst of human neutrophils (Elbim et al.,
1994; Sullivan et al., 1989) but, in contrast to G-CSF and LPS, does not retain a
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primed superoxide response after 24 hours in culture (Ichinose et al., 1990). In
addition, IL-8 has been shown to transiently enhance fMLP-induced responses of
neutrophils, including intracellular respiratory burst activity, superoxide anion
release, cytochalasin B-dependent arachidonic acid release, and PAF release (Daniels
et al., 1992; Roberts et al., 1993). These findings suggest that neutrophil priming
induced by certain, receptor-dependent cytokines may be a reversible process.
However, the former transient effects of IL-8 were not accompanied by a
concomitant reversal of CD1 lb expression (Roberts et al., 1993). Furthermore, the
priming effects of both IL-8 and IL-1 are relatively weak in comparison to other
cytokines, such as TNFa and GM-CSF (Elbim et al., 1994; Roberts et al., 1993).
Indeed, it was proposed that IL-8 might act predominantly as a regulator of
neutrophil adhesion and migration, rather than as a neutrophil priming agent in vivo
(Roberts et al., 1993); the same might be true for IL-1. Since PAF has well-
documented and unquestionable priming effects in human neutrophils, it was
selected for our investigations into the potential reversibility of neutrophil priming.
Most in vitro studies have investigated the actions of soluble PAF on isolated
neutrophils in suspension. However, it should be noted that PAF may also function
as a cell-associated, pro-inflammatory mediator, for example when it is co-expressed
with P-selectin on the surface of activated endothelial cells (Lorant et al., 1993;
Lorant et al., 1991). Although PAF has been shown to prime the respiratory burst
elicited by various neutrophil stimulants, including fMLP, PMA and C5a (Pinckard
et al., 1992; Dewald and Baggiolini, 1985; Gay et al., 1986), it cannot directly
activate this response. The priming of flVILP-induced superoxide anion release is
rapid, being maximal within minutes of the PAF addition (Pinckard and Prihoda,
1996; Gay et al., 1986). However, this primed response may not be sustained, since
it has been noted that by the end of a 60 min preincubation with 1 pM PAF, the
resultant priming of fMLP-stimulated superoxide anion generation had a "tendency
to diminish" (Gay et al., 1986). This finding was corroborated by a later report
which demonstrated a disappearance of the 10 nM PAF-induced priming effect by 60
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min, accompanied by a time-dependent priming of elastase release (Vercellotti et al.,
1988).
In view of the predicted, central role of PAF in vivo as an initiator of the early pro¬
inflammatory responses of circulating neutrophils, and the possibility that these
actions may contribute to the patho-physiological effects of PAF, this Chapter will
assess the potential for reversible PAF-induced neutrophil shape change,
CD1 lb/CD 18 acivation, and priming of superoxide anion generation. These




4.2.1 Determination of the Optimal Priming Conditions for PAF
Despite abundant demonstrations that PAF can prime human neutrophils, a lack of
inter-experimental consistency has produced many conflicting results. These
differences may be largely explained by the process of "synergistic priming" which
is known to occur between certain priming agents (Roberts et al., 1993; Elbim et al.,
1994; Yuo et al., 1991). Thus, if neutrophils were primed at any stage during their
isolation from peripheral blood or the subsequent incubation procedure (especially by
endogenous LPS), these basally-primed cells may well appear exquisitely sensitive to
very low concentrations of priming agents. Therefore, prior to examining the
potential for neutrophils to de-prime following PAF treatment, it was necessary to
establish the optimal conditions for PAF to elicit its priming effects in human
neutrophils.
4.2.1.1 PAF-Induced Priming of fMLP-Stimulated Superoxide Anion Release
Since it has previously been shown that PAF will elicit its maximal priming
responses within 0-10 min (Ingraham et al., 1987; Gay et al., 1986; Baggiolini and
Dewald, 1986), we selected a 10 min pre-incubation time for initial investigations
with PAF. The incubation of human neutrophils with 1 nM-10 pM PAF did not
affect spontaneous superoxide anion release, but caused a concentration-dependent
enhancement (EC50 50.2 ± 8.4 nM) of the subsequent superoxide response to 100 nM
fMLP that reached a plateau with 1 pM PAF (Figure 4.1). This observation is in
agreement with several other reports (Pinckard and Prihoda, 1996; Koenderman et
al., 1989; Baggiolini and Dewald, 1986; Walker et al., 1991; Gay, 1993).
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Figure 4.1
Concentration-Response for PAF-Induced Priming of fMLP-Stimulated
Superoxide Anion Release in Human Neutrophils.
Neutrophils were incubated with PAF (10 nM-10 pM, 10 min) or buffer control, then
treated with fMLP (100 nM, 10 min, light grey bars) or buffer (dark grey bars) in the
presence of 1 mg/ml cytochrome C. Superoxide anion release was assessed by
scanning spectrophotometry (mean of triplicate determination from representative
experiment of 6).
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The priming potential of PAF was compared quantitatively with that induced by
other pro-inflammatory agents used under their optimal priming conditions (Figure
4.2). Thus, whilst PAF (1 pM, 10 min) elicited a 5.5-fold priming of the 100 nM
fMLP-stimulated superoxide response, TNFa (200 U/ml, 30 min), LPS (100 ng/ml
plus 1% heat-inactivated autologous serum, 60 min) (Alison Condliffe, personal
communication), ATP (2 pM, 2 min) (Kuhns et al, 1988), and fMLP (10 nM, 10
min) (Kusner et al., 1991; Bender and Van Epps, 1983; English et al., 1981;
Bellavite et al., 1993) elicited priming effects of 6.7-, 6.5-, 1.3-, and 1.6-fold,
respectively, with minimal direct activation of superoxide anion release.
4.2.1.2 PAF-Induced Priming of Intracellular Respiratory Burst Activity
As a further index of the relative priming potentials of PAF and TNFa, the DHR
oxidation assay was performed as a complementary measure of intracellular
respiratory burst activity (Rothe et al., 1991; Royall and Ischiropoulos, 1993;
Emmendorffer et al., 1990). Although the respiratory burst activity elicited by either
agent alone was small, both PAF (1 pM, 10 min) and TNFa (200 U/ml, 30 min)




















































































The Priming of fMLP-Stimulated Superoxide Anion Release in Human
Neutrophils.
Neutrophils were incubated with buffer control or priming agent: (a) PAF (1 pM, 10
min); (b) TNFa (200 U/ml, 30 min); (c) LPS (100 ng/ml plus 1% heat-inactivated
autologous serum, 60 min); (d) ATP (2 pM, 2 min); or (e) fMLP (10 nM, 10 min).
Neutrophils were then treated with fMLP (100 nM, 10 min, light bars) or buffer
control (dark bars) in the presence of 1 mg/ml cytochrome C. Superoxide anion





The Induction of Intracellular Respiratory Burst Activity by Pro-inflammatory
Mediators.
Neutrophils were incubated with PAF (1 pM, 10 min, A and B), TNFa (200 U/ml. C
and D), or buffer (30 min, E), in the presence of 1 pM DHR, and then treated with
fMLP (100 nM, 10 min, B, D and E) or buffer (A and C). Samples were analyzed by
flow cytometry (black outlines) and plotted against control neutrophils incubated
with DHR alone (light grey outlines) (x-axis: logarithmic scale green fluorescence
(LFL); y-axis: relative cell number). Representative flow-cytometry (EPICS Profile
II) histograms (n = 10 in duplicate).
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4.2.1.3 PAF-Induced Neutrophil Shape Change
In vivo, escalating concentrations of pro-inflammatory mediators are believed to
guide neutrophils along a chemotactic gradient, whilst directing a specific sequence
of neutrophil effector responses. Thus, a mediator that can prime the respiratory
burst may simultaneously elicit other important functional responses. However,
since specific neutrophil functions are required at different times during the
activation sequence, one would expect that certain responses are more sensitive than
others to a given concentration of a pro-inflammatory agent (Baggiolini and Dewald,
1986). One of the earliest neutrophil responses initiated is a change of shape
(polarization), a very sensitive indicator of chemokinetic or chemotactic activity
(Haston and Shields, 1985) which has been shown to correlate with the degree of
priming of respiratory burst activity (Haslett et al., 1985). Therefore, the
concentration-dependency of PAF-induced neutrophil shape change was assessed in
parallel with the priming of fMLP-stimulated superoxide anion release.
A 10 min incubation with <10 nM PAF had only a minimal effect on resting
neutrophil morphology but, thereafter, PAF elicited a concentration-dependent
increase in neutrophil shape change (EC50 110 ± 27 nM) that was again maximal
with 1 pM PAF (Figure 4.4a). At a higher concentration of 10 pM PAF, there was
less deviation in the mean forward light scatter of neutrophils (assessed by flow
cytometry) than with 1 pM PAF: this observation agrees with a previous report
showing that the maximal chemotactic migration of neutrophils into cellulose filters
occurred with 1 pM PAF and was reduced at higher concentrations (Shaw et al.,
1981). However, the apparent reduction in neutrophil shape change seen with 10 pM
PAF correlated with the light-microscopic observation of large, round, "glassy"-
looking neutrophils, an appearance suggestive of cell swelling. A further increase in
the concentration to 100 pM PAF caused a 50% reduction in neutrophil viability
(assessed by trypan blue extrusion). This agrees with the previous reports that >1
pM PAF can disrupt both membrane bilayers and whole cells (Sawyer and Andersen,
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1989; Hoffman et al., 1984), possibly due to the detergent-like properties of micelles
that form at these concentrations (Kramp et al., 1984).
Numerous reports have suggested that PAF may bind to carrier proteins in the
circulation, especially albumin. These include the demonstration that when
exogenous PAF is added to plasma it co-elutes with albumin and other plasma
proteins (Ludwig et al., 1985), and that PAF release from neutrophils is dependent
upon the presence of extracellular albumin (Bratton et al., 1991; Ludwig et al.,
1985). Albumin can also inhibit the binding of PAF to human neutrophil membranes
(Valone, 1987), and may thus compete with cells and cell membranes for PAF. The
current theory therefore predicts that albumin and other plasma proteins bind to PAF
that is released from cells, and may even "extract" PAF and related molecules from
the outer leaflet of cell membranes (Bratton et al., 1994). In view of the potential
role of albumin in vivo, its influence upon PAF-induced neutrophil shape change was
examined. Human albumin (1.25 pg/ml) was found to have no significant effect
upon the concentration-dependent increase in neutrophil shape change induced by
PAF (Figure 4.4b). In view of these findings, a concentration of 1 pM PAF, without
albumin present, was used for all further investigations of PAF-induced neutrophil
responses.
The degree of neutrophil shape change elicited by PAF was compared to that induced
by other chemotactic agents. Thus, PAF (1 pM, 10 min), TNFa (200 U/ml. 30 min)
and tMLP (100 nM, 10 min) elicited 48 ± 8%, 68 ± 7% and 76 ± 5% shape change,
respectively (Figure 4.5). When PAF and TNFa-treated neutrophils were
subsequently stimulated with fMLP (100 nM. 10 min), there was a further 33 + 6%




Concentration-Response for PAF-Induced Neutrophil Shape Change.
(a) Concentration-response data for PAF-induced shape change. Neutrophils were
incubated with PAF (10 nM-10 pM, 10 min) or buffer control, then analyzed for
percent shape change by flow cytometry (mean ± SEM, n = 6 in duplicate), (b)
Effect of albumin on PAF-induced shape change. Neutrophils were treated as in (a)
in the presence (open symbols) or absence (closed symbols) of 1.25 pg/ml human
albumin (mean of triplicate determination from representative experiment of 3).
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Figure 4.5
The Induction ofNeutrophil Shape Change by Pro-inflammatory Mediators.
Neutrophils were incubated with PAF (1 pM, 10 min, A and B), TNFa (200 U/ml,
30 min, C and D), or buffer control (30 min, E), prior to treatment with fMLP (100
nM, 10 min, B, D and E) or buffer (A and C). Samples (black outlines) were
analyzed for percent shape change by flow cytometry and plotted against control
samples (light grey outlines) (x-axis: mean forward light scatter, FS; y-axis: relative
cell number). Representative flow-cytometry (EPICS Profile II) histograms (n = 12
in duplicate).
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4.2.1.4 Functional Upregulation of Adhesion Molecules
Although it has been demonstrated that neutrophil priming agents can increase the
surface expression of CD 1 lb/18, it is the functional upregulation of this molecule
that is a more predictable indicator of neutrophil priming (Condliffe et al., 1996).
Therefore, PAF (1 pM, 10 min) and TNFa (200 U/ml, 30 min) were assessed for
their ability to upregulate the binding capacity of CD1 lb/CD18, as a further index of
their relative priming potentials. When incubated with neutrophils under their
optimal priming conditions, PAF and TNFa caused a 3.6- and 4.2-fold functional
upregulation of CD1 lb/18, respectively, when compared to control samples (Figure
4.6).
4.2.2 The Reversible Priming Induced by PAF
Having established the optimal priming conditions for PAF and its priming potential
in relation to other pro-inflammatory agents, the next stage was to investigate
whether its priming effects in human neutrophils were reversible. Since there had
been two previous suggestions that priming of the fMLP-stimulated superoxide
response by PAF might diminish spontaneously over a prolonged period (Vercellotti
et al., 1988; Gay et al., 1986), we commenced with a detailed time-course of the
effects of PAF on each of the chosen indices of priming. Owing to the short
neutrophil life-span and the difficulty of maintaining isolated neutrophils in a
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Figure 4.6
PAF- and TNFa-Induced Binding of ACLB in Human Neutrophils.
Neutrophils were incubated with PAF (1 pM, 10 min), TNFa (200 U/ml, 30 min), or
buffer (30 min) in the presence of ACLB (0.75% v/v). Samples were analyzed by
flow cytometry and the percentage of neutrophils with attached ACLB calculated by
gating out the far left peak determined from control samples, (a) Mean ± SEM, n = 4
in duplicate, (b) Representative flow-cytometry (EPICS Profile II) histograms of
control neutrophils (A) and neutrophils incubated with PAF (B) or TNFa (C) (x-axis:
logarithmic scale green fluorescence, LFL; y-axis: relative cell number).
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4.2.2.1 The Priming of the fMLP-Superoxide Response by PAF is Reversible
The prolonged incubation procedure itself did not initiate neutrophil priming, since
cells at the end of the assay had a similar fMLP-superoxide response to those at the
start (Figure 4.7). However, the ability of PAF to enhance the subsequent release of
superoxide anions to fMLP was dependent upon the duration of the initial PAF pre¬
incubation. The maximal priming effect of 1 pM PAF occurred with a 10 min pre¬
incubation period; thereafter the enhancement of fMLP-stimulated superoxide anion
release decayed so that by 2 hours the priming effect had completely disappeared,
and when these "de-primed" neutrophils were stimulated with fMLP, the amount of
superoxide they released was equivalent to that observed in cells that had never been
primed. This spontaneous reversal of the priming effect of PAF displayed a
consistently biphasic pattern, with an initial rapid loss in priming (T/2 22 min)
occurring after 10 min PAF exposure, followed by a second slower phase of decay
(Ti/2 34 min) that began after 40 min.
4.2.2.2 The Shape Change Response Induced by PAF is Reversible
Although neutrophils were seen to revert to an unprimed state following PAF-
mediated priming of the fMLP-superoxide response, this recovery could have
represented the down-regulation of a single pathway specific for this response.
Therefore, the stability of the shape change elicited by PAF was also examined over
a 2 hour period. When neutrophils were incubated with 1 pM PAF they underwent a
rapid change in shape that was maximal within 2 min of the PAF addition (Figure
4.8). This shape change response subsequently reversed and by 30 min the PAF-
treated neutrophils had almost resumed the round morphology of resting neutrophils.
Following this recovery, these neutrophils gradually underwent a second phase of
cell polarization that paralleled the small changes seen in control cells and continued


























Time-Course for PAF-Induced Priming of fMLP-Stimulated Superoxide Anion
Release in Human Neutrophils.
Neutrophils were incubated with PAF (1 pM, closed symbols) or buffer (open
symbols) for 0-120 min, prior to treatment with fMLP (100 nM, 10 min. circles) or
buffer control (squares) in the presence of 1 mg/ml cytochrome C. Reactions were
terminated at the appropriate times by placing the cells on ice and superoxide anion




Time-Course for PAF-Inducetl Shape Change in Human Neutrophils.
(a) Time-course for PAF-induced shape change. Neutrophils were incubated with
PAF (1 pM, closed circles) or buffer (open squares) for 0-120 min. Samples were
analyzed for percent shape change by flow cytometry (mean ± SEM, n = 4 in
duplicate), (b) Representative flow-cytometry (EPICS Profile II) histograms of
control neutrophils (2 min. A) and neutrophils incubated with PAF for 2 min (B) or
30 min (C) (x-axis: mean forward light scatter, FS; y-axis: relative cell number).
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4.2.2.3 The Functional Upregulation of CDllb/CD18 by PAF is Reversible
The demonstration that both the priming of the fMLP-superoxide response and the
shape change induced by PAF are transient events might imply that neutrophil
priming is a reversible process. However, if PAF was also shown to elicit a transient
upregulation of the functional capacity of CD1 lb/CD 18, this would represent a more
global model of reversible neutrophil priming. The ability of 1 pM PAF to elicit a
functional upregulation of CD1 lb/CD 18 was measured as an increase in the binding
of albumin-coated latex beads (ACLB) over a 2 hour incubation period: this effect
was maximal after a 10 min incubation and then spontaneously declined to reach
control levels by 2 hours (Figure 4.9).
4.2.3 Re-priming of De-primed Neutrophils
The above data demonstrate that PAF can elicit a transient and reversible
enhancement of three different effector responses that are associated with neutrophil
priming. However, for this priming to be considered truly reversible, a
demonstration that these cells can be re-primed is also required. Thus, if sequentially
primed and de-primed neutrophils had the innate capacity to be primed again without
any significant loss in their priming potential, then a novel model of neutrophil
activation status could be proposed, whereby neutrophils could cycle between the
primed and quiescent state, as dictated by their inflammatory environment.
LFL
Figure 4.9
Time-Course for PAF-Induced Binding of ACLB in Human Neutrophils.
(a) Time-course for PAF-induced binding of ACLB. Neutrophils were incubated
with PAF (1 pM, closed circles) or buffer (open squares) for 0-120 min. ACLB
(0.75% v/v) were added 15 min before the termination of the reaction with 0.5%
glutaraldehyde, except for time-points <15 min where beads were added before the
agonist. Samples were analyzed for attached ACLB (against time-matched control
samples) by flow cytometry (mean ± SEM, n = 4 in duplicate), (b) Representative
flow-cytometry (EPICS Profile II) histograms of control neutrophils (10 min, A) and
neutrophils incubated with PAF for 10 min (B) or 120 min (C) (x-axis; logarithmic
scale green fluorescence, LFL; y-axis: relative cell number).
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4.2.3.1 Re-Priming of Neutrophils with PAF and TNFa
Since it was previously shown that a prolonged 2 hour incubation procedure did not
prime control neutrophils for an enhanced superoxide response to fMLP (Figure 4.7)
but did elicit a small degree of shape change in these cells (Figure 4.8), we selected
the cytochrome C reduction assay to address the more detailed and protracted
investigations into the potential for neutrophils to be re-primed. When neutrophils
that had primed and de-primed over a 2 hour incubation with PAF were challenged
again, with either PAF (1 pM, 10 min) or TNFa (200 U/ml, 30 min), they retained
their priming capacity, producing a similar superoxide anion response upon fMLP
stimulation as freshly-primed cells (Figure 4.10).
4.2.3.2 Re-Priming after Hypotonic Shock
The re-priming potential of neutrophils that had recovered after a hypotonic
challenge (see Chapter 3) was also investigated. PAF (1 pM, 10 min), by itself,
elicited minimal superoxide anion release from neutrophils that had been incubated
under isotonic conditions, but primed the fMLP response by 7.6-fold. Under
hypotonic conditions, PAF further augmented the basally-primed fMLP response by
3.0-fold (Figure 4.11). In incubations where isotonicity was restored after the period
of hypotonic priming, the resulting de-primed neutrophils could be re-primed by a
subsequent exposure to PAF, albeit to a lesser degree (3.9-fold) than that observed in
isotonically-maintained neutrophils. This reduction in priming potential was not a
reflection of cell necrosis, as neutrophil viability was routinely >99% for all
conditions studied. Thus, like neutrophils that had de-primed following a prolonged
exposure to PAF, osmotically primed and de-primed neutrophils retained their
capacity to be primed for a second time by a physiological agent such as PAF.
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Figure 4.10
Re-priming of Human Neutrophils with PAF or TNFa Following Initial
Priming with PAF.
(a) Superoxide anion priming with PAF and TNFa in freshly-isolated human
neutrophils. Neutrophils were incubated with buffer, PAF (1 pM, 10 min) or TNFa
(200 U/ml, 30 min), as these represent optimal priming conditions for later
comparisons with re-primed neutrophils (see (b)). Following subsequent treatment
with fMLP (100 nM, 10 min) or buffer in the presence of 1 mg/ml cytochrome C,
superoxide anion release was assessed spectrophotometrically. (b) Superoxide anion
re-priming of neutrophils with PAF and TNFa following a 120 min incubation with
PAF. Neutrophils were incubated for 120 min with PAF (1 pM, closed symbols) or
buffer (open symbols), followed by a second treatment with PAF (1 pM, 10 min,
circles), TNFa (200 U/ml, 30 min, diamonds), or buffer (30 min, squares). Samples
were then incubated with fMLP (100 nM, 10 min) and assessed for superoxide anion

















Re-priming of Human Neutrophils with PAF Following Initial Priming with
Hypotonic Challenge.
(a) Superoxide anion priming of freshly-isolated human neutrophils with a hypotonic
challenge. Neutrophils were incubated for 19 min in isotonic PBS (150 mM NaCl,
white bars) or hypotonic PBS (50 mM NaCl, grey and black bars), prior to 1 min
treatment with 5M NaCl (to reverse hypotonicity to isotonicity, black bars) or PBS
(to retain tonicity, white and grey bars). Following incubation with fMLP (100 nM,
10 min) or buffer in the presence of 1 mg/ml cytochrome C, superoxide anion release
was assessed spectrophotometrically. (b) Superoxide anion re-priming of neutrophils
with PAF following a hypotonic challenge. Neutrophils were incubated in
continuously isotonic (white symbols), continuously hypotonic (grey symbols), or
hypotonic then isotonic conditions (black symbols) as detailed above for 20 min.
This was followed by treatment with PAF (1 pM, 10 min, circles) or isotonic buffer
(10 min, squares), and subsequent incubation with fMLP (100 nM, 10 min). Samples




The neutrophil can exist in a number of different functional states, and this has a
significant bearing on its behaviour and responsiveness in vitro. Thus, in the
unprimed state, the neutrophil displays little or no secretory response when incubated
with an agent such as fMLP, whereas such a challenge in a fully primed cell results
in an explosive increase in the rate of respiratory burst activity (Gay et al.t 1986;
Pinckard et al., 1992); this priming-activation axis has been shown to be a major
determinant of neutrophil behaviour in vivo (Warren et al., 1989). However, the very
protracted priming effects of certain pro-inflammatory mediators such as LPS, G-
CSF. GM-CSF and IFN-y, together with the short neutrophil life-span, has implied
that priming by these agents is a largely irreversible process (Roberts et al., 1993;
Guthrie et al., 1984; Carey et al., 1994; Ichinose et al., 1990). Indeed, the sustained
nature of the neutrophil priming effect has been postulated to play a fundamental role
in the long-term inflammatory response observed with certain agents, including
endotoxin (Carey et al., 1994).
However, on detailed examination of the published literature, it became apparent that
neutrophil priming might, under certain circumstances, be a transient process. The
most convincing example of this was the reversible priming of the fMLP-superoxide
response induced by hypotonic shock (Edashige et al., 1993), which we confirmed in
Chapter 3. This priming may have been a result of the reversible neutrophil swelling
that occurs under hypotonic conditions (Miyahara et al., 1993), with its associated
disordering of plasma membrane-cytoskeletal interactions and net increase in cell-
surface negative charge. Similar membrane perturbations might also explain the
transient, receptor-independent, priming effects of InsP6 that were observed in
Chapter 3. However, if these afore-mentioned studies were collectively considered
as physico-chemical manipulations, the remaining literature provided little direct
information about whether established, receptor-mediated priming agents could
reversibly enhance neutrophil responses.
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In this Chapter, we have provided evidence that the neutrophil priming effects of an
important pro-inflammatory mediator, PAF, are transient. Since the spontaneous de-
priming of neutrophils observed following PAF treatment was apparent for fMLP-
stimulated superoxide anion generation, CD1 lb function, and cell polarization, it was
unlikely to represent the selective down-regulation of any one particular component
of the priming response. We have also demonstrated that these PAF-primed-de-
primed neutrophils can go through a further complete cycle of priming (by either
TNFa or PAF) and activation, with the maintenance of full viability throughout.
Thus, the spontaneous decay of the PAF priming effect was not merely a
consequence of the extended incubation procedure affecting cell integrity or
metabolic status, and was unlikely to reflect the down-regulation of receptor number
or affinity.
Following a 60 min pre-incubation with 1 p.M PAF, the priming of the fMLP-
superoxide response was reduced to approximately 50% of its maximal value, in line
with a previous observation (Gay et ah, 1986), and had completely disappeared
within 2 hours. However, the spontaneous reversal of this priming effect exhibited a
consistently biphasic pattern of decay, suggesting that two different, but interacting,
mechanisms might be responsible for the de-priming process. Furthermore, a two-
stage reversal of the primed response has been observed with 10 nM PAF, although
this effect was more rapid, being complete within 60 min (Vercellotti et al., 1988).
The apparent discrepancy in the rates of reversal may be a consequence of the
different concentrations of PAF used in these studies. Thus, if lower concentrations
of PAF elicit more transient priming responses, this implies that the rate of de-
priming might, in part, reflect: (i) the degree of PAF receptor occupancy and
intensity of the priming signal; and (ii) the rate of removal of PAF (e.g. by
metabolism or internalization) from the incubation medium.
However, a novel model has recently been proposed for PAF-induced priming of
superoxide responses (Pinckard and Prihoda. 1996). It was reported that PAF could
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elicit two different types of neutrophil priming: at low concentrations (10 pM-1 nM)
PAF induced a small priming effect that remained stable over time, whilst the much
greater priming effects of higher concentrations of PAF (1-100 nM) were more
transient. For example, the maximal enhancement of fMLP-stimulated superoxide
anion release by 10 nM PAF was reduced by approximately 25% within 10 min of
the PAF addition (Pinckard and Prihoda, 1996), an observation similar to that
previously reported (Vercellotti et al., 1988). Furthermore, reversal of the PAF (1-
100 nM)-primed C5a-induced superoxide response was even more dramatic, being
complete within 10 min (Pinckard and Prihoda, 1996). Thus, it was suggested that
there may be at least two effector pathways, mediated by high- and lower-affinity
PAF receptors, that modulate PAF-induced priming of respiratory burst activity in
human neutrophils. According to this model, the reversible priming we observed
with 1 pM PAF would largely be mediated by a subtype or conformational state of
the PAF receptor that was of relatively low-affinity.
As the second index of neutrophil priming, PAF-induced shape change occurred
rapidly, being maximal within 2 min of PAF (1 pM) addition. This response was
also transient and by 30 min had largely reversed, supporting the hypothesis that PAF
induced neutrophil priming might be a reversible phenomenon. In contrast, both C5a
and fMLP have been reported to elicit a rapid polarization response in neutrophils
that is sustained for at least 1 hour (Haston and Shields, 1985; Smith et al., 1979);
however, upon removal of the stimuli, this shape change subsequently reversed
(Smith et al., 1979). Taken together, these observations imply that neutrophil shape
change will be maintained if the chemotactic factor is continuously present, but may
reverse when neutrophils are no longer stimulated. Thus, the spontaneous reversal of
PAF-elicited shape change may be due to a "removal" of PAF from the incubation
medium during the 2 hour period.
The delayed, gradual increase in shape change that occurred when neutrophils were
incubated for >30 min with PAF was unlike the initial PAF-mediated response in that
it: (i) was smaller and much slower to evolve; (ii) paralleled changes seen in control
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neutrophils; and (iii) was not accompanied by a similar gradual increase in the
functional upregulation of CDllb/CD18 or priming of the superoxide response to
fMLP (although it may have contributed to its biphasic pattern of reversal).
Therefore, it is unlikely that this delayed neutrophil shape change was mediated
directly by PAF. However, it could have reflected an event that was secondary to
prolonged neutrophil incubation, for example the synthesis and/or release of an
autocrine/paracrine neutrophil chemotactic agent.
PAF also upregulated the functional capacity of CD1 lb/CD 18, with a similar time-
course to that observed for the priming of superoxide anion release. This transient
effect has recently been confirmed with 100 nM PAF (Condliffe et al., 1996).
However, in this latter report it was also demonstrated that the accompanying
upregulation of CDllb expression (in contrast to function) was not reversible, but
was maintained at high levels for at least 2 hours. Furthermore, since lower
concentrations of PAF were required to upregulate the functional capacity, as
opposed to the surface expression, of CDllb/CD18, it was suggested that
CD1 lb/CD 18 function (measured by the binding of ACLB) might be the more
sensitive indicator of neutrophil priming (Condliffe et al., 1996). Therefore in
retrospect, the small yet transient enhancement of respiratory burst activity elicited
by IL-8 (Daniels et al., 1992; Roberts et al., 1993) may have been another example
of reversible neutrophil priming, even though the increased surface expression of
CDllb was sustained; the patho-physiological significance of this event, however,
was entirely overlooked by these authors.
This chapter has focused solely on the in vitro effects of soluble PAF, which may
mimic the in vivo paracrine action of PAF (possibly bound to serum albumin) that
has been released from inflammatory cells. However, PAF may also be present in a
bound form within the vasculature when it is co-expressed with P-selectin on the
surface of activated endothelial cells, and thereby mediates a juxtacrine effect on
rolling (and thus momentarily immobilized) neutrophils (Lorant et al., 1993; Lorant
et al., 1991). PAF is expressed only transiently on the endothelial surface, being
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maximally up-regulated within 10 min (Prescott et al., 1984; Mclntyre et al., 1985),
and is then rapidly degraded (Mclntyre et al., 1986; Mclntyre et al., 1985). This
reversible expression of PAF has been shown to parallel both the transient adhesion
of neutrophils to the activated endothelial surface (Lorant et al., 1991) and the
priming of fMLP-stimulated superoxide anion release (Vercellotti et al., 1989),
responses that are facilitated by P-selectin (Lorant et al., 1993). Thus, it has been
postulated that the reversible endothelial co-expression of a tethering (P-selectin) and
a signalling (PAF) molecule may provide a strictly-controlled mechanism for the
efficient adhesion and functional upregulation of neutrophils at their first committed
step of an acute inflammatory response (Lorant et al., 1991).
It has subsequently been demonstrated that the majority of "PAF" synthesized by
vascular endothelial cells is actually not the classical alkyl-PAF but acyl-PAF
(Whatley et al., 1992; Triggiani et al., 1991). Thus, it may be acyl-PAF that
mediates the functional upregulation of neutrophils that are rolling along the
endothelium. Acyl-PAF in suspension has been shown to prime human neutrophils
for an enhanced superoxide anion response to fMLP and C5a but, in contrast to alkyl-
PAF, cannot elicit chemotaxis (Pinckard et al., 1992). Furthermore, the priming
induced by acyl-PAF is slower to evolve and more sustained than the priming
induced by fluid-phase alkyl-PAF (Pinckard and Prihoda, 1996). Flowever, since
certain bioassays for PAF cannot adequately distinguish between alkyl- and acyl-
PAF (Mueller et al., 1991; Bratton et al., 1994), it may be that previous
investigations with endothelial-cell associated "PAF" were actually performed with
acyl-PAF. If this was the case, then the apparently different priming characteristics
of endothelial cell-associated- and fluid-phase- acyl-PAF may be due to the
modulatory effects of P-selectin.
In view of the above observations, it would appear that there may be at least two
distinct types of PAF-induced neutrophil priming in vivo: (i) alkyl-PAF released
from activated inflammatory cells may bind to serum albumin and prime neutrophils
in suspension; and (ii) acyl-PAF expressed on the surface of activated endothelial
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cells may prime rolling neutrophils that have been temporarily immobilized by P-
selectin. In addition, the reversible nature of the responses induced by both fluid-
phase and endothelial cell-associated PAF may limit the effects of this potent pro¬
inflammatory mediator. Since the transient expression of PAF by activated
endothelial cells is believed to explain the resulting transient neutrophil responses
(Lorant et al., 1991), a similar short-lived appearance of PAF in the incubation
medium might explain the reversible priming that we observed with suspended
neutrophils. Thus, if this idea is applicable to the in vivo situation, then the PAF
released from activated inflammatory cells may remain only briefly in the circulation
and thereby limit the pleiotropic effects of PAF to the initial phase of an acute
inflammatory response.
The above hypothesis is supported by reports indicating a central role for endothelial
cell-associated PAF in the priming (Hill et al., 1994) and extravasation (Nourshargh
et al., 1995) of neutrophils exposed to IL-ip-activated endothelium. Thus, any delay
in neutrophil exit through an activated endothelial surface might permit cell recovery
and the return of un-primed neutrophils to the circulation. The recognition that
neutrophils have the potential to de-prime may therefore provide an additional point
of control in the earliest stage of an acute inflammatory response, whereby cells may
return to their former quiescent state and potentially re-join the circulating neutrophil
pool. These de-primed neutrophils, once fully recovered, could again attain their
maximal priming potential and mount subsequent inflammatory responses as dictated
by ensuing inflammatory challenges. However, in the wake of a more widespread or
prolonged inflammatory insult, it is unlikely that neutrophils would be exposed
solely to PAF or other transient priming agents, and the presence of agents such as
LPS, GM-CSF and G-CSF might promote a synergistic mechanism of priming to
maintain the prolonged up-regulation of neutrophil responses. Nevertheless, the
recognition of reversible neutrophil priming may provide a novel target for
counteracting the pro-inflammatory, and potentially tissue-damaging, effects of
primed and fully activated neutrophils.
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5. CHAPTER 5: POTENTIAL MECHANISMS UNDERLYING
THE REVERSIBLE PRIMING INDUCED BY PLATELET-
ACTIVATING FACTOR
5.1 Introduction
Having demonstrated in Chapter 4 that PAF can induce transient priming of human
neutrophils, the reasons for this reversibility were next considered. Initially, it was
important to exclude any effects that were merely a consequence of the prolonged
incubation procedure, for example, the decline of either reagent or neutrophil
activity. Following this, several potential mechanisms were targeted, including:
(i) receptor-dependent events; (ii) the tyrosine phosphorylation of intracellular
proteins; (iii) the metabolism of PAF; and (iv) modulatory effects of other
inflammatory agents.
There is a general consensus that neutrophils contain specific, high-affinity PAF
receptors that transmit the bioactions of PAF and are inhibitable by a wide variety of
PAF receptor antagonists (Casals-Stenzel et al., 1987; Shen et al., 1985; O'Flaherty
et al., 1989; Dent et al., 1989; Marquis et al., 1988; Hwang, 1988). A down-
regulation of either the number or functional capacity (i.e. coupling) of neutrophil
PAF receptors could underlie the reversal of PAF-mediated priming. Thus,
neutrophil de-priming may be similar to the homologous desensitization that has
previously been observed when cells become unresponsive to PAF following
repeated exposure (Schwertschlag and Whorton, 1988; O'Flaherty et al., 1981;
Henson, 1976; Benveniste et al., 1972). Several mechanisms have been proposed to
mediate this process, including: receptor down-regulation (Sibley et al., 1987;
O'Flaherty et al., 1992; Scarpace and Abrass, 1982); direct inactivation of G-proteins
(OFlaherty et al., 1992; Milligan and Green, 1991); or the modulation of intracellular
signal transduction pathways (Galizzi et al., 1987). Since these same, receptor-
144
dependent mechanisms may apply to the reversal of PAF-mediated priming, we
initially investigated the contribution of PAF receptor occupancy using the PAF
receptor antagonists, WEB 2086 and UK-74,505.
Recently, there has been growing interest in a group of intracellular proteins that
become tyrosine-phosphorylated upon neutrophil priming and/or activation.
Virtually all of the known neutrophil stimulants, including PAF (Nick et al., 1997;
Gomez-Cambronero et al., 1991), TNFa (Lloyds et al., 1995; Akimaru et al., 1992)
and fMLP (Nick et al., 1997; Ohta et al., 1992), have been shown to elicit these
events in a concentration- and time-dependent manner, often producing a very
similar pattern of tyrosine phosphorylation (Richard et al., 1994). Furthermore,
tyrosine phosphorylation of certain proteins has been linked to diverse functional
responses of neutrophils, including priming (Lloyds and Hallett, 1994; Kanbara et
al., 1993; Akimaru et al., 1992; Lloyds et al., 1995) and, in the case of hypotonic
shock, to reversible priming (Edashige et al., 1993). This intracellular signalling
mechanism is reminiscent of that used by growth factors, which act through receptors
with intrinsic tyrosine kinase activity (Cadena and Gill, 1992). Although the
majority of neutrophil stimulants signal through receptors which do not possess an
intrinsic tyrosine kinase domain, neutrophils do contain tyrosine-specific protein
kinases (Kraft and Berkow, 1987; Fluang et al., 1988) and phosphatases (Fialkow et
al., 1994; Kansha et al., 1993). Thus, these enzymes may mediate the tyrosine
phosphorylation, and subsequent de-phosphorylation. of intracellular proteins as part
of a rapid and reversible signalling pathway for neutrophil stimulation.
A gradual decline in the bioactivity of PAF during the assay might also explain the
transient priming effects of PAF. For instance, if PAF was degraded extracellularly,
or internalized by neutrophils and subsequently metabolized, one would predict that
the actual concentration of PAF would decrease over the incubation period and
perhaps fall below a critical ihreshold for neutrophil priming (approximately 1-10
nM, Chapter 4). It is known, for example, that PAF can be degraded by the action of
PAF acetylhydrolases, a group of enzymes which remove the acetyl group at the sn-2
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position of the PAF molecule to yield the biologically-inactive products, lyso-PAF
and acetate (Figure 5.1). These enzymes regulate the levels of PAF in the plasma
(Pinckard et al., 1979; Farr et al., 1980) and in tissues (Alam et al., 1983; Blank et
al., 1981): human neutrophils have been shown to inactivate PAF in their plasma
membranes at a rate of 1 nmol PAF per 107 neutrophils per minute (O'Flaherty et al.,
1986). However, if an iV-methylcarbamyl residue is introduced at the sn-2 acetyl
position of PAF, this yields a biologically-active PAF analogue, C-PAF (Figure 5.1),
which is completely resistant to metabolic inactivation by human neutrophils or
serum (Tessner et al., 1989; O'Flaherty et al., 1987). Thus, we used C-PAF to
investigate whether the metabolism of PAF played a significant role in the reversal of
PAF-mediated priming.
Many inflammatory agents have been reported to modulate the responses of
stimulated neutrophils. These agents include: (i) prostaglandins, such as PGE2
(Rossi and O'Flaherty, 1989); (ii) leukotrienes, such as LTB4 (Ford-Hutchinson et
al., 1980; Lin et al., 1982); and (iii) adenine nucleotides, such as ATP, ADP, AMP,
and adenosine (Ward et al., 1988; McGarrity et al., 1989). Some of these agents may
be released upon neutrophil stimulation to act as autocrine/paracrine regulators of
neutrophil function. For example, activated human neutrophils have been shown to
synthesize and release LTB4 (Hopkins et al., 1983), a potent neutrophil
chemoattractant (Ford-Hutchinson et al., 1980) and inducer of shape change (Rossi et
al., 1993), but a relatively weak priming agent for superoxide anion release
(Baggiolini and Dewald, 1986). Thus, it is possible that the release of such an agent
might underlie the secondary, delayed increase in neutrophil shape change that
occurred following the reversal of PAF-mediated shape change. However, in order
to mediate the spontaneous reversal of neutrophil priming, the agent in question
would also have to inhibit the early PAF-induced responses.
Adenosine acts through specific, cell-surface receptors to inhibit many neutrophil
functions, especially those elicited by fMLP or C5a. For example, micromolar
concentrations of adenosine have been shown to inhibit: neutrophil rolling (Asako et
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al., 1993) and adhesion to endothelial cells (Cronstein et al., 1992); the generation of
reactive oxygen species, including superoxide anions (Stewart and Harris, 1993;
Walker et al., 1990; Ward et al., 1988; Cronstein et al., 1983) and H202 (Cronstein et
al., 1987), possibly by the uncoupling of G-proteins from fMLP receptors (Burkey
and Webster, 1993); and neutrophil-mediated injury to endothelial cells (Cronstein et
al., 1986). Furthermore, adenosine has been reported to completely inhibit PAF (1
pM)-induced priming of fMLP-stimulated superoxide anion release in human
neutrophils (Stewart and Harris, 1993). However, in contrast to these inhibitory
actions, adenosine has also been reported to have no effect on (McGarrity et al.,
1989), or even promote (Rose et al., 1988; Garcia-Castro et al., 1983), neutrophil
chemotactic responses to fMLP. Since adenosine is a ubiquitous product of normal
cellular activity, its release from neutrophils (or any contaminating platelets) might
mediate the paracrine modulation of neutrophil responsiveness. Thus, adenosine
release was investigated as a potential explanation for both the early reversal of PAF-




























TheMetabolism of PAF by PAF Acetylhydrolase.
PAF acetylhydrolase removes the sn-2acetyl group (red) of PAF to yield
the biologically-inactive products lyso-PAF and acetate. C-PAF contains
an N-methylcarbamyl residue at the 2position and is a non-
metabolizable, yet biologically-active, analogue ofPAF.
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5.2 Results
5.2.1 Degradation of Cytochrome C
The possibility that neutrophil "de-priming" might reflect the degradation of
cytochrome C during the 2 hour incubation could not be overlooked. Hence, its
intra-assay stability was examined. A direct comparison of cytochrome C that had
been incubating at 37°C for the whole 2 hour period, with cytochrome C that was
prepared immediately before the 2 hour time-point, revealed no significant difference
in the calculated superoxide responses to fMLP (nmol/106 neutrophils: 4.7 ± 0.4 (2
hour-old cytochrome C); 5.0 ± 0.3 (fresh); n = 3). Thus, the degradation of
cytochrome C during the assay was not responsible for the reversal of PAF-mediated
priming.
5.2.2 Altered Responsiveness of Neutrophils
It was considered possible that the priming potential of neutrophils may have altered
during the prolonged incubation procedure, resulting in a diminished secretagogue
response at the later time-points. Since neutrophil viability remained >99%
throughout the 2 hour incubation period, and neutrophils could subsequently be re-
primed without a significant reduction in their activation potential (Chapter 4), the
reversal of PAF-primed responses was not secondary to a decline in cell viability.
Nevertheless, it was still possible that the overall responsiveness of neutrophils could
have fluctuated over the incubation period.
PMA is a phorbol ester that activates PKC directly and has been used widely in
neutrophil signal transduction studies to evoke consistent and large respiratory burst
responses (Daniels et al., 1994; Smith and Weidemann, 1993; Keller et al., 1995;
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Majumdar et al., 1991). This agent can therefore provide an indication of the overall
responsiveness of a neutrophil population, as well as the intrinsic activity of PKC.
Thus, neutrophils were stimulated with PMA (100 ng/ml, 60 min) at various times
throughout the 2 hour incubation period and assessed for superoxide anion release
and shape change (Figure 5.2). Both responses remained stable throughout, again
implying that there was no significant loss in neutrophil responsiveness over the 2
hour incubation procedure.
5.2.3 Metabolism of PAF
Neutrophils can use PAF acetylhydrolase to rapidly inactivate PAF (O'Flaherty et
al., 1986). Therefore, as significant PAF metabolism may have occurred during the 2
hour incubation, the time-course for priming of fMLP-stimulated superoxide anion
release by PAF was compared with that of its non-metabolizable analogue. C-PAF
(Calbiochem, Nottingham, UK) (Figure 5.1). The time-courses were found to be
almost identical (Figure 5.3). Thus, the spontaneous reversal of the PAF-primed
superoxide response was not secondary to the intra-assay metabolism of PAF:
however, a metabolically-independent reduction in the bioactivity of PAF (and C-
PAF) could not be excluded.
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Preincubation Time (min) Preincubation Time (min)
Figure 5.2
Responsiveness of Human Neutrophils to PMA.
(a) Superoxide anion response of human neutrophils to PMA. Neutrophils were
incubated for 10-120 min, prior to stimulation with PMA (100 ng/ml, 60 min) or
buffer, in the presence of 1 mg/ml cytochrome C. Superoxide anion release was
assessed spectrophotometrically. (b) Shape change response of human neutrophils to
PMA. Neutrophils were incubated as detailed in (a) in the absence of cytochrome C,




Time-Course for Priming of fMLP-Stimulated Superoxide Anion Release in
Human Neutrophils by PAF and C-PAF.
Neutrophils were incubated with PAF (1 pM, closed symbols) or C-PAF (1 pM,
open symbols) for 0-120 min, prior to treatment with fMLP (100 nM. 10 min) in the
presence of 1 mg/ml cytochrome C. Reactions were terminated at the appropriate
times by placing the cells on ice and superoxide anion release was assessed by
scanning spectrophotometry (mean ± SEM, n = 3 in triplicate.
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5.2.4 Adenosine Release
Having ruled out the possibility that the reversal of PAF-mediated priming was
secondary to a decrease in neutrophil viability or activation potential, the degradation
of cytochrome C, or the metabolism of PAF, the involvement of a paracrine "anti¬
inflammatory / anti-priming" mediator was next addressed. Since there have been
many reports that adenosine can modulate various neutrophil responses, the potential
generation of this mediator during the 2 hour incubation may have affected the
priming induced by PAF and thereby contributed to the observed de-priming.
Extracellular adenosine can be metabolized rapidly by the enzyme adenosine
deaminase (ADA), and a concentration of 1 U/ml ADA has been shown to
completely inhibit the effects of adenosine on neutrophils (McGarrity et al., 1989;
Bullough et al., 1995). Therefore, by repeating the 2 hour incubation in the presence
of 1 U/ml ADA, the effects of adenosine on the reversible priming induced by PAF
could be evaluated.
5.2.4.1 Effects of Adenosine Deaminase on Superoxide Anion Release
Using either a 10 min or 120 min preincubation period, ADA was shown to have no
effect on superoxide anion release from control or fMLP (100 nM)-stimulated
neutrophils (Figure 5.4); however, ADA partially inhibited both the small superoxide
response to 1 pM PAF alone and the PAF-primed fMLP response.
5.2.4.2 Effects of Adenosine Deaminase on Neutrophil Morphology
The effects of ADA on neutrophil morphology were also examined. Unlike its
inhibition of superoxide anion responses, ADA did not alter the morphology of either
control or PAF-treated (1 pM, 10 min) neutrophils. However, the shape change
induced by fMLP (100 nM. 10 min) was inhibited by 39 ± 12% (Figure 5.5).
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10 min 120 min
Control fMLP PAF PAF +
fMLP
Control fMLP PAF PAF +
fMLP
Figure 5.4
Effect of Adenosine Deaminase on Superoxide Anion Responses.
Neutrophils were incubated (± 1 U/ml adenosine deaminase) with PAF (1 pM) or
buffer, for 10 min or 120 min. Following treatment with fMLP (100 nM, 10 min) or
buffer, in the presence of 1 mg/ml cytochrome C, superoxide anion release was




Effect of Adenosine Deaminase on Neutrophil Morphology.
Neutrophils were incubated with PAF (1 pM, 10 min, B), fMLP (100 nM. 10 min,
C), or buffer control (A), in the presence (black outlines) or absence (light grey
outlines) of 1 U/ml adenosine deaminase. Samples were analyzed for percent shape
change by flow cytometry (x-axis: mean forward light scatter; FS; y-axis: relative
cell number). Representative flow-cytometry (EPICS Profile II) histograms (n = 3 in
triplicate).
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In the absence of any direct toxic or non-specific inhibitory effects of ADA, these
observations imply that adenosine is both present in the incubation medium and
plays a role in enhancing the superoxide anion release of PAF-treated neutrophils,
whilst playing no part in PAF-mediated polarization responses. This disagrees with a
previous report in human neutrophils where adenosine completely inhibited the
superoxide priming effect of 1 pM PAF (Stewart and Harris, 1993). In contrast,
adenosine may facilitate fMLP-induced shape change, a finding which correlates
with the increased chemotactic motility reported previously (Rose et al., 1988;
Garcia-Castro et al., 1983). However, these findings do not support a role for
adenosine release as a relevant mechanism underlying de-priming, since neutralizing
its effects inhibited, rather than augmented, certain PAF-induced priming events.
5.2.5 Receptor-Dependency of PAF-Mediated Priming/De-priming Effects in
Human Neutrophils
To ascertain whether the transient nature of PAF-induced priming reflected events
occurring at a receptor (or sub-receptor) level, the effect ofPAF receptor blockade on
the priming and de-priming responses was investigated. From the large number of
commercially-available PAF receptor antagonists, three compounds were selected
that were specific and of high affinity, yet differed in their chemical structure (Figure
5.6), thereby eliminating any potential, structurally-dependent artefacts. Primarily,
the thieno-triazolodiazepine WEB 2086 was chosen, as this compound has been one
of the most widely-studied PAF receptor antagonists in a variety of model systems
both in vitro and in vivo (Casals-Stenzel et al., 1987). WEB 2086 has also been
shown to antagonize PAF-induced responses in human neutrophils, including:
aggregation (Casals-Stenzel et al., 1987); chemotaxis (Fukuda et al., 1989);
degranulation (Dent et al., 1989); and priming of the respiratory burst to fMLP
(Pinckard and Prihoda, 1996; Gay, 1993). Secondly, the 1,4-dihydropyridine
calcium channel blocker UK-74,505 was selected, since this agent has independent
actions as a potent and long-lasting PAF receptor antagonist in vivo (Parry et al,
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1990). A direct structural analogue of PAF, l-0-hexadecyl-2-acetyl-.s??-glycero-3-
phospho-(A(Ar,Ar-trimethyl)-hexanolamine was also chosen.
5.2.5.1 Concentration-Dependent Inhibition of Respiratory Burst Activity by
PAF Receptor Antagonists
In order to assess whether the three selected compounds were effective PAF receptor
antagonists in our system, and to determine appropriate drug concentrations for use
in subsequent experiments, we examined their effects upon neutrophil viability and
superoxide anion release in control and fMLP-treated neutrophils. At concentrations
<10 pM, both WEB 2086 (Boehringer Ingelheim Ltd., Berks, UK) and UK-74,505 (a
kind gift from Dr J. Parry, Pfizer, UK) had no effect on neutrophil viability or
superoxide responses of control or 100 nM fMLP-stimulated neutrophils (Figure
5.7). These null effects of WEB 2086 are in agreement with a number of previous
observations (Pinckard and Prihoda, 1996; Gay, 1993). Flowever, the third
antagonist tested, the PAF analogue l-0-hexadecyl-2-acetyl-x«-glycero-3-phospho-
(A,A,A-trimethyl)-hexanolamine (Calbiochem, Nottingham, UK), displayed a
number of direct and toxic effects upon neutrophils: at a concentration of 0.1 nM it
increased basal and fMLP-stimulated superoxide responses (Figure 5.7); at
concentrations >1 pM it reduced neutrophil viability by >50%; and at >10 pM it
caused overt neutrophil lysis with DNA leakage. Thus, only WEB 2086 and UK-

















Effect of PAF Receptor Antagonists on Basal and fMLP-Stimulated Superoxide
Anion Release in Human Neutrophils.
Neutrophils were pre-incubated for 30 min with: (a) WEB 2086 (10 (iM, mid-grey
bars), UK-74,505 (10 (iM, dark-grey bars), buffer control (closed bars), or (b) 1 -O-
hexadecyl-2-acetyl-OT-glycero-3-phospho-(A,A,A-trimethyl)-hexanolamine (0.1 nM.
light bars). Following treatment with fMLP (100 nM, 10 min) or buffer control in
the presence of 1 mg/ml cytochrome C, superoxide anion release was assessed by
scanning spectrophotometry (mean ± SEM, n = 4 in triplicate). *P<0.05, significantly
different from values obtained in the absence of antagonist (ANOVA).
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Preliminary studies were designed to establish the optimal concentrations of WEB
2086 and UK-74,505 for inhibition of PAF-induced responses of human neutrophils.
When neutrophils were preincubated for 30 min with either antagonist, there was a
concentration-dependent inhibition of the PAF-primed fMLP-stimulated superoxide
response (Figure 5.8). The inhibition by UK-74,505 had an IC50 value of 68 ± 9 nM
and was complete at 1 pM, whereas the inhibition by WEB 2086 was biphasic
(reaching a plateau at 300 nM-1 pM) and incomplete at the highest concentration
tested (55 ± 4% inhibition with 10 pM WEB 2086). This degree of antagonism of
PAF-primed fMLP-stimulated superoxide anion release by WEB 2086 is similar to
that previously reported (Gay, 1993).
As a further indication of the antagonistic capacity of WEB 2086 in human
neutrophils, its ability to attenuate intracellular respiratory burst activity was also
examined. Although WEB 2086 (1 pM, 30 min) caused a small increase (25%) in
the DHR oxidation of control neutrophils, it had no significant effect on fMLP (100
nM)-stimulated respiratory burst activity (Figure 5.9). Furthermore, WEB 2086
inhibited the direct intracellular response to 1 pM PAF (yielding fluorescence values
lower than WEB 2086-treated control neutrophils), and caused a small (28%) yet
significant reduction in PAF-induced priming of the fMLP response.
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Figure 5.8
Concentration-Response of (a) UK-74,505 and (b) WEB-2086 on PAF-Induced
Priming of fMLP-Stimulated Superoxide Anion Release in Human Neutrophils.
Neutrophils were pre-incubated for 30 min with: (a) UK-74,505 (10 nM-10 pM,
closed circles), (b) WEB-2086 (10 nM-10 pM, closed diamonds), or buffer control.
Following treatment with PAF (1 pM, 10 min) or buffer (open squares), neutrophils
were incubated with fMLP (100 nM, 10 min) in the presence of 1 mg/ml cytochrome
C, and superoxide anion release was assessed by scanning spectrophotometry (mean




Effect of WEB 2086 on PAF-Induced Priming of fMLP-Stimulated Intracellular
Respiratory Burst Activity.
Neutrophils were pre-incubated for 30 min with WEB-2086 (1 pM, black outlines) or
buffer (light grey outlines), and then treated with PAF (1 pM, 10 min, B and D) or
buffer (A and C) in the presence of 1 pM DHR. Following a further incubation with
fMLP (100 nM, 10 min, C and D) or buffer (A and B), samples were analyzed by
flow cytometry (x-axis: logarithmic scale green fluorescence, LFL; y-axis: relative
cell number). Representative flow-cytometry (EPICS Profile II) histograms (n = 3 in
duplicate).
162
5.2.5.2 Concentration-Dependent Inhibition of PAF-Induced Shape Change by
PAF Receptor Antagonists
WEB 2086 was also used to inhibit neutrophil shape change induced by PAF. This
enabled its inhibitory capacity to be quantified for an effector response that was due
solely to PAF receptor activation and independent of other neutrophil stimulants.
Following a 30 min pre-incubation with human neutrophils, WEB 2086 had no effect
on the morphological appearance of control cells, but caused a concentration-
dependent inhibition of PAF-induced shape change that was again biphasic and
incomplete (73 ± 7%) up to 10 pM (Figure 5.10). Since [JH]WEB 2086, at
concentrations <200 nM, has been reported to bind specifically to a homogeneous
population of high-affinity PAF receptors in human neutrophils (Dent et al., 1989),
the biphasic nature of the antagonism by WEB 2086 in our experiments may have
represented binding, at concentrations >1 pM, to a lower-affinity
subtype/conformational state of extracellular or intracellular PAF receptors (De
Kimpeeta/., 1995; Stewart et al., 1990).
5.2.5.3 The Reversal of the PAF-Primed Superoxide Response is Enhanced by
PAF Receptor Antagonism
Having shown that pre-incubation of neutrophils with PAF receptor antagonists
inhibited both PAF-induced superoxide priming and shape change, we next
investigated whether the time-course for de-priming could be influenced by the
subsequent blockade of PAF receptors. When either 1 pM WEB 2086 or 1 pM UK-
74,505 was added 10 min after PAF (1 pM), there was a small, but significant,
increase in the rate of decay of the PAF-primed superoxide anion response (Figure
5.11), with UK-74,505 having the greater effect. This implies that at least a
proportion of PAF receptors remain in a functional state at the cell surface 10 min
after the addition of PAF, and that the rate of de-priming may be influenced by the
availability of functional PAF receptors.
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Figure 5.10
Concentration-Response of WEB-2086 on PAF-Induced Neutrophil Shape
Change.
(a) Neutrophils were pre-incubated for 30 min with WEB-2086 (10 nM-10 pM,
closed diamonds) or buffer control, and then treated with PAF (1 pM, 10 min) or
buffer (open squares). Samples were analyzed for percent shape change by flow
cytometry (mean ± SEM, n = 4 in triplicate), (b) Representative flow-cytometry
(EPICS Profile II) histograms of neutrophils incubated with (A) 1 pM PAF or (B) 10







Effect of WEB 2086 and UK-74,505 on Time-Course for PAF-Induced Priming
of fMLP-Stimulated Superoxide Anion Release in Human Neutrophils.
Neutrophils were incubated with PAF (1 pM. circles) or buffer (squares) for 0-120
min, with a further addition ofWEB 2086 (1 pM, white circles), UK-74,505 (1 pM.
grey circles) or buffer (black circles) 10 min after PAF. Following treatment with
fMLP (100 nM, 10 min) in the presence of 1 mg/ml cytochrome C, superoxide anion
release was assessed by scanning spectrophotometry (mean, n = 3 in triplicate. SEM
values all <10% of mean and are omitted for reasons of clarity). *P<0.05.
significantly different from values obtained in the absence of antagonist (ANOVA).
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It should be noted that the biphasic pattern of de-priming was preserved in the
presence of PAF receptor antagonists, again implicating a two-stage "recovery"
mechanism (Chapter 4). WEB 2086 also inhibited the secondary increase (between
30-120 min) in PAF-mediated neutrophil shape change (data not shown).
5.2.6 Tyrosine Phosphorylation of Intracellular Proteins
The stimulation of neutrophils by various priming agents has been reported to elicit
the tyrosine phosphorylation of several intracellular proteins (Lloyds and Hallett,
1994; Kanbara et al., 1993; Akimaru et al., 1992; Lloyds et al., 1995). Indeed, both
PAF and C-PAF have been shown to phosphorylate the same group of proteins, in a
concentration-, time-, and receptor-dependent manner (Gomez-Cambronero et al.,
1991). Some of these proteins are of similar molecular weight to those tyrosine
phosphorylated when neutrophils are primed by hypotonic shock or TNFa (Edashige
et al., 1993). Furthermore, the time-course of tyrosine phosphorylation of a 115-kDa
protein has been shown to correlate with the reversible, hypotonic priming of
neutrophils (Edashige et al., 1993): a similar protein (116-kDa) is affected within 2
min of PAF (100 nM) treatment, and remains phosphorylated for at least 10 min
(Gomez-Cambronero et al., 1991).
Therefore, by screening for proteins that were tyrosine phosphorylated in a transient
manner in parallel with the functional (superoxide) priming effects of PAF, we
ultimately aimed to identify specific proteins which were central to the priming
process. Parallel incubations were performed with TNFa, a neutrophil priming agent
that does not signal through the G-protein-linked receptor family utilized by classical
chemoattractants. PAF (1 pM, 10 min) and TNFa (lOOU/ml, 30 min) both primed
the fMLP-superoxide anion response of neutrophils: an effect that was more transient
with PAF than TNFa (Figure 5.12). However, despite detection of a number of
consistent, tyrosine-phosphorylated protein bands (using a monoclonal anti-
phosphotyrosine antibody), there was no detectable difference between the tyrosine
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phosphorylation levels of control, primed or de-primed neutrophils. This finding was
reproduced in eight out of nine experiments, all controlled for protein concentration
(assessed by the Coomassie Brilliant Blue staining of parallel gels). In the remaining
experiment, a protein of approximately 120-kDa was tyrosine phosphorylated in
primed (PAF 10 min, TNFa 30 min, and less so with TNFa 120 min), but not in
control or de-primed (PAF 120 min), neutrophils. Although this may have
represented the 115-116-kDa protein that has previously been associated with
neutrophil priming (Gomez-Cambronero et al., 1991; Edashige et al., 1993), it was
not a consistent association in our hands. Therefore, in an attempt to identify
whether our protein extraction or detection methodolgy was at fault, identical
experiments were repeated by Dr. V. Cherepanov and Professor G. Downey (Dept. of
Medicine, University of Toronto, Canada) using an alternative immunoblotting
protocol: again, optimal priming incubations with both PAF (10 min) and TNFa (30
min) failed to increase phospho-tyrosine levels in human neutrophils.
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(a) (b)
lOmin 30min 120min lOmin 30min 120min
(C)
10 min 30 min 120 min
Control 4.89 ±0.57 4.78 ±0.46 5.14 ±0.73
PAF 16.06 ±1.35 n/a 8.20 ± 1.21
TNFa n/a 23.44 ±3.19 21.90 ±2.45
Figure 5.12
Effect of PAF and TNFa on Neutrophil Protein Tyrosine Phosphorylation.
(a) Representative Immunoblot of Phosphorylated Tyrosine Residues. Neutrophils
were incubated, with PAF (1 pM), TNFa (100 U/ml) or buffer for 10-120 min.
Reactions were stopped at the appropriate times with 20% TCA, and PAGE was
performed using 4-20% Tris-glycine gels. Following transfer to nitrocellulose
membranes, proteins were immunoblotted with monoclonal anti-phosphotyrosine
antibody (4G10), and visualized by ECL. (b) Parallel gel stained with Coomassie
Brilliant Blue, (c) Parallel superoxide anion responses. Neutrophils were primed
with PAF (1 pM) or TNFa (100 /ml) for 10-120 min, prior to treatment with fMLP
(100 nM 10 min) in the presence of 1 mg/ml cytochrome C. Superoxide anion
release was assessed spectrophotometrically (mean ± SEM for triplicate
determination of representative experiment of 8).
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5.3 Discussion
While the basis for the decline in PAF-mediated priming is uncertain, the
maintenance of PMA responsiveness and re-priming potential indicate that it does
not reflect a diminished viablity or superoxide anion-generating capacity of human
neutrophils. However, neutrophils can synthesize a variety of inflammatory
mediators, some of which may act in a paracrine fashion to modulate neutrophil
responses: it was considered that such an agent with inhibitory properties might
contribute to the reversal of PAF-mediated neutrophil priming. Since adenosine is a
product of normal cellular activity that has been shown to inhibit both respiratory
burst and adhesion responses of human neutrophils (Cronstein et al., 1987; Stewart
and Harris, 1993; Walker et al., 1990; Ward et al., 1988; Cronstein et al., 1983;
Cronstein et al., 1992; Asako et al., 1993), it seemed an ideal candidate for this role.
However, the inclusion of adenosine deaminase (which degrades extracellular
adenosine) during the 2 hour neutrophil incubation with PAF, failed to maintain
PAF-mediated priming of fMLP-stimulated superoxide anion release. These data
contrast with a previous report where adenosine inhibited the superoxide priming
effect of 1 pM PAF (Stewart and Harris, 1993). It should be noted, however, that the
neutrophils used in this latter study were primed at the beginning of the assay, and
that this effect was also inhibited by adenosine. Basal neutrophil priming is a
confounding factor in many neutrophil activation studies and its importance in the ex
vivo manipulation of neutrophils is often underestimated. Nevertheless, the
neutrophil responses elicited by PAF may be modulated by other inflammatory
mediators, such as LTB4 or PGE2, but this possibility has not been pursued.
The two, structurally-unrelated PAF receptor antagonists, UK-74,505 and WEB
2086, were shown to suppress the priming effects of PAF. However, the biphasic,
partial inhibitory effects of WEB 2086 (<10 pM) implied that, unlike UK-74,505,
this compound was having complex effects, possibly via interaction with a non-
homogeneous population of PAF receptors. Although [JH]WEB 2086 has been
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reported to bind (KD 18.9 nM) to a homogeneous population of non-interacting
binding sites in human neutrophils when used at concentrations <200 nM (Dent et
al., 1989), it has since been proposed that the hydrophilic nature ofWEB 2086 might
allow it to traverse neutrophil membranes (at higher concentrations), and thereby
inhibit both the extracellular and the putative intracellular PAF receptor (Koike et al.,
1994; De Kimpe et al., 1995; Stewart et al., 1990). Since various priming agents,
including PAF (Doebber and Wu, 1987) and C-PAF (Tessner et al., 1989), have been
shown to promote PAF synthesis in human neutrophils (De Nichilo et al., 1991;
Wirthmueller et al., 1989; Stewart and Harris, 1991; Stewart et al., 1991; Worthen et
al., 1988), a role for intracellularly-retained PAF in neutrophil priming cannot be
excluded (Pabst, 1994).
Previous groups have demonstrated that exogenous PAF mediates its effects through
high-affinity receptors on the neutrophil surface; it is therefore possible that these
receptors play a central role in the reversal of PAF-induced responses. Indeed, the
functional uncoupling and subsequent down-regulation of cell-surface PAF receptors
has been proposed to underlie the homologous desensitization that occurs when
neutrophils are repeatedly exposed to PAF (O'Flaherty et al., 1992). PAF receptor
desensitization is rapid, occurring maximally within 15 s of PAF addition (0.1-10
nM) (O'Flaherty et al., 1992). However, the ability ofUK-74,505 and WEB 2086 to
increase the rate of de-priming following PAF treatment suggests that a population of
PAF receptors remains functionally active for at least 10 min. PAF receptor
desensitization is transient, with neutrophils beginning to recover their sensitivity to
PAF and regain high-affinity PAF receptors within approximately 10 min of PAF
exposure, a process which is completed by 60 min (O'Flaherty et al., 1992). This
explains why a second PAF challenge could re-prime the fMLP-superoxide response
after 2 hours, with no significant reduction in its priming potential (Chapter 4).
Furthermore, since TNFa could also re-prime PAF-recovered neutrophils, any
heterologous desensitization to TNFa had reversed within 2 hours. Heterologous
desensitization to fMLP has been shown not to occur (Gay, 1993; O'Flaherty et al.,
1992) and thus can be excluded as a potential mechanism of de-priming.
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Although binding studies have provided clear evidence that human neutrophils
express specific, high-affinity PAF receptors, they have also demonstrated high
levels of non-specific PAF binding to neutrophil plasma membranes (Bussolino et
al., 1984; O'Flaherty et al., 1986). More recently, it has been shown that the
internalization of PAF occurs via a receptor-independent, non-endocytic process,
which may involve the "flipping" of intact PAF across the perturbed plasma
membrane of stimulated neutrophils (Bratton et al., 1992). Furthermore, this uptake
process appears to be the rate-limiting step in PAF metabolism (Bratton et al., 1992;
Tokumura et al., 1990). Therefore, it was proposed that PAF may initially associate
with the external leaflet of the neutrophil plasma membrane, before either binding to
its high-affinity receptor or being internalized for subsequent metabolism (O'Flaherty
et al., 1992). The internalization of PAF may sequester ligand from specific PAF
receptors and indirectly promote its intramembranous metabolism and subsequent
removal to granular membranes (O'Flaherty et al., 1986). Thus, internalization may
represent a mechanism aside from homologous receptor desensitization that limits
the stimulation of neutrophils by PAF. Although PAF internalization begins within
approximately 2 min of PAF accumulating on the neutrophil surface (O'Flaherty et
al., 1992), it is a more gradual process than receptor desensitization, and requires at
least 20 min with PAF (200 pM-75 nM) to near completion (Bratton et al., 1992;
O'Flaherty et al., 1986). However, the capacity of neutrophils to internalize PAF
increases with increasing concentrations of extracellular PAF (O'Flaherty et al.,
1986). Therefore, the continual clearance of PAF from the immediate vicinity of
neutrophils may provide a mechanism to limit re-stimulation of neutrophils through
newly-expressed PAF receptors (O'Flaherty et al., 1992).
This putative desensitization-internalization-resensitization sequence may underlie
the reversal of PAF-mediated priming. For example, priming may be initiated by the
stimulation of PAF receptors on the neutrophil surface, which uncouple rapidly from
their signal transduction pathways once the signal has been transmitted to the cell
interior: whilst neutrophil priming is becoming established and apparent, PAF
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receptors become quantitatively down-regulated (O'Flaherty et al., 1992). After
approximately 10 min, neutrophils begin to recover their sensitivity to PAF as high-
affinity PAF receptors are either being re-expressed or uncovered. However, since
PAF may have been cleared by internalization at this stage, the amount of ligand
available for receptor occupancy is much reduced. If the intracellular signalling
pathways that mediate PAF-induced priming are subject to feedback mechanisms or
are short-lived and spontaneously abort, then priming will reverse unless a new
stimulus is applied to the cell. Therefore, as the extent of priming induced by PAF
appears to be linked directly to receptor occupancy (as implicated by its
concentration-dependence (Chapter 4)), priming will decline (intracellular signalling
permitted) as the extracellular concentration of PAF diminishes. This would explain
the increased rate of de-priming: (i) upon PAF receptor blockade with UK-74,505
and WEB 2086; and (ii) with a lower concentration of 10 nM PAF (Vercellotti et al.,
1988).
Despite such arguments, the identical, transient time-courses of superoxide priming
by PAF and C-PAF (a biologically active, yet non-metabolizable, analogue of PAF),
imply that the metabolism of PAF does not form the basis of the de-priming process.
Indeed, since C-PAF can also be internalized by neutrophils (Bratton et al., 1992)
and its biological potency correlates precisely with its binding affinity for the PAF
receptor (O'Flaherty et al., 1987), it is possible that the internalization, rather than
the metabolism, of PAF is the process which limits the duration of PAF-mediated
priming. However, the biphasic nature of superoxide de-priming following PAF
treatment suggests that two different mechanisms may be involved: since the second,
slower phase of decay occurred concurrently with the delayed, secondary increase in
neutrophil shape change (an event which was also inhibited by WEB 2086), the same
PAF receptor-dependent mechanisms may underlie both events.
The intracellular signalling mechanisms involved in neutrophil priming remain
uncertain, making it impossible to predict the mechanisms which contribute to the
reversal of this effect. Nevertheless, the time- and concentration-dependence of
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certain PAF-induced intracellular events have been shown to correlate with
functional priming responses. For example, PAF-induced priming of fMLP-
stimulated superoxide anion release concurs with: (i) the translocation of Gia2 to the
neutrophil plasma membrane (Alison Condliffe, personal communication); and (ii)
the tyrosine phosphorylation of several intracellular proteins (Nick et al., 1997;
Gomez-Cambronero et al., 1991). However, we were unable to confirm this latter
observation and hence could not establish a role for reversible protein tyrosine
phosphorylation in the transient neutrophil priming effects of PAF.
Other intracellular events, such as PKC activation (Gay, 1993; Gay and Stitt, 1988;
O'Flaherty and Nishihira, 1987) and [Ca2+]; elevation (Ingraham et al., 1982), have
2+
also been associated with PAF-mediated neutrophil priming, although Ca~ -
independent pathways of priming may also exist (Gay, 1993; Walker et al., 1991;
Koenderman et al., 1989). The activation of phospholipase A2 and D (Kanaho et al.,
1991; Nakashima et al., 1989), phosphoinositide turnover (Naccache, 1985) and
intracellular alkalinization (Naccache et al., 1986), also occur in PAF-treated
neutrophils. Thus, the subsequent reversibility/inhibition of any of the above events
may contribute to the transient nature of the priming effects of PAF. Furthermore,
the regulation of divergent intracellular signalling pathways may dictate the rate of
onset and subsequent duration of: (i) different priming-associated responses (e.g.
NADPH oxidase activity and cell polarization); and (ii) the priming effects of
individual agents (e.g. LPS, G-CSF and PAF).
In conclusion, the mechanisms underlying the reversible priming effects of PAF
remain uncertain. However, a diminished viablity or superoxide anion-generating
capacity of human neutrophils is not involved. In addition, de-priming is not solely
secondary to the metabolism of PAF, the paracrine effects of adenosine, or
homologous receptor desensitization (since PAF receptor antagonists increased the
rate of decay). The transient priming effects of PAF are most likely to reflect
reversal of intracellular events: the tyrosine phosphorylation of specific proteins and
the translocation of G-protein subunits to the plasma membrane warrant further
investigation.
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6. CHAPTER 6: THE PRIMING OF HUMAN NEUTROPHILS BY
TTJMOTJR NECROSIS FACTOR a
6.1 Introduction
The studies with PAF (Chapters 4 and 5) have provided clear evidence of receptor-
mediated priming that spontaneously and completely reverses. The primary aim of
the work in this Chapter was to establish whether the reported, more sustained,
priming effects of other pro-inflammatory mediators could be manipulated and
reversed.
PAF, InsP6 and hypotonic shock all prime neutrophils rapidly, which contrasts with
LPS (Guthrie et al., 1984; Condliffe et al., 1996), GM-CSF (Weisbart et al., 1985)
and IFN-y (Roberts et al., 1993) which all require at least one hour to elicit their
maximal priming effects. Since these latter agents are also amongst those reported to
have the most prolonged priming effects in neutrophils (Roberts et al., 1993; Carey
et al., 1994; Ichinose et al., 1990), this suggests that the rate of onset of neutrophil
priming may determine its subsequent reversibility. However, neutrophils have a
relatively short life-span in vitro due to their high rate of constitutive apoptosis, and
together with the long pre-incubation times required for LPS, GM-CSF and IFN-y to
induce their priming effects, this limits the subsequent manipulation of these
responses. It is also very difficult (as observed in our shape change experiments,
Chapter 4) to prevent some degree of spontaneous priming in neutrophils incubated
for >60 min ex vivo. Thus, a priming agent with a pre-incubation period longer than
that of PAF, but ideally less than one hour was required.
TNFa is an established pro-inflammatory agent (Berkow et al., 1987; Larrick et al.,
1987) that has been reported to elicit its optimal, receptor-mediated priming effects
within 30 min of exposure to suspension neutrophils (Condliffe et al., 1996; Elbim et
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al., 1993; Roberts et ah, 1993). Furthermore, it has been shown that the in vitro
priming effects of TNFa are long-lived. For example, priming of fMLP-stimulated
superoxide anion release has been reported to persist for at least 4 hours following
TNFa treatment (Ferrante et al., 1988), potentiation of the opsonised zymosan-
induced respiratory burst to be maintained for at least 90 min (Ozaki et al., 1988),
and enhancement of fMLP-induced degranulation to be preserved for at least 1 hour
(O'Flaherty et al., 1991). In addition, neutrophil shape change induced by TNFa has
been reported to remain unaltered for at least 50 min (Shimizu et al, 1993). It
should be noted that these times all represent the end of the respective study periods
and no attempt was made to follow these effects over a longer time-period.
Therefore, TNFa was selected as the receptor-mediated agent of choice whose
priming effects were sufficiently rapid, robust and sustained, to allow examination of
the potential for primed neutrophils to be "artificially" de-primed.
It was postulated in Chapter 5 that the duration of neutrophil priming might be linked
to the duration of cell-surface receptor occupancy, and that the spontaneous reversal
or negative-feedback regulation of intracellular signalling pathways might allow
termination of priming events, unless continual stimulatory signals were received by
the cell. This proposal was based on several observations, namely that: (i) the
specific blockade of PAF receptors (with two, structurally-different PAF receptor
antagonists) could increase the rate of reversibility of the superoxide priming effect
of PAF; (ii) the priming induced by a lower concentration of 10 nM PAF (Vercellotti
et al., 1988) appeared to be more transient than that observed with 1 pM PAF in our
studies; and (iii) the shape change induced by fMLP and C5a persisted until the
stimulus was removed by washing (Smith et al., 1979). Therefore, our initial
experiments were designed to adopt such strategies in an attempt to manipulate the
duration ofTNFa-induced neutrophil priming.
TNFa signals through two distinct receptor subtypes, of molecular masses 55 kDa
(TNF-R55) and 75 kDa (TNF-R75) (Brockhaus et al., 1990). However, since certain
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TNF-R-directed antibodies can fully mimic the activities of TNFa (especially
following their crosslinking) (Bigda et al., 1994; Espevik et al., 1990), it has been
suggested that the sole function of the native, trimeric TNFa ligand is to elicit
receptor oligomerization. Despite this, a complete lack of homology between the
intracellular domains of the two TNF-Rs implicates a divergence in both their
signalling mechanisms and their biological function (Tartaglia and Goeddel, 1992;
Dembic et al., 1990). Specific TNF-R antagonistic antibodies have been used to
examine the independent effects of the two receptors. TNF-R55 appears to be the
predominant mediator of the majority of the biological effects of TNFa (Tartaglia
and Goeddel, 1992; Barbara et al., 1994; Loetscher et al., 1993; Espevik et al.,
1990), including neutrophil priming (Barbara et al., 1994; Abe et al., 1995). In
systems where inhibition of TNF-R75 does attenuate the functional effects of TNFa,
a ligand passing model has been proposed (Tartaglia and Goeddel, 1992) in which
TNF-R75 (having the higher affinity and dissociation rate for TNFa) preferentially
binds TNFa and then passes it to neighbouring TNF-R55 to mediate its biological
effects. However, the exact functional relationship between the two receptors is still
unclear.
Therefore, the central aim of the work in this Chapter was to establish and
characterize a TNFa-induced model of sustained neutrophil priming, in order to
investigate whether such priming was also potentially reversible. In addition, the
availability of subtype-specific TNF-R blocking antibodies allowed examination of
the individual contributions made by TNF-R55 and TNF-R75 to the maintenance of
the TNFa-induced primed state.
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6.2 Results
6.2.1 The Reversibility of TNFa-Induced Priming of Human Neutrophils
In Chapter 4, it was established that TNFa could elicit a number of priming-
associated responses in human neutrophils, including shape change, adhesion
molecule upregulation, and priming of both superoxide anion release and
intracellular respiratory burst activity to fMLP. Based upon consistent reports of its
optimal priming effects in human neutrophils, a 30 min preincubation with TNFa
was used for these preliminary studies (Condliffe et al.t 1996; Elbim et al.t 1993;
Roberts et al., 1993). However, since TNFa also has the capacity to directly activate
neutrophils that are adherent (Nathan, 1987), the inadequate suspension of
neutrophils may explain the marked variability that exists in the literature regarding
the concentration-dependence and priming potential of TNFa in vitro. Therefore, in
order to minimize adherence, neutrophils were incubated at low cell density in round-
bottomed, polypropylene Eppendorf tubes and shaken continuously, yet gently (110
cycles/min), for the duration of the assay. Both the macroscopic and light-
microscopic evaluation of these neutrophils revealed that they remained in
suspension (i.e. did not become adherent or form cell aggregates) for at least 2 hours.
6.2.1.1 Time-Course for the Induction ofNeutrophil Shape Change by TNFa
The induction of neutrophil shape change by PAF was shown to be the most rapid
and transient of the three indices of priming (Chapter 4). This suggested that the
polarization response might provide the earliest indication of whether the priming
elicited by a particular agent would/could reverse. Therefore, as a verification of the
prolonged actions of TNFa in human neutrophils, the time-course for the induction
of shape change was examined. When neutrophils were incubated with 200 U/ml
TNFa they underwent a gradual change in shape that reached a plateau (70 ± 5%)
within 30 min and was maintained for at least 2 hours (Figure 6.1). This
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demonstration of a persistent polarization response to TNFa confirms a previous
observation (Shimizu et al., 1993).
6.2.1.2 Time-Course for the Functional Upregulation ofCDllb/CD18 by TNFa
As a second assessment of the stability of the priming effect of TNFa, the time-
course for the functional upregulation of CD1 lb/CD 18 was determined. The number
of neutrophils with surface-bound ACLB was maximal (50 ± 6%) within 30-60 min
exposure to 200 U/ml TNFa (Figure 6.2). Although this absolute effect (i.e. the
percentage of neutrophils with attached beads) was maintained thereafter, there was a
reproducible shift in the number ofACLB bound per neutrophil, so that after 2 hours
the majority of neutrophils had 1-2 beads on their surface, in contrast to the 30 min
and 60 min time-points where a higher number of beads bound per cell was common.
Thus, whilst the number of neutrophils with functionally upregulated CDllb/CD18
was maintained, the overall "effectiveness" of CD 1 lb/CD 18-ACLB interactions on
these cells (which may reflect CD1 lb/CD 18 affinity, avidity or expression) showed
signs of decaying between 60 min and 120 min post TNFa exposure. This implies
that the functional upregulation of CD1 lb/CD 18 by TNFa, at the single cell level,
may be more transient than the accompanying neutrophil shape change response.
6.2.1.3 The Priming of fMLP-Induced Superoxide Anion Release by TNFa
As the gold standard indicator of neutrophil priming, the duration of the
enhancement of fMLP-stimulated superoxide anion release was next investigated.
Initially, it was important to establish the optimal priming concentration of TNFa to
be used in these studies. A 30 min incubation with TNFa (0.1-1000 U/ml) elicited
minimal direct superoxide anion release from human neutrophils (verifying the lack
of cell adhesion), but caused a concentration-dependent enhancement (EC50 21 ±3
U/ml) of the subsequent superoxide response to fMLP (100 nM, 10 min) that was
maximal with >100 U/ml TNFa (Figure 6.3). Therefore, a concentration of 100




Time-Course for TNFa-Induced Shape Change in Human Neutrophils.
(a) Time-course for TNFa-induced shape change. Neutrophils were incubated with
TNFa (200 U/ml, closed circles) or buffer (open squares) for 0-120 min. Samples
were analyzed for percent shape change by flow cytometry (mean ± SEM, n = 4 in
duplicate. Where not shown, SEM values fall within symbols), (b) Representative
flow-cytometry (EPICS Profile II) histograms of control neutrophils (A) and
neutrophils incubated with TNFa for 30 min (B) or 120 min (C) (x-axis: mean




Time-Course for TNFa-Induced Binding ofACLB in Human Neutrophils.
(a) Time-course for TNFa-induced binding of ACLB. Neutrophils were incubated
with TNFa (200 U/ml, closed circles) or buffer (open squares) for 0-120 min. ACLB
(0.75% v/v) were added 15 min before the termination of the reaction with 0.5%
glutaraldehyde, except for time-points <15 min where beads were added before the
agonist. Samples were analyzed for attached ACLB by flow cytometry (mean ±
SEM, n = 4 in duplicate. Where not shown, SEM values fall within symbols), (b)
Representative flow-cytometry (EPICS Profile II) histograms of control neutrophils
(A) and neutrophils incubated with TNFa for 60 min (B) or 120 min (C) (x-axis:


















i i i i i i r
0 0.1 1 10 100 1000
[TNFa](U/ml)
Figure 6.3
Concentration-Response for TNFa-Induced Priming of fMLP-Stimulated
Superoxide Anion Release in Human Neutrophils.
Neutrophils were incubated with TNFa (0.1-1000U/ml, 30 min) or buffer, and then
treated with fMLP (100 nM, 10 min. closed circles) or buffer control (open squares)
in the presence of 1 mg/ml cytochrome C. Superoxide anion release was assessed by
scanning spectrophotometry (mean ± SEM. n = 3 in duplicate).
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6.2.1.4 Time-course for the Priming of Superoxide Anion Release by TNFa
In previous experiments (e.g. Figure 5.13), the effect of TNFa on fMLP-stimulated
superoxide anion release was examined only at very selected time-points. Hence, a
far more detailed time-course was required to determine the precise kinetics and
persistence of this priming effect.
In agreement with previous studies (O'Flaherty et al., 1991; Condliffe et al., 1996),
the priming of human neutrophils for fMLP-stimulated (100 nM, 10 min) superoxide
anion release reached a plateau following 30 min exposure to 100 U/ml TNFa
(Figure 6.4a). Although this response was maintained for 2 hours in certain
individuals, the maintenance of the priming effect was highly variable with
decreases, no change, or even further increases (30-120 min) in the level of
enhancement. This variability did not reflect inter-assay differences in either the
basal level of neutrophil priming or the absolute degree of priming elicited after a 30
min treatment with TNFa (Figure 6.4b). Thus, the duration of the superoxide-
priming effect of TNFa appeared to be donor-dependent. It should also be noted that
where TNFa-induced priming did reverse spontaneously, this differed from the
pattern observed following PAF exposure: (i) irrespective of the rate of decay, the
pattern was exponential and never biphasic; and (ii) a residual priming effect was




Time-Course for TNFa-Induced Priming of fMLP-Stimulated Superoxide
Anion Release in Human Neutrophils.
(a) Representative time-course for TNFa-induced superoxide priming. Neutrophils
were incubated with TNFa (100 U/ml, closed circles) or buffer (open squares) for 0-
120 min. Following treatment with fMLP (100 nM, 10 min) in the presence of 1
mg/ml cytochrome C, superoxide anion release was assessed by scanning
spectrophotometry (mean of triplicate determination from single experiment), (b)
Variability in the degree and duration of TNFa-induced priming of IMLP-stimulated
superoxide anion release (mean of triplicate determinations from 6 experiments).
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6.2.1.5 Summary of the Time-Courses for TNFa-Induced Priming Effects in
Human Neutrophils
(i) TNFa elicits its maximal effects on neutrophil morphology after 30 min, and this
shape change effect is maintained for at least 2 hours.
(ii) The functional upregulation of CDllb/CD18 is maximal within 30-60 min
exposure to TNFa. Thereafter, the degree of this activation appears to partially
reverse, at the single cell level.
(iii) TNFa primes the superoxide response to fMLP after an optimal 30 min pre¬
incubation with human neutrophils. Although there is marked variability in the
subsequent reversal of this enhancement, a residual priming effect is always apparent
at 150 min.
184
6.2.2 Manipulation of the Priming Effects of TNFa
The principal aim of this Chapter was to establish whether sustained, receptor-
mediated priming effects could be manipulated and reversed. However, the
unexpected variability in the duration of the superoxide-priming effects of TNFa,
together with the finding that neutrophils could remain polarized whilst de-priming
with respect to respiratory burst activity, confounded the subsequent manipulation of
these responses. Nevertheless, we decided to continue with our investigations, in the
knowledge that the neutrophils of approximately 50% of donors showed no
significant reduction in their superoxide-priming effect within the 2 hour period
(Figure 6.4). Two strategies were chosen to evaluate the contribution of sustained
TNFa receptor occupancy to the maintenance of the primed state. Since it was
suggested that the extracellular ligand concentration (and hence the magnitude of the
initial and ongoing response) might determine the rate of neutrophil de-priming
(Chapter 5), the reversibility of priming induced by different concentrations of TNFa
was first investigated.
6.2.2.1 The Influence of Ligand Concentration on the Reversibility of TNFa-
Induced Neutrophil Priming
Human neutrophils were preincubated for 2 hours with three different concentrations
of TNFa. The selected TNFa concentrations were: (i) the optimal priming
concentration of 100 U/ml; (ii) a sub-maximal concentration of 20 U/ml,
approximating the IC50 value for priming of the fMLP-superoxide anion response;
and (iii) a supra-maximal concentration of 300 U/ml. A 30 min preincubation period
with each of these concentrations was optimal for the priming of fMLP-stimulated
superoxide anion release (data not shown). As expected from the concentration-
dependency of these priming effects (Figure 6.3), 100 U/ml TNFa elicited the
greatest degree of priming, whilst 20 U/ml TNFa elicited the least. However, when
these different priming potentials were accounted for, there was no significant
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difference in the rate of de-priming between the three ligand concentrations (Figure
6.5). Furthermore, within 90 min of TNFa exposure, the superoxide priming effect
had reached a level that was similar for all three TNFa concentrations, and remained
so for a further 30 min period.
6.2.2.2 The Differential Effects of Anti-TNF-R55 and Anti-TNF-R75 Antibodies
on TNFa-Induced Priming of Superoxide Anion Release
Since the concentration of TNFa (20-300 U/ml) was found to affect neither the rate
nor the extent of spontaneous reversal of the superoxide-priming effect, the
contribution of each TNF-R subtype to the maintenance of the primed response was
next investigated. Two, specific, mouse monoclonal, antagonistic antibodies (mAb)
were utilized: (i) an IgG, anti-human TNF-R55 mAb, and (ii) an IgG2A anti-human
TNF-R75 mAb.
Preliminary flow-cytometric (antibody titration) analysis demonstrated that the
neutrophil binding of each antibody reached a plateau at approximately 28 pg/ml.
Furthermore, a 30 min pre-incubation with either anti-TNF-R55 (28 pg/ml) or anti-
TNF-R75 (28 pg/ml) was shown to cause optimal inhibition of the early pro-
apoptotic effect of TNFa (250 U/ml) in cultured human neutrophils (Joanna Murray,
personal communication): control antibodies (isotype-matched, anti-human IL-2-R
a-chain) failed to affect this response, and neither anti-TNF-R mAb affected the
basal rate of neutrophil apoptosis following 6 or 20 hours in culture.
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Figure 6.5
Effect of Ligand Concentration on the Time-Course for TNFa-Induced Priming
of fMLP-Stimulated Superoxide Anion Release.
Neutrophils were incubated for 0-120 min with 100 U/ml TNFa (black circles), 20
U/ml TNFa (grey circles) or 300 U/ml TNFa (white circles). Following treatment
with fMLP (100 nM, 10 min) in the presence of 1 mg/ml cytochrome C, superoxide
anion release was assessed by scanning spectrophotometry. Values are expressed as
% maximal superoxide anion release at 30 min for each TNFa concentration (100%
values (nmol/106 cells): 100 U/ml TNFa 22.7 ± 3.2; 20 U/ml 15.3 ± 2.7; 300 U/ml
20.8 ± 2.9. Mean, n = 4 in duplicate. SEM values all <10% ofmean and are omitted
for reasons of clarity).
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Human neutrophils were pre-incubated for 30 min with anti-TNF-R55 (28 pg/ml),
anti-TNF-R75 (28 pg/ml), or both antibodies together, in order to establish the
contribution of each TNF-R subtype to the priming effects of TNFa. After a 30 min
pre-incubation, neither antibody alone nor in combination had any significant effect
on the superoxide responses of control or 100 nM fMLP-stimulated neutrophils
(Figure 6.6). However, anti-TNF-R55 mAb markedly inhibited (86 ± 6%) the
TNFa-primed superoxide response; anti-TNF-R75 mAb had a far smaller inibitory
effect (8 ± 5%). When both antibodies were used together, the priming effect of
TNFa was effectively abolished (96 ± 3% inhibition). Following an extended 2 hour
mAb pre-incubation with human neutrophils, these inhibitory actions persisted.
These findings imply that TNF-R55 is the principal TNF-R subtype mediating the
superoxide-priming effects of TNFa in suspension neutrophils whilst TNF-R75 plays
a very minor role.
6.2.2.3 The Potential for TNF-R55 and TNF-R75 Blockade to Reverse TNFa-
Induced Priming of Superoxide Anion Release
Having established the contribution of each TNF-R subtype to the initiation of
TNFa-mediated priming of superoxide anion release, we next investigated the role of
TNF-R55 and TNF-R75 in the maintenance of the primed state. Therefore, anti-
TNF-R55 mAb (28 pg/ml), anti-TNF-R75 mAb (28 pg/ml) or both antibodies
together, were introduced into the neutrophil incubation 30 min after the addition of
TNFa (100 U/ml). A 90 min incubation with anti-TNF-R55 mAb caused a
significant reduction (76 ± 6%) in the residual TNFa-mediated priming of fMLP-
stimulated superoxide anion release (Figure 6.7); a smaller reduction was observed
with anti-TNF-R75 mAb (44 ± 5%). When both TNF-R55 and TNF-R75 mAbs were
combined, the reduction was approximately mid-way (60 ± 7%) between the
individual effects of the two antibodies. Although investigations were hampered by
the spontaneous reversibility of the TNFa-mediated superoxide-priming effect, these
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Figure 6.6
Effect of TNF-R55 and TNF-R75 Blockade on TNFa-Induced Priming of fMLP-
Stimulated Superoxide Anion Release.
Neutrophils were pre-incubated for 30 min with anti-TNF-R55 mAb (28 jig/ml, black
bars), anti-TNF-R75 mAb (28 |ig/ml, white bars), anti-TNF-R55 plus anti-TNF-R75
mAbs (dark grey bars), or buffer (light grey bars). Following treatment with TNFa
(100 U/ml, 30 min) or buffer control, neutrophils were incubated with fMLP (100
nM, 10 min) or buffer in the presence of 1 mg/ml cytochrome C. Superoxide anion
release was assessed by scanning spectrophotometry (mean ± SEM. n = 4 in
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Figure 6.7
Effect of TNF-R55 and TNF-R75 Blockade on the Reversibility of TNFa-
Induced Priming of fMLP-Stimulated Superoxide Anion Release.
Neutrophils were incubated for 30 min with 100 U/ml TNFa (represents "post-
priming value") or PBS control prior to a further 90 min incubation in the presence of
anti-TNF-R55 mAb (28 pg/ml, 55), anti-TNF-R75 mAb (28 pg/ml, 75), anti-TNF-
R55 plus anti-TNF-R75 mAbs (55 + 75) or buffer control. Neutrophils were then
incubated with fMLP (100 nM, 10 min) and superoxide anion release was assessed
spectrophotometrically. Data represent percent of post-priming value remaining at
120 min (100% value = 22.6 ± 3.4 nmol CF /IO6 cells). Mean ± SEM, n = 4 in
duplicate. *P<0.05, significantly different from values obtained in the absence of
antibody (ANOVA).
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6.2.2.4 The Differential Effects of Anti-TNF-R55 and Anti-TNF-R75 Antibodies
on TNFa-Induced Neutrophil Shape Change
Owing to the limitations incurred by the spontaneous reversal of TNFa-mediated
priming of superoxide anion release, the capacity to reverse the associated, persistent
shape change response was next investigated. In order to establish the contribution
of each TNF-R subtype to the initiation of the polarization response, human
neutrophils were pre-incubated for 30 min with anti-TNF-R55 mAb (28 pg/ml), anti-
TNF-R75 mAb (28 pg/ml) or both antibodies together, before the addition of 100
U/ml TNFa or buffer for 30 min. Neither antibody had any effect upon the resting
morphology of control neutrophils (Figure 6.8). However, while anti-TNF-R55 mAb
could markedly inhibit (78 ± 7%) the shape change elicited by TNFa, anti-TNF-R75
had no inhibitory effect (11+ 2% enhancement). When the two antibodies were used
in combination, no augmentation of the action of anti-TNF-R55 mAb was observed
(70 ± 6% inhibition). Thus, it would appear that TNF-R55 is also the principal TNF-
R subtype through which TNFa mediates the shape change of human neutrophils.
6.2.2.5 The Influence of TNF-R55 Blockade on the Reversibility of TNFa-
Induced Neutrophil Shape Change
The demonstration that TNF-R55 was the predominant TNF-R subtype involved in
the induction of shape change by TNFa suggested that the subsequent blockade of
this receptor might promote the reversal of the sustained polarization response.
Therefore, human neutrophils were primed with TNFa under optimal conditions
(100 U/ml, 30 min) prior to incubation with anti-TNF-R55 mAb (28 pg/ml) for a
further 90 min. However, to our surprise, the TNFa-induced polarization response
was not diminished (9 ± 2% enhancement) by the inclusion of anti-TNF-R55 mAb
(Figure 6.9) (there was also a small increase (15 ± 4%) in the shape change of control
neutrophils following antibody treatment). These observations imply that the
maintenance of TNFa-induced neutrophil shape change does not require sustained









Effect of TNF-R55 and TNF-R75 Blockade on TNFa-Induced Neutrophil Shape
Change.
Neutrophils were pre-incubated with anti-TNF-R55 mAb (28 pg/ml, A and B), anti-
TNF-R75 mAb (28 pg/ml, C and D), anti-TNF-R55 plus anti-TNF-R75 mAbs (F) or
buffer (E) for 30 min. Following treatment with TNFa (100 U/ml, 30 min, B. D, E
and F) or buffer control (A and C), samples (black outlines) were analyzed for
percent shape change and plotted against control samples (light grey outlines) (x-
axis: mean forward light scatter, FS; y-axis: relative cell number). Representative




Effect of TNF-R55 Blockade on the Reversibility of TNFa-Induced Neutrophil
Shape Change.
Neutrophils were incubated for 30 min with INfFa (100 U/ml, B and C) or buffer
(A), prior to a further 90 min incubation in the presence of anti-TNF-R55 mAb (28
pg/ml, C) or buffer (A and B). Samples were analyzed for percent shape change by
flow cytometry (x-axis: mean forward light scatter, FS; y-axis: relative cell number).
Representative flow-cytometry (EPICS Profile II) histograms (n = 3 in duplicate).
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6.3 Discussion
TNFa is an established, receptor-mediated priming agent that has been reported to
have prolonged effects in human neutrophils (Shimizu et al., 1993; Ozaki et al.,
1988; Ferrante et al., 1988). Thus, it was selected as a model to investigate whether
the duration of priming could be limited by the modulation of receptor occupancy.
The responses elicited by TNFa were much slower in onset than those induced by
PAF (Chapter 4), in agreement with our previous hypothesis that the time required to
establish neutrophil priming may determine its subsequent reversibility. However,
considerable differences were observed in the potential for each of the three indices
of TNFa-mediated neutrophil priming to reverse. Indeed, a distinct and unique
pattern of TNFa-mediated priming emerged, that is outlined below.
The shape change induced by TNFa was sustained, showing no significant reversal
during the 2 hour period. This persistent polarization response confirms a previous
observation (Shimizu et al., 1993). Although the rapid and transient nature of PAF-
induced neutrophil shape change (Chapter 4) suggested that this might be the earliest
(and possibly the most sensitive) indicator of whether neutrophil priming would
reverse spontaneously, the shape change response elicited by TNFa was the most
stable of the three tested indices of priming. Thus, the relative duration of different
priming responses may be agonist-specific.
TNFa elicited the functional upregulation of CD1 lb/CD 18 on the surface of human
neutrophils. When this response was quantified by sub-dividing neutrophils into
those with or without attached fluorescent beads, the number of bead-binding
neutrophils was maintained for at least 2 hours. This observation concurs with the
recent report that TNFa causes a sustained increase in the surface expression of these
adhesion molecules (Condliffe et al., 1996). However, the sub-division of
neutrophils into bead-binding or non-bead-binding populations takes no account of
the actual number of beads bound to an individual neutrophil. Indeed, when
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neutrophils were categorized with respect to the extent of bead-binding, the
activation of CD1 lb/CD 18 at the single cell level was seen to diminish after 60 min.
This implies that TNFa-induced upregulation of CDllb/CD18 affinity or avidity
(following integrin clustering) is more transient than either the increased expression
of CD1 lb/CD 18 or the accompanying neutrophil shape change.
In marked contrast to TNFa-induced shape change and the functional upregulation of
CD1 lb/CD 18, the duration of priming for enhanced superoxide anion release was
highly variable. The rate of de-priming following TNFa treatment showed no
correlation with the basal level of neutrophil priming, the concentration of TNFa, or
the extent of TNFa-induced priming after 30 min, implying that such variability may
be donor-dependent. In approximately 50% of cases there was no significant
reduction in the enhancement of fMLP-stimulated superoxide anion release within
the 2 hour period, confirming the prolonged priming effects of TNFa reported
previously (Ozaki et al., 1988; Atkinson et al., 1988; Ferrante et al., 1988).
Although the remaining cases showed variable degrees of spontaneous reversibility, a
residual priming effect of TNFa was always present at the end of the incubation:
upon re-examination of the available literature, this reversibility was similar to that
reported for the priming of fMLP-induced intracellular respiratory burst activity by
100 U/ml TNFa, where a residual (30% of maximal) priming effect was still present
after 2 hours (Roberts et al., 1993). However, a different group of investigators
found that the sub-population of neutrophils primed by 100 U/ml TNFa had
completely disappeared within 60 min (Elbim et al., 1994), suggesting that
neutrophils may have the potential to recover following TNFa-induced priming.
Although different neutrophil isolation and incubation procedures may underlie such
discrepancies between studies, it is clearly possible that the presentation of mean
values may have masked genuine inter-donor variability in the capacity of
neutrophils to de-prime following TNFa exposure.
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Minimally primed human neutrophils that have been freshly isolated by Plasma-
percoll separation express approximately equal numbers of the two TNF-R subtypes
(Sarah Dunkley and Joanna Murray, personal communication). However, it is
currently believed that TNF-R55 is the principal mediator of the bioactivities of
TNFa in all cell types, including neutrophils (Tartaglia and Goeddel, 1992; Barbara
et ah, 1994; Loetscher et ah, 1993; Espevik et ah, 1990). In agreement with this,
both the induction of neutrophil shape change by TNFa, and the priming of fMLP-
stimulated superoxide anion release were found to be almost exclusively dependent
upon the activation of TNF-R55. This confirms a previous report where agonistic
anti-TNF-R55 antibodies were shown to upregulate the surface expression of
CDllb/CD18 on human neutrophils, and to enhance fMLP-stimulated release of
superoxide anions, elastase and lactoferrin (Abe et ah, 1995). Whilst agonistic anti-
TNF-R75 antibodies were without effect in this latter study, the use of selective,
mutein (mutant protein) receptor agonists has implicated an accessory role for TNF-
R75 in the priming of superoxide anion release (Barbara et ah, 1994). Our own
investigations suggest that: (i) any co-operative effect of TNF-R75 with TNF-R55
for the priming of superoxide anion release is very modest; and (ii) TNF-R75 plays
no part in (or even inhibits) the polarization response to TNFa.
In Chapter 5, it was proposed that the primed neutrophil state would be maintained
so long as stimulatory signals were received by the cell. This was based upon the
demonstration that neutrophil polarization to both C5a and fMLP is sustained until
the cells are washed (Smith et ah, 1979), and the notion that the transient priming
effects of PAF may be secondary to PAF receptor desensitization and the rapid
internalization of this ligand by neutrophils (Bratton et ah, 1992; O'Flaherty et al.t
1986). However, following incubation with TNFa, there is a rapid and dramatic
reduction (at least 60% by 60 min) in the surface expression of both TNF-R55 and
TNF-R75 (Sarah Dunkley, personal communication). The almost instantaneous
down-regulation observed in TNF-R55 may be secondary to its rapid internalization
(maximal within 5 min) (Mosselmans et ah, 1988); although TNF-R75 lacks the
tyrosine consensus sequence necessary for internalization (Collawn et al. 1990), both
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TNF-75R and TNF-R55 can be shed from the surface of stimulated neutrophils
(Porteu and Hieblot, 1994; Lantz et al., 1990; Schleiffenbaum and Fehr, 1990; Porteu
and Nathan, 1990). These proteolytically cleaved TNF-Rs were initially identified as
soluble TNFa-binding proteins in serum (Peetre et al, 1988; Gatanaga et al., 1990),
and may serve to dampen the effects of TNFa by sequestering it from membrane-
bound receptors or, at lower concentrations, prolong the effects of TNFa by serving
as a reservoir of biologically-active TNFa (Aderka et al., 1992).
Despite the rapid down-regulation of both TNF-R subtypes that occurs in the
presence of TNFa, neutrophils remained polarized for at least 2 hours following
TNFa treatment. Furthermore, optimally-established shape change could not be
reversed by the selective blockade of TNF-R55 (the dominant, if not exclusive,
receptor subtype involved in the initiation of neutrophil polarization to TNFa).
These observations imply that persistence of TNFa-mediated shape change is not
dependent upon the continual stimulation of neutrophils through surface TNF-Rs.
In contrast, the residual primed state of respiratory burst activity observed 2 hours
after the addition of TNFa does appear to depend upon the ongoing activation of
TNF-R55 by TNFa. Although these investigations were hampered by the
spontaneous reversal of the TNFa-induced priming effect, they suggest that
stimulation of the small population of TNF-Rs remaining at the cell surface may be
sufficient to maintain a primed state of oxidase activity. However, TNF-R75
appeared to hinder, rather than aid, the function of TNF-R55 in the maintenance of
the superoxide priming effect: this might be secondary to the re-expression of TNF-
R75, but not TNF-R55, which begins approximately 2-3 hours following TNFa
treatment (Sarah Dunkley, personal communication). Consequently, the higher
affinity of TNF-R75 for TNFa (Schall et al., 1990; Loetscher et al., 1990) may
sequester ligand from TNF-R55, arguing against a ligand passing model. On the
contrary, agonistic anti-TNF-R75 and anti-TNF-R55 antibodies have been shown to
act synergistically to maintain CDllb/CD18 expression and neutrophil adhesion
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following a 2-3 hour exposure to TNFa (Abe et al., 1995). Thus, any interaction
between the two TNF-R subtypes may depend upon the functional response.
In conclusion, it appears that the inherent reversibility of TNFa-mediated priming of
superoxide anion generation may depend on negative feedback of intracellular
events, as proposed previously for PAF (Chapter 5). The rate of onset and efficiency
of the various feedback steps may underlie the differences between the duration of:
(i) the three indices of priming; and (ii) PAF- and TNFa-primed responses.
However, maintenance of the superoxide priming effect (and possibly CD1 lb/CD 18
avidity) may also rely upon the availability of functional TNF-R (especially TNF-
R55) and therefore, ultimately, on the combined rate of TNF-R internalization and
shedding. Since TNF-R expression can be influenced by various pro-inflammatory
stimuli (Porteu and Nathan, 1990), the pre-stimulation of neutrophils in vivo may
also contribute to the subsequent in vitro variability in the superoxide priming effects
of TNFa. Thus, the regulation of receptor expression may provide an effective
means of limiting certain neutrophil responses to TNFa. Finally, if inter-donor
variability does exist in the capacity of neutrophils to maintain a primed response to
TNFa, this may reflect important differences in TNF-R function and regulation
between subjects, and therefore merits further investigation.
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7. CHAPTER 7: SUMMARY
The work in this thesis has addressed the potential for neutrophil priming to reverse.
It was essential to commence with a population of pure yet minimally-primed human
neutrophils in order to avoid the restrictions engendered by basally-primed control
responses. Thus, peripheral blood neutrophils were isolated using dextran
sedimentation and plasma/Percoll gradients, with meticulous attention paid to the
maintenance of a sterile "LPS-free" environment at all times. The continual
maintenance of incubation temperature and neutrophil suspension allowed prolonged
in vitro investigations to be performed using "quiescent" and viable neutrophils.
The priming effects of certain pro-inflammatory agents (e.g. LPS, GM-CSF, G-CSF
and IFN-y) have been reported to persist for several hours. However, the observation
that physico-chemical stimuli (such as hypotonic shock and cell swelling) could
prime neutrophils in a reversible manner suggested that priming may not always be
sustained. To examine the possible in vivo significance of this reversible priming
process, we initially selected InsP6 as a potential priming agent present at high
micromolar concentrations in the cytoplasm of cells (and hence likely to be released
from effete cells at inflammatory foci). Although the previously reported in vitro
priming effect of InsP6 (100 pM) was confirmed and found to be rapid (30-120 s), the
magnitude of the priming effect was slight in comparison to LPS and was not
mediated by specific extracellular receptors. Thus, an alternative mechanism, such as
the cation-chelating properties of InsP6, is proposed to underlie the observed priming
ability. Nevertheless, the capacity of InsP6 to induce membrane perturbations may
link the transient priming effects of this agent, hypotonic shock and cell swelling.
An alternative approach for examining potential neutrophil de-priming was then
pursued using PAF, a well-established, receptor-mediated priming agent. PAF
(1 pM) was shown to act rapidly (<10 min), eliciting considerable enhancement of
fMLP-stimulated respiratory burst activity (the gold standard indicator of priming),
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whilst inducing cell polarization and the functional up-regulation of CDllb/CD18.
However, these priming-associated effects were not sustained, but underwent
spontaneous and complete reversal within 2 hours: neutrophils remained viable and
fully responsive to PMA throughout this time. Neither the release of adenosine (a
paracrine inhibitor of neutrophil responses) nor the metabolism of PAF appeared to
be involved in the reversal of the priming effects of PAF. On the contrary, the
specific blockade of PAF receptors with WEB 2086 and UK-74,505 (added 10 min
after PAF) increased the rate of decay of the PAF-primed superoxide response,
suggesting that PAF receptor desensitization was not complete 10 min after PAF
treatment. Since PAF-primed neutrophils that had spontaneously recovered could
subsequently be fully re-primed when challenged with either PAF or TNFa, this
represented the first demonstration that priming in response to a receptor-mediated
agent was fully reversible.
We then investigated whether the receptor-mediated priming effects of TNFa, which
had previously been reported to be more sustained than those induced by PAF, could
be artificially manipulated and reversed. Optimal neutrophil priming by TNFa (100
U/ml) required a 30 min incubation and was shown to be mediated predominantly
through the TNF-R55 subtype. Whilst the TNFa-induced polarization response was
maintained for at least 2 hours, the accompanying functional up-regulation of
CD1 lb/CD18 showed signs of decay (at the single cell level) within this time period,
and the duration of priming for fMLP-stimulated superoxide anion release varied
dramatically between experiments. Since inter-donor variability is inherent to many
studies of neutrophil activation, it may have been responsible for the latter effect of
TNFa; however, the pronounced variability in the priming effects of TNFa is in
marked contrast to the reproducible effects of PAF, InsP6 or hypotonic shock, and
suggests that the mechanism of priming induced by TNFa is more complex than that
elicited by these other agents.
From the data presented in this thesis and other published reports, it would appear
that neutrophil priming in vitro may fall into two distinct categories: (1) fully
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reversible (e.g. that induced by PAF, hypotonic shock, cell swelling, InsP6 and
potentially IL-8); or (2) largely irreversible (e.g. with GM-CSF, G-CSF, IFNy and
LPS). Since the boundaries between these two groups are indistinct, further study is
required to classify agents such as TNFa. However, in general, agents in group (1)
require shorter incubation periods to elicit their optimal priming effects than group
(2) members. Thus, the rate of onset of neutrophil priming may be a key determinant
of its subsequent reversibility. In the absence of any clear mechanistic basis for
neutrophil priming, it is possible that the discrete signalling pathways used by
individual priming agents will ultimately dictate both the speed and duration of the
elicited responses. Nevertheless, it is also possible that neutrophils, given sufficient
time, may eventually recover from all types of priming: their inherently short life¬
span dictates whether recovery will be detected.
It is unlikely that neutrophils within an inflammatory focus would be exposed in
isolation to PAF or indeed other "transient" priming agents. It is more plausible that
a number of pro-inflammatory mediators act in synergy to allow fine-tuning of the
overall inflammatory response, thereby defining the exact balance between the
microbicidal and potentially tissue-damaging consequences of neutrophil activation.
However, individual agents clearly have a characteristic pattern of priming responses
in vitro which probably reflects their functional roles in vivo. One might speculate
that priming agents with a long duration of action may be responsible for
maintenance of functionally-upregulated neutrophils following widespread or
prolonged inflammatory insults; priming agents with transient effects may be more
important in the early stages of the acute inflammatory response. In this model, a
persistent state of neutrophil hyper-responsiveness following minimal focal trauma
would be more detrimental than beneficial to the host. Since neutrophil priming is
becoming increasingly associated with a variety of pathological states such as ARDS
and rheumatoid arthritis, the recognition that neutrophils have the potential to de-
prime may allow the pro-inflammatory effects of neutrophil priming/activation to be
counteracted in its very earliest stages.
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Characterization of inositol hexakisphosphate (InsP6)-mediated
priming in human neutrophils: lack of extracellular [ H]-InsP6
receptors
E. Kitchen, A.M. Condlifife, A.G. Rossi, C. Haslett & 'E.R. Chilvers
Respiratory Medicine Unit, Department of Medicine (RIE), Rayne Laboratory, University of Edinburgh, Medical School, Teviot
Place, Edinburgh EH8 9AG
1 Inositol hexakisphosphate (InsP6) is a ubiquitous and abundant cytosolic inositol phosphate that has
been reported to prime human neutrophils for enhanced agonist-stimulated superoxide anion generation.
This led to the proposal that the release of InsP6 from necrotic cells may augment the functional
responsiveness of neutrophils at an inflammatory focus. The aim of this study was to examine whether
the functional effects of InsP6 in neutrophils are receptor-mediated and establish the magnitude of this
priming effect relative to other better characterized priming agents.
2 Analysis of [3H]-InsP6 binding to human neutrophil membranes in 20 mM Tris, 20 mM NaCl,
100 mM KC1, 5 mM EDTA (pH 7.7) buffer using 0.1 mg ml-1 membrane protein and 2.5 nM [3H]-InsP6
(90 min, 4°C), demonstrated specific low affinity [3H]-InsP6 binding that was non-saturable up to a
radioligand concentration of 10 nM.
3 [3H]-InsP6 displacement by lnsP6 gave a Hill coefficient of 0.55 and best fitted a two-site logistic
model (53% KD 150 nM, 47% KD 5 /tm). [3H]-InsP6 binding also displayed low (3 fold) selectivity for
InsP6 over Ins(l,3,4,5,6)P5.
4 The specific [3H]-InsP6 binding displayed a pH optimum of 8, was abolished by pre-boiling the
membranes, and was enhanced by Ca2+, Mg2+ and Na + .
5 In incubations with intact neutrophils, where high levels of specific [3H]-LTB4 binding was observed,
no [3H]-InsP6 binding could be identified.
6 Preincubation of neutrophils with 100 /xM InsP6 had no effect on resting cell morphology, but caused
a minor and transient (maximal at 30 s) enhancement of (0.1 nM) fMLP-induced shape change (% cells
shape changed: fMLP 53 + 3%, fMLP+InsP6 66 + 4%). Similarly, InsPg (100 fiM, 30 s) had no effect on
basal superoxide anion generation and, compared to lipopolysaccharide (LPS, lOOngml-1, 60 min),
tumour necrosis factor-a (TNFa, 200 u ml-1, 30 min) or platelet-activating factor (PAF, 100 nM, 5 min)
caused only a small enhancement of 100 nM fMLP-stimulated superoxide anion generation (fold-increase
in superoxide anion generation over fMLP alone: InsP6 1.8+0.3, LPS 6.8 + 0.6, TNFa 5.2+ 0.7, PAF
5.8+0.6).
7 While these data support the presence of a specific, albeit low affinity, [3H]-InsP6 binding site in
human neutrophil membrane preparations, the lack of binding to intact cells implies that the functional
effects of InsP6 (ie. enhanced fMLP-stimulated superoxide anion generation and shape change) are not
receptor-mediated.
Keywords: Inflammation; neutrophil priming; inositol hexakisphosphate; superoxide anions; neutrophil shape-change
Introduction
Inositol hexakisphosphate (InsP6) is the most abundant in¬
ositol phosphate found in nature (Cosgrove, 1980), being
present in mammalian cells at concentrations between 10 /<M
and 1 mM (Szwergold et al., 1987). It is an intriguing molecule,
whose true physiological role has yet to be revealed. In-
tracellularly, InsP6 has been proposed to function as a general
antioxidant (Graf & Eaton, 1990), Ca2+ chelator (Luttrell,
1993), inhibitor of iron-catalysed hydroxyl radical formation
(Hawkins et al., 1993) and phosphate store (Berridge & Irvine,
1989). It is also a specific inhibitor of a number of the enzymes
involved in inositol polyphosphate metabolism, for example
the Ins(l,3,4,5)P4 3-phosphatase (Hughes & Shears, 1990;
Hoer & Oberdisse, 1991), and can itself be metabolized into a
series of more polar inositol polyphosphates termed pyr¬
ophosphates (Mennite et al., 1993; Stephens 1993). Investiga¬
tions into the effects of calcium-mobilizing agonists on cellular
InsP6 levels have demonstrated either no effect (Glennon &
Shears, 1993), or a rapid, transient increase that parallels
Ins(l,4,5)P3 accumulation (Sasakawa et al., 1993). In addition,
quite marked changes in the concentrations of both InsP5 and
1 Author for correspondence.
InsP6 can be seen with progression through the cell cycle or
changes in cell phenotype (e.g. during neutrophilic differ¬
entiation of HL-60 cells) (French et al., 1991; Guse et al.,
1993).
There is growing evidence that InsP6 may also have a
number of extracellular actions. Initial interest focused on its
ability to suppress the development of colonic cancer in animal
models, probably by chelating metal ions and thereby limiting
mitogenic iron-catalysed redox reactions (Graf & Eaton,
1993). It has also been shown to lower blood pressure and
heart rate in a reversible manner when infused into specific
regions of the rat brainstem (Vallejo et al., 1987). At a cellular
level, InsP6 has been shown to elicit Ca2 4 influx and catecho¬
lamine release in bovine adrenal chromaffin cells (Regunathan
et al., 1992) and to enhance Ca2 4 influx in cultured neuronal
cells (Nicoletti et al., 1989). However, the powerful Ca2+
chelation (Cosgrove, 1980) and autofluorescence properties of
InsP6 complicate the interpretation of such studies (Sun et al.,
1992).
It has recently been reported that InsP6 may also function as
a neutrophil priming agent and hence have a pro-inflammatory
role (Eggleton et al., 1991). Preincubation of neutrophils with
10-250 /xm InsP6 was shown to enhance subsequent agonist-
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induced superoxide anion generation and result in a rapid and
sustained assembly of F-actin (Crawford & Eggleton, 1992).
This led to the proposal that release of InsP6 from necrotic cells
at an inflammatory focus may upregulate, or prime, the
functional responsiveness of adjacent neutrophils to secreta-
gogue agonists. Since priming has been shown to be a pre¬
requisite for neutrophil-mediated tissue injury, this event could
play a vital role in modulating the extent of inflammation-
induced organ damage (Smedley et al., 1986).
In view of recent reports identifying the presence of specific,
high affinity [3H]-InsP6 receptors in the rat brain (Hawkins et
al., 1990), and their subsequent characterization as the a-sub-
units of the clathrin assembly protein AP-2 (Volgmaier et al.,
1992), we have examined whether the reported functional ef¬
fects of InsP6 in human neutrophils are mediated by similar
receptors. Our findings indicate that while specific [3H]-InsP6
binding sites are present on neutrophil membranes, they do not
display the characteristic high affinity and selective InsP6
binding properties reported in other cell types, and more im¬
portantly, are not present on intact cells: hence it is unlikely
that the functional effects of InsP6 are receptor-mediated. A
more complete re-evaluation of the functional effects of InsP6
demonstrates that this molecule has only very modest and
transient effects on human neutrophil function compared to
more established priming agents.
Methods
Neutrophil preparation
Blood was taken from healthy adult volunteers, anticoagulated
with 4 ml 3.8% sodium citrate 40 ml"1 blood, and centrifuged
(300 g) for 20 min. Neutrophils were isolated as detailed by
Haslett et al. (1985) using dextran sedimentation and dis¬
continuous plasma-Percoll gradients. The purified neutrophils
were washed sequentially in platelet-poor plasma, PBS with¬
out, and then PBS with Ca2+ and Mg2+. All procedures were
conducted at 25°C. Cell purity and viability (assessed by try¬
pan blue exclusion), were routinely >95% (<0.5% monocyte
contamination) and >99.5% respectively.
[3H]-InsP6 binding to neutrophil membranes
Membranes were prepared as detailed by Hawkins et al.
(1990). In brief, neutrophils were resuspended at 15 x 106 cells
ml"1 in 20 mM Tris (pH 7.7), 20 mM NaCl, 100 mM K.C1 and
5 mM EDTA (4°C), homogenized (Polytron), centrifuged
(35,000 g, 30 min), and the resulting membranes washed twice
before use. Membrane protein concentrations were determined
by the Pierce-BCA protein assay with BSA as standard.
[3H]-InsP6 binding was performed according to the method
of Hawkins et al. (1990). Freshly prepared membranes
(0.1 mg ml"1) were incubated at 4°C in 20 mM Tris (pH 7.7),
20 mM NaCl, 100 mM KC1 and 5 mM EDTA with 2.5 nM
(90,000 d.p.m.) [3H]-InsP6, in a final volume of 1 ml. Separation
of bound from free radioligand was achieved by centrifugation
(13,000 g, 6 min, 4°C), with non-specific binding (NSB) de¬
termined in the presence of 100 pM InsP6. Pellets were dissolved
overnight in Soluene and their radioactivity determined by li¬
quid scintillation counting. In preliminary experiments, [3H]-
InsP6 binding was found to be linear up to a protein con¬
centration of 0.2 mg ml"1 with equilibrium between free and
bound [3H]-InsP6 achieved by 90 min (data not shown).
To assess whether there was any metabolism of [3H]-InsP6
during these assays, pre- and post-incubation supernatants
were analysed by anion exchange h.p.l.c., using a Partisphere
5-SAX column (250 x 4.6 mm) fitted with a Whatman SAX
guard cartridge eluted (flow rate 1.25 ml min"1, 0.3 min
fractions) with the following gradient: A (H20), B (3.5 M
ammonium formate, pH adjusted to 3.7 with orthophosphoric
acid): 0-5 min 0% B; 10-12 min 21.4% B; 18-23 min 28.5%
B; 30 min 40.0% B; 40 min 42.0% B; 60-65 min 100% B.
In competition assays, displacing agents (InsP6, 0.1 nM-
0.1 mM; Ins(l,3,4,5,6)P5, lOnM-O.lmM and Ins(l,4,5)P3,
10 nM-0.1 mM) were added in 100 /fl (10 x final concentra¬
tions) aliquots. The pH-dependency of [3H]-InsP6 binding was
examined by resuspending the neutrophil membranes in
20 mM Tris, 20 mM NaCl, 100 mM KC1, 5 mM EDTA buffered
over an appropriate pH range with Trizma maleate-HCl (pH
5.5-7.0) or Trizma base-HCl (7.5-9.0). The effect of the ca¬
tions Mg2+ and Ca2+ on [3H]-InsP6 binding was investigated
using predetermined EDTA, EGTA and MgCl2 additions to
the above buffer, as detailed in the results section. The effect of
protein denaturation on [3H]-InsP6 binding was assessed by
heating the membranes to 100°C for 90 min prior to use.
To examine whether the [3H]-InsP6 binding observed was to
an intra- or extracellular site, assays were performed with in¬
tact, freshly prepared neutrophils (3 x 106 ml"1, equivalent to
0.1 mg ml"1 protein) incubated at 4°C in either PBS contain¬
ing 25 mM HEPES (pH 7.4) or 20 mM Tris (pH 7.5), 20 mM
NaCl, 100 mM KC1 and 5 mM EDTA. Cells were layered over
0.4 ml silicone oil, incubated for 90 min on ice and then cen¬
trifuged (15,000 g, 1 min). Aliquots (200 ^1) of the super¬
natants were removed and transferred to scintillation vials.
The remaining supernatant and oil layers were aspirated and
discarded, and the cell pellets dissolved in methanol and
radioactivity determined. Parallel incubations were performed
to assess [3H]-InsP6 binding to neutrophil membranes prepared
from the same batch of cells and [3H]-LTB4 binding to intact
cells, as detailed previously (O'Flaherty et al., 1986; 1991).
Neutrophil shape change assay
The effect of InsP6 on fMLP-induced shape-change was as¬
sessed by incubating 3 x 106 neutrophils in 500 ^1 PBS con¬
taining 1 mM MgCl2, 1 mM CaCl2 and 25 mM HEPES (pH
7.3) at 37°C, with a pre-determined optimal concentration of
InsP6 (100 /rM), for 0.5-30 min prior to addition of 0.1 nM
fMLP for 5 min. Preliminary concentration-response studies
had identified this as the fMLP concentration required to in¬
duce submaximal (approx. 50%) shape change (data not
shown). Incubations were terminated by the addition of 500 p\
2.5% gluteraldehyde and shape-change was quantified by
phase contrast light microscopy as the percentage of neu¬
trophils extruding more than one pseudopodium. Identical
incubations were performed with LPS (100 ng ml"1, 60 min),
TNFa (200 u ml"1, 30 min) and PAF (100 nM, 5 min).
Superoxide anion generation
Neutrophils were resuspended at 1 x 106 cells ml"1 in PBS
containing 1 mM CaCl2, 1 mM MgCl2 and 25 mM HEPES (pH
7.3) and preincubated at 37°C with buffer, InsP6 (100 pM,
30 s), LPS (100 ng ml"1, 60 min), TNFa (200 u ml"1, 30 min)
or PAF (100 nM, 5 min) in a final volume of 100 pi. These
pretreatment periods and agonist concentrations were estab¬
lished in preliminary experiments designed to ascertain optimal
priming conditions for each agent. The cells were then stimu¬
lated with fMLP (100 nM, 15 min) in the presence of 80 pM
cytochrome C, with superoxide dismutase (375 u) added to one
tube in each set of quadruplicate incubations. Reactions were
terminated by placing the cells on ice followed by centrifuga¬
tion (15,000 g, 5 min, 4°C). The superoxide-dismutase-in-
hibitable reduction of cytochrome C was determined in each
supernatant by measurement of the peak absorbance between
535-565 nm, with a Pye-Unicam scanning spectro¬
photometer, and expressed as nmol superoxide anion gener¬
ated per 106 cells.
Drugs and chemicals
Inositol hexakisphosphate (InsP6, di-potassium salt), N-for-
myl-methionyl-leucyl-phenylalanine (fMLP), superoxide dis¬
mutase, cytochrome C, platelet-activating factor (PAF),
lipopolysaccharide (LPS, E. coli 0111:B4), phosphate-buffered
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saline (PBS, with or without CaCl2 and MgCl2), dextran-500
and Percoll were all purchased from Sigma (Poole). Tumour
necrosis factor-a (TNFa) was obtained from Genzyme (Cam¬
bridge, MA, U.S.A.). Inositol pentakisphosphate
(Ins(l,3,4,5,6)P5) was purchased from Calbiochem (Notting¬
ham) and inositol 1,4,5-trisphosphate (Ins(l,4,5)P3) from RBI
(St Albans). [3H]-inositol hexakisphosphate (specific activity
15-24 Ci mmol"') was obtained from DuPont-New England
Nuclear (Stevenage, Herts.). Silicone oil F-50 was obtained
from Croylek Ltd. (Surrey). All other reagents and chemicals
were purchased from Life Technologies (Paisley), BDH
(Poole), Phoenix Pharmaceuticals Ltd. (Gloucester) or Pack¬
ard (Pangbourne, Berks.) and were of the highest grade
available.
Statistics
All values are expressed as means+ s.e.mean of («) separate
experiments. Values, where applicable, were compared by
ANOVA or Student's t test for paired data, with P<0.05
considered to be significant. Significant differences between
groups were determined by the Newman-Keuls procedure.
Results
[3H]-InsP6 binding sites in human neutrophil membranes
Under the assay conditions defined (2.5 nM [3H]-InsP6, 0.1 mg
membrane protein, 90 min incubations on ice), total and non¬
specific [3H]-InsP6 binding represented approximately 3,000
(approximately 200 fmol mg-' protein) and 300 d.p.m. re¬
spectively. Analysis of [3H]-InsP6 displacement by InsP6 (Figure
la) gave a Hill coefficient of 0.55 and a curvilinear bound versus
bound x inhibitor plot (Figure lb), indicating the presence of at
least two binding sites. The curve was best-fitted to a two-site
logistic model, where 53% of the InsP6 bound to a site with a KD
of 150 nM and the remainder to a 5 pM KD site. As predicted
from these values, [3H]-InsP6 binding failed to saturate fully up
to a radioligand concentration of 10 nM and kinetic experiments
demonstrated incomplete displacement of steady-state [3H]-
InsP6 binding following addition of 100 pM unlabelled InsP6
(60% displacement at 45 min, data not shown). Ins(l,3,4,5,6)P5
and Ins(l,4,5)P3 displaced [3H]-InsP6 binding with IC50 values of
430 nM and 30 ^M respectively (« = 8) (Figure la). In the ab¬
sence of membranes, total [3H]-InsP6 binding was equal to the
non-specific binding determined in the presence of membranes.
Incubations with pre-boiled membranes reduced specific [3H]-
InsP6 binding by > 90% (n = 8, data not shown).
The possibility that the multi-site, low affinity [3H]-InsP6
binding observed was due to metabolism of the radioligand
was investigated by h.p.l.c. analysis of the post-incubation
supernatants, by a method designed to detect inositol hexaki¬
sphosphate metabolites ([3H]-InsPN5) (Hawkins et al., 1990).
These experiments demonstrated a start radioligand purity of
> 99.9% and no detectable [3H]-InsP6 metabolism during the
90 min incubation period (data not shown).
Effect ofpH on [3H]-InsP6 binding in human neutrophil
membranes
Specific [3H]-InsP6 binding was markedly enhanced under al¬
kaline conditions, with maximum binding at pH 8.0
(750 fmol mg-1 protein) (Figure 2). Non-specific binding was
similar at all pH values studied (313 + 24 d.p.m.).
Modulation of [3H]-InsP6 binding in human neutrophil
membranes by mono- and divalent cations
In view of the suggestion that [3H]-InsP6 may associate with
membranes through non-protein interactions, in a manner
dependent upon trace metals (Poyner et al., 1993), we ex¬
amined the ability of various mono- and divalent cations to
a
b
% [3H]-lnsP6 bound x [inhibitor (|iM)l
Figure 1 (a) Displacement of [3H]-InsP6 binding to human
neutrophil membranes by InsP6, Ins(l,3,4,5,6)P5 and Ins (1,4,5)P3;
(b) bound versus bound x inhibitor plot for competition of [ H]-
InsP6 binding by InsP6. Assays were performed with 2.5 nM [3H]-
InsP^, 0.1 mg of human neutrophil membrane fraction and increasing
concentrations of InsP6, (•), Ins(l,3,4,5,6)Ps (□) and Ins(l,4,5)P3
(O) in 20mM Tris/HCl/20mM NaCl/lOOmM KCl/5mM EDTA
buffer, pH 7.7 (final volume 1 ml). Incubations were performed for
90min at 4°C, with separation of bound from free radioligand by
centrifugation. Non-specific binding was determined in the presence
of 100 jiM unlabelled InsP6. Values represent mean + s.e.mean for 8
experiments each performed in duplicate.
influence total [3H]-InsP6 binding to neutrophil membranes.
For each buffer condition, [3H]-InsP6 binding was compared to
that obtained in 20 mM Tris (pH 7.7), 20 mM NaCl, 100 mM
KC1 and 5 mM EDTA, with this value referred to as 100%
binding (Figure 3). Omission of 5 mM EDTA increased total
binding by 158 + 20%. Replacement of the EDTA with 5 mM
EGTA caused a 76 ±25% increase in binding, with the further
addition of 1 mM Mg2+ augmenting the binding by an addi¬
tional 89 + 3%. [3H]-InsP6 binding was also influenced by
manipulating the concentration of Na+ and K+ present, with
an increase in binding of 79+ 18% seen in the absence of KC1
and a decrease of 61 +6% seen with NaCl exclusion. Thus, the
presence of Ca2 + , Mg2+ and Na+ all appear to enhance,
whereas K+ inhibits, [3H]-InsP6 binding to human neutrophil
membranes. Non-specific binding, determined in the presence
of 100 pM InsP6, was similar under all conditions studied
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Figure 2 pH-dependence of specific [3H]-InsP6 binding to human
neutrophil membranes. [3H]-InsP6 binding to human neutrophil
membranes was determined using 2.5 nM [3H]-InsP6 and 0.1 mg
membrane protein (as detailed in the legend to Figure 1) in a range
of 25mM Tris (pH 7.5-9) and Tris-maleate (pH 5.5-7) buffers (see
Methods). Incubations were performed at 4°C for 90min and non¬
specific binding determined in the presence of 100/rM unlabelled
InsP6. Values represent mean + s.e.mean of maximal specific [3H]-




Figure 3 Effects of Mg2 + , Ca2 + , Na+ and K+ on [3H]-InsP6
binding to human neutrophil membranes. Assays were performed as
outlined in the legend to Figure 1 except that following isolation,
neutrophils were resuspended in a series of 20mM Tris/HCl buffers
(pFI 7.7) with varying amounts of EDTA/EGTA/KCl/NaCl/MgCF
as detailed below. The cells were then homogenized, pelleted and
resuspended in the same series of buffers at 0.1 mg protein ml"1 and
[3H]-InsP6 binding (hatched columns) determined using 2.5 nM [3H]-
InsP6 and an incubation period on ice of 90min. Non-specific
binding (solid columns) was determined in the presence of 100 /tm
unlabelled InsP6. The buffers used were: Column (1), 5mM EDTA,
lOOmM KC1, 20 mM NaCl; Column (2), 5mM EDTA, 20 mM NaCl;
Column (3), 5mM EDTA, 100mM KC1; Column (4), 5mM EDTA;
Column (5), 100 mM KC1, 20 mM NaCl; Column (6), 5mM EGTA,
lOOmM K.C1, 20mM NaCl; Column (7), 5mM EGTA, 100mM KC1,
20mM NaCl, 1 mM MgCl2. Values represent mean+ s.e.mean of 3
experiments each performed in duplicate. (Where not shown,
s.e.means were <2% of means and fall within symbols). 100%
binding represents 4,958 ± 197 d.p.m. Non-specific binding in buffer 7
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Figure 4 (a) Effect of InsP6 preincubation time on fMLP-induced
neutrophil shape change. Purified human neutrophils (3xl06ml_1)
were preincubated for various periods (0.5-30min) with either InsP6
(100/im, closed symbols) or 20 mM F1EPES PBS buffer (pH 7.3)
(open symbols) prior to 5 min treatment with fMLP (0.1 nM, circles)
or buffer (squares). Reactions were terminated, and shape change
assessed as detailed in the Methods section. Values represent
mean + s.e.mean of 3 experiments, each performed in duplicate.
*P<0.05, significantly different from fMLP alone (ANOVA). (b)
Effect of InsP6 on fMLP concentration-response curve for neutrophil
shape change. Neutrophils were preincubated for 30 s with either
InsP6 (100/jm, closed symbols) or buffer (open symbols), prior to a
5min treatment with fMLP. Values represent mean + s.e.mean of
triplicate determinations from a single experiment, with similar
results obtained in a further 4 experiments.
(7.3 + 0.8% of total binding) except that in the presence of
5 mM EGTA plus 1 mM MgCl2 there was a dramatic increase
in membrane pellet associated [3H]-InsP6 (52,014+
4,362 d.p.m. ie. approximately 70% of the total [3H]-InsP6
added), suggesting precipitation of an InsP6-Mg2+ complex
similar to that observed with Fe3+ concentrations > 10 /rM
(Poyner et al., 1993).
[3H]-InsP6 binding to intact human neutrophils
A number of methods were used to assess whether the [3H]-
InsP6 binding observed in neutrophil membranes represented
binding to an intra- or extracellular recognition site. Incuba¬
tion of freshly prepared neutrophils at 4°C for 90 min with




Figure 5 Effect of TNFa, PAF and LPS on neutrophil shape
change. Human neutrophils (3 x 106mU') were incubated with TNFa
(200uml-1, 30min), PAF (100 nM, 5 min), LPS (lOOngml-1,
60min), fMLP (100 nM, 15min), or 25 mM HEPES PBS buffer (pH
7.3) (control). Reactions were terminated, and shape change assessed
as detailed in the Methods section. Values represent mean + s.e.mean
of 3 experiments, each performed in duplicate. Where not shown,
s.e.means are <2% of means and fall within symbols. *P<0.05
significantly different from control (ANOVA).
Table 1 Effects of TNFa and PAF on unstimulated and
fMLP-induced superoxide anion generation in human
neutrophils











Human neutrophils were suspended in PBS containing
25 mM HEPES as detailed in the Methods section, and
preincubated with TNFa (200 u ml-1, 30 min) or PAF
(100 nM, 5 min) prior to a 15 min treatment with fMLP
(100 nM). Superoxide anion release was assessed spectro-
photometrically by a cytochrome C reduction assay and
expressed as nmol superoxide anion generated/106 cells.
Values represent mean ± s.e.mean of 3 separate experiments,
each performed in triplicate.
Control
lnsP6 (0.1 mM)







Figure 6 Comparison of the effects of InsP6 and LPS on fMLP-
induced superoxide anion generation in human neutrophils. Human
neutrophils were suspended in PBS containing 25 mM HEPES as
detailed in the Methods section and preincubated with 100^M InsP6
for 30 s or lOOngml-1 LPS for 60min prior to a 15min challenge
with fMLP (100 nM). Superoxide anion release was measured with a
spectrophotometric cytochrome C reduction assay and expressed as
nmol superoxide anion generated/106 cells. Values represent mean +
s.e.mean from 10 experiments each carried out in triplicate.
"P< 0.005, significantly different from fMLP alone.
2.5 nM [3H]-InsP6 in either the above intracellular-like binding
buffer or in 25 mM HEPES-buffered PBS containing 1 mM
CaCl2 and MgCl2 (pH 7.5) produced a marked reduction in
specific [3H]-InsP6 binding (76 + 0.8% and 74+1.2% respec¬
tively) compared to that observed in membranes. However,
since assessment of cell viability demonstrated that approxi¬
mately 10% of the pelleted neutrophils were trypan blue po¬
sitive, an alternative separation method was followed using
centrifugation through an inert oil cushion. Using this proto¬
col, <0.03% of the [3H]-InsP6 added was associated with the
cell pellet irrespective of the incubation buffer used. Under
identical conditions, and in the same experiment, >16% spe¬
cific [3H]-LTB4 binding was observed (n = 2, data not shown).
Effect of InsP6 on fMLP-stimulated shape change and
superoxide anion generation
In view of the above data indicating the absence of true ex¬
tracellular InsP6 receptors in neutrophils, we sought to re¬
evaluate the functional effects of InsP6 in these cells using re¬
spiratory burst activity and shape change as activation indices.
The effect of InsP6 on basal and fMLP-induced shape change
was used as a sensitive indicator of potential chemotactic (Qu
et al., 1995) and priming (Haslett et al., 1985) activity and also
to determine the optimal InsP6 preincubation period required
for subsequent superoxide anion-priming experiments. Figure
4a illustrates the effects of incubating unprimed neutrophils
with 100 pM InsP6 for 0.5-30 min on basal and submaximal
(0.1 nM) fMLP-induced neutrophil shape-change. InsP6
(100 pM), unlike other established priming agents (Figure 5),
had no effect on basal shape change (Figure 4a), but did cause
a small and transient enhancement (26+1.2% at 30 s) of
fMLP-induced shape change (Figure 4a). TNFa, PAF and
LPS did not enhance fMLP (100 nM)-induced shape change
(data not shown). This pattern of effects (ie. transient en¬
hancement of fMLP-induced shape change, but no effect of
InsP6 alone) correlates well with the time course effects of InsP6
on fMLP-induced superoxide anion release reported by Eg-
gleton & colleagues (1991) but is not observed with LPS,
TNFa or PAF and hence appears to be unique to this priming
agent (Young et al., 1990). InsP6 (100 pM, 30 s) also caused a
small leftwards shift in the concentration-response curve for
fMLP-induced shape change (fMLP alone, EC50 76 pM;
fMLP + InsP6, EC50 33 pM, P<0.01).
The ability of InsP6 to prime human neutrophils for en¬
hanced fMLP-stimulated superoxide anion release was com¬
pared to the effects of lipopolysaccharide (100 ng ml-1,
60 min), a well established neutrophil priming agent. InsP6
alone (100 pM, 30 s) had no effect on basal superoxide anion
release and caused only a very minor (1.8+0.3 fold, P<0.005,
n = 4) enhancement of fMLP-stimulated superoxide anion
generation compared with LPS (6.8 + 0.6 fold, P< 0.005, n = 4)
(Figure 6). This degree of priming of the fMLP-stimulated
superoxide anion response by InsP6 is very similar to that re¬
ported by Eggleton et al. (1991). In a separate series of ex¬
periments TNFa (200 u ml-1, 30 min) and PAF (100 nM,
5 min) also enhanced fMLP-induced superoxide anion gen¬
eration to a considerably greater extent than observed formerly
with InsP6 (Table 1).
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Discussion
Neutrophils play a key role in defending the body against in¬
fection. However, the enormous histotoxic capacity of these
cells dictates that uncontrolled or inappropriate activation can
cause significant host tissue damage. One of the most im¬
portant control steps involved in regulating respiratory burst
activity is the requirement for the neutrophil to be primed
before it will respond to a secretagogue challenge. While a wide
variety of cell- and bacterial-derived products (eg. granulocyte-
macrophage colony stimulating factor, PAF, TNFa and LPS)
and physicochemical insults (eg. hypotonic challenge) can
prime neutrophils, the specific intracellular mechanisms re¬
sponsible for this process are yet to be fully defined.
Recently, InsP6, a ubiquitous and abundant cytosolic in¬
ositol polyphosphate (Bunce et al., 1993; Stuart et al., 1994),
was identified as a novel neutrophil priming agent, being able
to facilitate fMLP-induced superoxide anion release without
affecting basal superoxide anion generation (Eggleton et al.,
1991). In this study, preincubation of human neutrophils with
InsP6 (up to 250 nM) had no effect on basal superoxide anion
generation but caused a 2 fold enhancement of the response to
fMLP (2 nm). This led to the proposal that InsP6, released
from dying or effete cells at an inflammatory focus, may serve
to augment local neutrophil respiratory burst activity. Our
experiments sought to identify whether this effect of InsP6 is
receptor-mediated and re-evaluate its priming potential re¬
lative to other more established agents. Our data indicate that
while specific, low affinity [3H]-InsP6 binding can be detected in
neutrophil membranes, intact cells do not bind [3H]-InsP6, and
that the absolute priming effect of InsP6 is extremely weak and
short-lived in comparison to other priming agents such as LPS
and granulocyte macrophage colony stimulating factor, where
the priming effect lasts for several hours (Balazovich et al.,
1991).
Analysis of [3H]-InsP6 binding to neutrophil membranes
demonstrated the presence of at least two low affinity binding
sites (Kd values of 0.15 and 5 pM), and displayed only a 3 fold
selectivity for InsP6 over Ins(l,3,4,5,6)Ps. These data contrast
to the readily saturable, high affinity [3H]-InsP6 binding pre¬
viously reported in, for example, rat cerebellum (Hawkins et
al., 1990), bovine adrenal chromaffin cells (Regunathan et al.,
1992) and canine cardiac microsomes (Kijima & Fleischer,
1992), and suggest that InsP6 binding in human neutrophils
may not reflect an interaction with any of the currently iden¬
tified membrane-associated InsP6 binding sites: these include
the G-protein receptor regulatory protein arrestin (Reg¬
unathan et al., 1992; Palczewski et al., 1991), the IGF-II re¬
ceptor (Kar et al., 1994), the Golgi KT channel coatomer
(Fleischer et al., 1994) and the a-subunit of the clathrin as¬
sembly protein AP-2, recently identified as the InsP6 receptor
in rat cerebellum (Volgmaier et al., 1992). This latter molecule
is a 300-350 kDa protein involved in the formation of cla-
thrin-coated vesicles at the plasma membrane, and is com¬
prised ofmultiple subunits, including two doublets of 115 kDa
and 105 kDa, which bind InsP6 with a KD of 12 nM (Theibert
et al., 1992), and two non-binding singlets of 50 and 17 kDa.
The pH-dependency of [3H]-InsP6 binding in neutrophil
membranes also differs from that obtained in rat cerebellum
(Theibert et al., 1992) and rat cerebral cortex (Nicoletti et al.,
1990), where maximal binding occurred at pH 7 and 6, re¬
spectively. In addition, a pH optimum of 8, with marked in¬
hibition of [3H]-InsP6 binding observed at more alkaline
values, makes a simple charge-based membrane interaction
unlikely. The ability of Mg2+ to potentiate [3H]-InsP6 binding
in neutrophil membranes is qualitatively very similar to find¬
ings reported in rat cerebellum, where multivalent cations
(Mg2+ and trace amounts of contaminating Fe3+ and Al3 + )
augmented specific [3H]-InsP6 binding, possibly by acting as
bridges between InsP6 and negatively charged membrane
phospholipid phosphates (Poyner et al., 1993).
A variety of potential non-receptor mechanisms may un-
derly the ability of InsP6 to function as a weak priming agent.
For example, it has recently been shown that negatively
charged agents per se potentiate superoxide anion generation
(Miyahara et al., 1993) and also that InsP6 can inhibit CD62-L
(L-selectin)-mediated adherence of neutrophils to activated
endothelial cells (Cecconi et al., 1994). It is uncertain however
how relevant this latter observation is to the priming effect of
InsP6 since cross-linking of CD62-L has recently been reported
to induce rather than inhibit, neutrophil priming (Waddell et
al., 1994). It is also clearly possible that the powerful Ca2 +
chelation properties or other, as yet unidentified, effects of
InsP6 may perturb neutrophil homeostasis. It should be noted
however, that the studies of Eggleton and co-workers (1991)
indicated that a similar priming effect is not observed with the
lower inositol polyphosphates including Ins(l,3,4,5,6)P5.
In summary, this study provides evidence for specific, low
affinity, membrane associated [3H]-InsP6 binding in human
neutrophils that is pH-dependent, heat-labile, augmented by
Mg2+, Ca2+ and Na+ and located intracellularly. InsP6, re¬
leased from damaged or necrotic cells at an inflammatory fo¬
cus, may interact with the neutrophil surface in a non-receptor-
mediated fashion, to cause priming of NADPH oxidase func¬
tion and polarization responses, but these effects are modest in
comparison to other established priming agents.
This work was funded by The Wellcome Trust. E.R.C. is a
Wellcome Senior Research Fellow in Clinical Science and E.K.
holds a Wellcome Prize Studentship.
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Demonstration of Reversible Priming of Human Neutrophils Using
Platelet-Activating Factor
By Elizabeth Kitchen, Adriano G. Rossi, Alison M. Condliffe, Christopher Haslett, and Edwin R. Chilvers
Exposure of neutrophils to agents such as lipopolysaccha-
ride, tumor necrosis factor-a (TNF-a), and the granulocyte-
macrophage colony-stimulating factor causes a major
upregulation of subsequent agonist-induced NADPH oxi¬
dase activation. This priming effect is a prerequisite for
neutrophil-mediated tissue damage and has been widely
considered to be an irreversible process. We have investi¬
gated the potential for neutrophils to recover from a prim¬
ing stimulus by studying the effects of platelet-activating
factor (PAF). PAF did not stimulate respiratory burst activ¬
ity directly, but caused a rapid (maximal at 10 minutes)
and concentration-dependent (EC 50 50.2 nmol/L) increase
in N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimu-
lated superoxide anion release. At time-points >10 min¬
utes, this priming effect spontaneously declined, with re¬
turn to basal levels of fMLP-stimuiated superoxide anion
generation by 120 minutes. An identical priming time-
course was observed with N-methyl carbamyl PAF, a non-
metabolizable analogue of PAF, indicating that the tran¬
sient nature of PAF-induced priming was not secondary
to PAF metabolism. Two structurally diverse PAF receptor
antagonists (UK-74,505 and WEB 2086), added 10 minutes
after PAF addition, increased the rate of decay of the prim¬
ing effect. In contrast, TNF-a-induced priming, which was
of a similar magnitude to that observed for PAF, was
slower to evolve (maximal at 30 minutes) and remained
constant for at least 120 minutes. The reversible nature
of PAF-induced priming was confirmed by demonstrating
that PAF-, but not TI\IF-a-, induced cell polarization (shape
change) and CD1 lb-dependent neutrophil binding of albu¬
min-coated latex beads was also transient, with return to
basal, unstimulated levels by 120 minutes. Furthermore,
cells that had spontaneously deprimed following PAF ex¬
posure retained their capacity to be fully reprimed by a
subsequent addition of either PAF or TNF-a. These data
imply that neutrophil priming is not an irreversible event:
the demonstration of a cycle of complete priming, deprim-
ing, and repriming offers the potential for functional recy¬
cling of neutrophils at sites of inflammation.
© 1996 by The American Society of Hematology.
NEUTROPHILS PLAY a fundamental role in the acuteinflammatory response, destroying invading microbial
pathogens and thereby minimizing infection of the host. The
response of neutrophils to various proinflammatory stimuli
is largely determined by their previous exposure to agents
such as cytokines (eg, tumor necrosis factor-a [TNF-a], and
interleukin-8, [IL-8]), lipid mediators (eg, platelet-activating
factor [PAF] and leukotriene B4 [LTB4]) or bacterial prod¬
ucts (eg, N-formyl-methionyl-leucyl-phenylalanine [fMLP],
and lipopolysaccharide [LPS]). At physiologically relevant
concentrations these agonists elicit cell polarization, recruit¬
ment, and activation of cell-surface /32-integrins (eg, CD1 lb/
CD 18), and enhance, or "prime," neutrophil responses (eg,
phagocytosis, respiratory burst activation, degranulation) to
other secretagogue agonists.1"4 In vivo data suggest that prim¬
ing also plays a critical role in the recruitment of neutrophils
to an inflammed site.5 However, although this switching of
neutrophils from a relatively unresponsive to a hyperrespon-
sive state is a prerequisite for physiological neutrophil-medi¬
ated bacterial destruction, it may, if uncontrolled, lead to
neutrophil-mediated tissue damage.6
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Previous studies have demonstrated that human peripheral
blood neutrophils, incubated with the priming agents granu¬
locyte colony-stimulating factor G-CSF or LPS, maintain an
enhanced superoxide anion secretory response to 1MLP for
at least 24 hours.7 Studies undertaken in vivo have demon¬
strated that sheep peripheral blood and bone marrov'-derived
neutrophils also remain primed for at least 24 hout s follow¬
ing endotoxin LPS infusion, suggesting that maintenance
of the primed state is an important part of the long-term
inflammatory response to endotoxin.8 These observations
have been widely interpreted as indicating that neutrophil
priming is an essentially irreversible phenomenon.8
Despite its obvious importance to the regulation of in¬
flammation, little attention has been given to the potential
for neutrophils, once primed, to revert to their former quies¬
cent state, ie, to be "deprimed." However, in two studies
where neutrophil priming has been induced using physico-
chemical stimuli ie, hypotonic treatment,9 or exposure to the
highly-charged Ca2+-chelator, inositol hexakisphosphate,10
priming of the superoxide anion response appeared to be
transient. The lack of study in this area may, at least in part,
reflect the difficulties encountered in isolating and main¬
taining these cells in an unprimed state ex-vivo, or ensuring
complete removal or antagonism of the initial priming signal.
In addition, isolated neutrophils have a relatively short life¬
span due to their high rate of constitutive programmed cell
death or apoptosis."'12 For these reasons, most in vitro stud¬
ies have focused on the short-term effects of priming agents
and the cellular mechanisms responsible for such events.
In view of the potential pathophysiological, and hence
therapeutic, importance of being able to rescue neutrophils
from the primed state, we have investigated the possible
reversibility of neutrophil priming induced by physiological,
receptor-mediated priming agents. Using human peripheral
blood neutrophils incubated at a concentration of PAF that
causes a rapid enhancement of fMLP-stimulated respiratory
burst activity without any direct effect on superoxide anion
release, we observed a spontaneous and complete decay of
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the PAF-primed superoxide anion response and PAF-
induced CD lib/CD 18 activation and to a lesser extent,
PAF-induced shape change. The rate of neutrophil recovery
following PAF addition could be enhanced by the use of
selective PAF receptor antagonists (WEB 2086 and UK-
74,505). Furthermore, the deprimed cells retained their full
capacity to be reprinted by an alternative priming agent
(TNF-a) or a further addition of PAF. The ability of neutro¬
phils to participate in a complete priming/depriming/reprim-
ing cycle allows far greater flexibility in the control of neu¬
trophil behavior at an inflammatory site than was hitherto
realized.
MATERIALS AND METHODS
Neutrophil preparation. Peripheral venous blood was taken
from healthy adult volunteers, anticoagulated with 4 mL 3.8% so¬
dium citrate/40 mL blood, and centrifuged (30()g) for 20 minutes.
Neutrophils were isolated exactly as previously detailed2 using dex-
tran sedimentation and discontinuous plasma-PercoIl gradients. This
isolation technique yields neutrophils that display very low levels
of basal shape change (<8% assessed flow-cytometrically) or direct
fMLP-induced superoxide anion generation. The purified neutrophils
were washed sequentially in platelet-poor plasma, phosphate-buf¬
fered saline (PBS) without, and PBS with, CaCb and MgCl2. Cell
purity and viability (trypan blue exclusion) were routinely >95%
(<0.5% monocyte contamination) and >99.5%, respectively.
Shape change assay. Neutrophils (106 in 90 pL PBS containing
CaCL and MgCl2) were equilibrated in a gently shaking water-bath
for 5 minutes at 37°C. Priming agents were added in a 10-^iL volume
to achieve the required drug concentrations (PAF 1 nmol/L to 10
/umoI/L, TNF-a 200 U/mL) and incubations continued for the peri¬
ods stated. Preliminary experiments demonstrated this concentration
of TNF-a to be optimal in causing maximal enhancement of fMLP-
induced superoxide anion generation with minimal direct respiratory
burst activation (data not shown). To determine the 1C50 values of
the PAF receptor antagonists used, neutrophils were incubated with
WEB 2086 or UK-74,505 (both at 10 nmol/L to 10 pmo\IL) for 30
minutes before the addition of priming agents. For investigations
examining the reversibility of PAF-induced priming, neutrophils
were treated with PAF (1 /nmol/L) for 10 minutes before addition
of 1 ^mol/L WEB 2086 or UK-74,505. l'MLP (100 nmol/L) or buffer
(PBS) was added to samples (final volume 1 mL) 10 minutes before
the addition of an equal volume of 2.5% glutaraldehyde. Samples
were analyzed for shape change by flow cytometry (Coulter EPICS
Profile II; Coulter Electronics, Luton, UK) using a slight modifica¬
tion of a previously published method.13 Percentage shape change
was calculated from the mean forward light scatter of each sample by
gating on the non-shape changed neutrophil population. The values
obtained using this method correlate closely with those derived by
direct visual assessment of shape change, with the exception that
the flow cytometric method of assessment slightly overestimates the
extent of basal shape change.13
Superoxide anion release assay. Neutrophils were isolated,
equilibrated at 37°C, and incubated with PAF or PBS exactly as
detailed above, except that cytochrome C (800 pL, 1 mg/mL) was
added immediately before the addition of fMLP. One of each set of
quadruplicate determinations included superoxide dismutase (375 U)
to allow confirmation of the specificity of cytochrome C reduction.
Reactions were stopped by placing the cells on ice, followed by
centrifugation (12,500g, 2 minutes, 4°C). The superoxide dismutase-
inhibitable reduction of cytochrome C was determined in each super¬
natant by measuring the peak absorbance between 535 and 565 nm
using a Pye-Unicam scanning spectrophotometer, and expressed as
nanomoles superoxide anions generated per 10'' neutrophils. In ex¬
periments designed to assess the ability of PAF-recovered neutro¬
phils to be reprimed with either TNF-a or a further addtion of PAF,
cells were treated with PAF (1 pmol/L) or PBS for 120 minutes,
before a final incubation with PAF (1 jumol/L, 10 minutes) or TNF-
a (200 U/mL, 30 minutes) and assessment of fMLP-stimulated su¬
peroxide anion release.
To examine the effects of hypotonic challenge on neutrophil func¬
tion, cells (106 in 250 pL PBS) were equilibrated at 37°C as outlined
above and incubated for 19 minutes in PBS containing 80 pmo\IL
cytochrome C, with 150 mmol/L NaCl (isotonic incubations) or 50
mmol/L NaCl (hypotonic incubations). Neutrophils were then treated
for 1 minute with 20 pL of either 5 mol/L NaCl (to reverse hypoto-
nicity to isotonicity) or PBS (to retain hypotonicity or isotonicity).
The effects of the hypotonic challenge itself on basal and fMLP-
stimulated superoxide anion generation, together with the ability of
these cells to deprime following restoration of isotonicity and there¬
after be reprimed with PAF, was then assessed as detailed above.
Neurophil adhesion to albumin-coated latex beads (ACLB).
Fluorescent latex beads (2.5% packed vol/vol stock solution as pur¬
chased) were washed (three times) in PBS, resuspended at 2.5%
(vol/vol) in PBS containing 10 mg/mL human serum albumin, and
incubated for 10 minutes at 25°C. The resultant ACLB were again
washed (three times) in PBS and finally resuspended at 0.75% (vol/
vol). Neutrophils (175 pL aliquots at 107/mL, in PBS with CaCl2
and MgCl2) were incubated in a shaking water-bath at 37°C for 5
minutes, and then treated with PAF (I /rmol/L), TNF-a (200 U/mL)
or PBS (all added in a 15-^L volume) for 0 to 120 minutes. ACLB
(25 pL of 0.75% vol/vol solution) were added to each tube 15
minutes before the termination of each reaction, except for time
points <15 minutes where the beads were added before the agonist.
Neutrophils were then fixed by the addition of 0.5 mL of 0.5%
glutaraldehyde. After 30 minutes at room temperature, nonadherent
ACLB were removed by washing with PBS (three times) and bead-
binding to the neutrophil assessed using an EPICS Profile II (Coulter
Electronics), as previously detailed.14
Statistics. All values are expressed as means ± standard error
of mean (SEM) of (n) number of separate experiments. Values,
where applicable, were compared by ANOVA or the Student's t-
test for paired data, with P < .05 considered to be significant.
Significant differences between groups were determined by the New-
man-Keuls procedure.
Materials. fMLP, PAF, superoxide dismutase (SOD), cyto¬
chrome C, PBS (with or without CaCl2 and MgCl2), dextran-500,
Percoll, human serum albumin and glutaraldehyde (25%) were pur¬
chased from Sigma (Poole, UK). TNF-a was obtained from Gen-
zyme (Cambridge, MA). One micron fluorescent microspheres were
purchased as a 2.5% solids-latex (2.5% vol/vol) stock solution from
Polysciences Inc through the UK supplier Park Scientific (Notting¬
ham, UK). WEB 2086 and UK-74,505 were gifts from Boehringer
Ingelheim Ltd (Berks, UK) and Dr J. Parry (Pfizer, Sandwich, UK),
respectively. I -O-alkyl-2-V-methylcarbamyl-glycerophosphocholine
(N-methyl carbamyl PAF) was obtained from Calbiochem (Notting¬
ham, UK).
RESULTS
PAF is an established and important inflammatory media¬
tor in vivo.13 It was selected for this study because its priming
effect in neutrophils is rapid, receptor-mediated,16 associated
with minimal direct activation of superoxide anion re¬
lease,1718 and inhibitable by specific, high-affinity PAF re¬
ceptor antagonists. Under our own experimental conditions,
PAF (1 nmol/L to 10 /u.mol/L) did not affect spontaneous
superoxide anion release (Fig 1 A), but caused a rapid (maxi¬
mal at 10 minutes), concentration-dependent increase in
fMLP-stimulated superoxide anion release (EC;0 50.2 nmol/
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Fig 1. Effect of PAF on basal and fMLP-stimulated superoxide anion
generation and shape change in human neutrophils. (A) Concentration-
response data for superoxide anion generation. Isolated human neutro¬
phils (106 in 90 fxL PBS) were equilibrated for 5 minutes at 37°C and
incubated with 10 fA. of PAF (10 nmol/L to 10 /Ltmol/L final concentra¬
tion) for 10 minutes. Cells were then stimulated with 100 nmol/L fMLP
(hatched bars) or buffer (closed bars) for 10 minutes in the presence of
cytochrome C (1 mg/mL), in a final volume of 1 mL. Reactions were
terminated by placing samples on ice and superoxide anion release was
assessed by scanning spectrophotometry. Values represent mean of
triplicate determinations from a single experiment, representative of
six. (B) Concentration-response data for shape change. Neutrophils
were incubated as outlined above for superoxide anion generation,
except that buffer replaced the cytochrome C and reactions were termi¬
nated by the addition of 1 mL 2.5% glutaraldehyde. Samples were ana¬
lyzed by flow cytometry and percent shape change calculated from the
mean forward light scatter values, by gating on the non-shape changed
population. Values represent mean ± SEM for six independent experi¬
ments each performed in duplicate.
L, Fig 1A), and a similar concentration-dependent increase
in shape change (EC50 HO nmol/L. Fig IB). In the shape
change experiments, 10 /umol/L PAF appeared to have less
effect than l /imol/L PAF. but this correlated with the light-
microscopic observation of large, round, "glassy"-looking
cells, suggestive of cell swelling. In view of these findings,
a PAF concentration of l pmol/L was chosen for all further
priming studies.
PAF-induced priming of superoxide anion generation in
neutrophils is reversible. Figure 2 illustrates how the
length of the initial PAF incubation period affects the subse¬
quent enhancement of superoxide anion release in response
to fMLP. The ability of PAF to prime the fMLP-response
was maximal after a 10-minute PAF preincubation, with the
priming effect decaying thereafter, to approach unprimed
levels by 2 hours (Fig 2). Notably, the pattern of reversal of
the PAF priming effect was consistently biphasic, with an
initial rapid loss in priming occurring within 15 to 30 minutes
of PAF addition, followed by a second, slower phase of
decay. This progressive decline in the magnitude of the
primed fMLP-superoxide anion response was not due to cell
necrosis, as viability (assessed by trypan blue exclusion) was











Fig 2. Time-course for PAF-priming of fMLP-stimulated superox¬
ide anion release in human neutrophils. Isolated human neutrophils
(106 in 80 fxL PBS) were equilibrated for 5 minutes at 37°C and incu¬
bated with 10 fxL PAF (1 /xmol/L) (closed symbols) or buffer (open
symbols) for 10 minutes. A 10-/*L aliquot of WEB 2086 (1 /xmol/L,
triangles), UK-74,505 (1 /umol/L, diamonds), or buffer (circles) was
added 10 minutes after PAF. Cells were incubated for a further 0 to
120 minutes before a final 10-minute stimulation with 100 nmol/L
fMLP (circles, triangles, diamonds) or buffer (squares) in the presence
of cytochrome C (1 mg/mL). Reactions were terminated at the appro¬
priate times by placing the cells on ice and superoxide anion release
assessed by scanning spectrophotometry. Data points represent
mean values for triplicate determinations from three separate experi¬
ments. SEM values were all <10 % of mean and are omitted for
reasons of clarity.
REVERSIBLE PRIMING OF HUMAN NEUTROPHILS USING PAF 4333
In an attempt to elucidate some of the possible factors
responsible for this time-dependent reversal of PAF-medi-
ated neutrophil priming, additional experiments were under¬
taken to assess the role of PAF metabolism and PAF receptor
desensitization. Firstly, PAF was substituted by a nonmetab-
olizable analogue, N-methyl carbamyl PAF. This resulted in
a near identical time course (data not shown) to that illus¬
trated in Fig 2, indicating that PAF degradation was not
responsible for the loss in the priming effect. Secondly, we
examined the ability of two specific, but structurally differ¬
ent, PAF receptor antagonists, WEB 2086 and UK-74,505,
to influence the rate of depriming. Preliminary studies estab¬
lished optimal conditions for the use of these antagonists: a
30-minute preincubation with UK-74,505 caused a concen¬
tration-dependent (IC50 68 nmol/L) and complete (at I prnol/
L) inhibition of the PAF-primed superoxide anion response,
whereas inhibition by WEB 2086 was biphasic and incom¬
plete (55% ± 4% inhibition with 10 /^mol/L WEB 2086,
data not shown). Neither of these compounds, at the concen¬
trations used, affected neutrophil viability nor superoxide
anion release in control or fMLP-treated cells (data not
shown). Thus, to investigate the influence of PAF receptor
blockade on the rate of decay of PAF-induced priming, both
antagonists were used at a concentration of 1 pmol/L. When
WEB 2086 (1 pmol/L) or UK-74,505 (1 ^tmol/L) was added
10 minutes after PAF, a small but significantly faster (P <
.05) rate of decay of the PAF-primed superoxide anion re¬
sponse was observed (Fig 2), with UK-74,505 having the
greater effect. This data suggests that although PAF receptor
desensitization or uncoupling may play a role in the decay
of the priming effect, this process is not complete following
a 10-minute incubation with 1 pmoML PAF.
In marked contrast to the priming time course observed
with PAF, TNF-a-induced priming, although slower to
evolve (maximal at 30 minutes), remained constant for at
least 2 hours (nanomoles superoxide anion released: at 30
minutes: fMLP (100 nmol/L) 4.6 ± 1.6, TNF-a (200 U/mL)
+ fMLP 20.1 ± 3.2; at 2 hours: fMLP 5.0 ± 0.7, TNF-a +
fMLP 19.2 ± 4.9, n = 3).
Transient effects of PAF on neutrophil shape change and
ACLB binding. To validate our observations of neutrophil
recovery following PAF-mediated priming of the respiratory
burst, we undertook further time course studies to examine the
effects of PAF on neutrophil shape change and CD1 lb activa¬
tion. Shape change was chosen because previous studies have
demonstrated a tight correlation between priming of the super¬
oxide anion response and the extent or proportion of neutrophils
that have undergone cell polarization.2 In addition, the relatively
weak priming effect of IL-8 on superoxide anion generation
has been reported to partially reverse with time without any
concomitant recovery of CD1 lb expression.19
Incubation of neutrophils with 1 /jmol/L PAF caused a rapid
(maximal at 2 minutes) increase in shape change, which then
declined spontaneously towards basal levels by 30 minutes (Fig
3). The subsequent small increase in percent shape change,
observed between 30 to 120 minutes, paralleled the changes
seen in control cells. The extent of the initial shape change
response to PAF was similar to that observed following a 10-
minute incubation with 100 nmol/L fMLP (80.8% ± 7.1%, n
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Fig 3. Time-course for PAF- and TNF-a-induced shape change in hu¬
man neutrophils, (a) Representative flow-cytometry (EPICS Profile II) his¬
tograms of control cells (A) and cells incubated with PAF for 2 minutes
(B) or 30 minutes (C) (x-axis shows mean forward light scatter (FS) and
y-axis shows relative cell number). Percent shape change was calculated
from the FS of each sample by gating out the population of non-shape
changed neutrophils determined from control samples, (b) Time-course
data for PAF- and TNF-a-induced shape change. Isolated human neutro¬
phils (106 in 90 /uL PBS) were equilibrated for 5 minutes at 37°C and
incubated with 10 pL PAF (1 /rmol/L) (closed circles), TNF-a (200 U/mL)
(closed squares), or buffer (open squares) for 0 to 120 minutes. Reactions
were terminated at the appropriate times by addition of an equal volume
of 2.5% glutaraldehyde. Samples were analyzed by flow cytometry and
percent shape change calculated as detailed above. Values represent
mean ± SEM for four independent sets of duplicate determinations.
Where not shown, SEM values fall within the symbols.
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Fig 4. Time-course for PAF- and TNF-o-induced binding of ACLB. (a) Representative flow-cytometry histograms of control cells (A) and
cells incubated with PAF for 10 minutes (B) or 120 minutes (C) (x-axis shows logarithmic scale green fluorescence (LFL) and y-axis shows
relative cell number). The lowest fluorescent (far left) peak represents neutrophils with no attached ACLB then, with increasing binding, single,
double, and triple bead peaks (correlated by fluorescence microscopy) can be distinguished. The percent neutrophils with attached ACLB was
calculated by gating out the far left peak determined from time-matched control samples, (b) Time-course data for PAF- and TNF-a-induced
binding of ACLB. Isolated human neutrophils (1.75 x 106 in 175 fj.L PBS) were equilibrated for 5 minutes at 37°C and incubated with 15 /*L
PAF (1 /amol/L) (closed circles), TNF-tr (200 U/mL) (closed squares), or buffer (open squares) for 0 to 120 minutes. ACLB (25 /uL) were added
15 minutes before termination of the reaction with 0.5 mL 0.5% glutaraldehyde, except for time points <15 minutes where the beads were
added before the agonist. Samples were analyzed by flow cytometry and the percent neutrophils with attached ACLB was calculated, as
detailed above. Values represent mean ± SEM for four independent sets of determinations, each performed in duplicate. Where not shown,
SEM values fall within the symbols.
of shape change, although a convenient and highly reproducible
assay, gives consistently higher levels of basal shape change
(approximately 8%n) than those obtained by direct visual as¬
sessment of cell morphology. Our data confirm, however, that
PAF-induced shape change, like priming of the superoxide
anion response, is a transient event. Neutrophil shape change
to TNF-a (200 U/mL) was of a similar magnitude (70.1% ±
1.8%, n = 4) to that induced by PAF, but was slower to evolve
(plateau at 30 minutes) and remained constant for the 2-hour
incubation period (Fig 3).
As a third index of priming, we followed the /?2-integrin-
dependent binding of ACLB over a 2-hour incubation with
either PAF or TNF-a. Again, PAF (1 /xmol/L) induced a
time-dependent increase in ACLB binding, maximal after
10 minutes, which declined to reach control levels by 2 hours
(Fig 4). TNF-a (200 U/mL) also augmented ACLB binding
but, unlike PAF, the extent of bead binding reached a plateau
at 30 minutes and remained constant for the ensuing 90-
minute incubation period (Fig 4).
Reprinting of neutrophils with PAF or TNF-a. We next
investigated whether neutrophils that had primed and then
spontaneously deprimed during a 120-minute incubation
with PAF were capable of being reprimed. Figure 5 demon¬
strates that PAF-recovered neutrophils retain their full capac¬
ity to be reprimed when challenged again with either PAF
(1 pmol/L, 10 minutes) or TNF-a (200 U/mL, 30 minutes),
generating similar amounts of superoxide anions upon fMLP
stimulation as freshly-primed cells. This finding was re¬
peated when neutrophils were primed and deprimed using a
modification of a previously described hypotonic challenge
protocol.9 Under isotonic conditions, fMLP (100 nmol/L)
and PAF (1 /zmol/L) alone elicited little superoxide anion
release, with PAF enhancing the fMLP-stimulated superox¬
ide anion response by 3.8-fold (Table 1). A 20-minute hypo¬
tonic challenge resulted in a modest (twofold) priming of
the fMLP response, which recovered towards control levels
when isotonicity was restored for 1 minute. Subsequent treat¬
ment with PAF reprimed the fMLP response, albeit to a
slightly lower level than that observed in cells maintained
under isotonic conditions. Cell viability was routinely >95%
for all conditions studied. Thus, like cells that had deprimed
following PAF exposure, osmotically primed and deprimed
neutrophils also retained their capacity to be primed for a
second time by a physiological agonist such as PAF.
DISCUSSION
The neutrophil can exist in a number of different func¬
tional states and this has a significant bearing on its behavior
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Fig 5. Repriming of human neutrophils with PAF and TNF-cr following initial priming with PAF. (A) Superoxide anion priming with PAF and
TNF-a in freshly isolated cells. Neutrophils (10s in 90 /xL PBS) were equilibrated for 5 minutes at 37°C, and then incubated with 10 /aL of buffer,
PAF (1 /umol/L, 10 minutes) or TNF-n (200 U/mL, 30 minutes), as these represent optimal priming conditions for later comparisons with
reprimed neutrophils (see [B]). Cells were subsequently stimulated with 100 nmol/LfMLP or buffer for 10 minutes, in the presence of cytochrome
C (1 mg/mLI, in a final volume of 1 mL. Superoxide anion release was finally assessed spectrophotometrically. (B) Superoxide anion repriming
of neutrophils with PAF and TNF-cr following a 120-minute incubation with PAF. Neutrophils (106 in 80 /xL PBS) were incubated with 1 /*mol/
L PAF (closed symbols) or buffer (open symbols) for 120 minutes, followed by a second optimal priming challenge with PAF (1 pmol/L, 10
minutes, circles), TNF-or (200 U/mL, 30 minutes, diamonds), or buffer (30 minutes, squares). All samples were then stimulated with fMLP (100
nmol/L, 10 minutes) in the presence of cytochrome C (1 mg/mL), in a final volume of 1 mL, and analyzed for superoxide anion release, as
above. Values represent mean ± SEM for triplicate determinations from three independent experiments.
and responsiveness in vitro. Thus, in the unprimed state,
the neutrophil displays little or no secretory response when
incubated with an agent such as fMLP, whereas such a chal¬
lenge in a fully primed cell results in an explosive increase
in respiratory burst activity; this priming-activation axis has
been shown to be a major determinant of neutrophil behavior
Table 1. Effect of Transient Hypotonic Challenge on Basal,
fMLP-Stimulated and PAF-Primed Superoxide Anion
Generation in Human Neutrophils
Isotonic Hypotonic Hypo-lsotonic
Control 2.8 ± 0.5 6.0 -1- *o 4.1 ± 0.6
PAF (1 ;/mol/L) 3.6 1+ o 4^ 7.1 ± 0.1* 5.7 l+ o CO
fMLP (100 nmol/L) 4.9 ± 0.6 10.1 -+- 0.1* 6.0 ± 0.7
PAF + fMLP 18.9 ± 1.4 18.4 0.5 11.5 ± 1.0*
Isolated peripheral blood neutrophils (106 in 250 p.L PBS) were equil¬
ibrated for 5 minutes at 37°C and incubated for 19 minutes in PBS
containing 150 mmol/L NaCI (isotonic incubations) or 50 mmol/L NaCI
(hypotonic incubations). Neutrophils were then treated for 1 minute
with 20 f/L of either 5 mol/L NaCI (to reverse hypotonicity to isotonic-
ity) or PBS (to retain hypotonicity or isotonicity). Superoxide anion
release was assessed spectrophotometrically following incubation
with buffer alone for 20 minutes (Control), buffer for 10 minutes fol¬
lowed by PAF for 10 minutes (PAF, 1 p,mol/L), buffer for 10 minutes
followed by fMLP for 10 minutes (fMLP, 100 nmol/L), or PAF for 10
minutes followed by fMLP for 10 minutes (PAF + fMLP). Values repre¬
sent mean ± SEM for three separate experiments each performed in
triplicate.
* P < .05 compared with values obtained under isotonic conditions.
in vivo.2" However, the very protracted priming effect of
agents such as LPS, G-CSF, and GM-CSF, together with the
short life-span of the neutrophil, has led to the belief that
priming is a largely irreversible process.7,8 Indeed, the sus¬
tained nature of the priming effect has been postulated to
play a fundamental role in the long-term inflammatory re¬
sponse observed with certain agents, including endotoxin.8
In this report, we provide evidence that neutrophil priming
is not an irreversible process and, moreover, that these cells,
once deprimed, can go through a further complete cycle of
priming and activation.
The depriming of neutrophils observed following PAF
treatment was apparent for fMLP-stimulated superoxide
anion generation, CD1 lb function, and cell polarization, and
hence was unlikely to represent selective downregulation of
one particular component of the priming response, as re¬
ported with IL-8.19 The ability of neutrophils to be reprimed
by TNF-cr and PAF after a 2-hour incubation, with mainte¬
nance of full viability throughout, excludes the possibility
that the loss of the PAF priming effect was merely a conse¬
quence of the extended incubation procedure affecting cell
integrity or metabolic status. While the basis for the decline
in PAF-mediated priming is uncertain, the identical nature
of the time-course of priming of superoxide anion release
with N-methyl carbamyl PAF, a biologically active PAF
analog that is completely resistant to metabolic inactivation
by neutrophils or human serum,21,22 makes PAF metabolism
unlikely. We have also shown that inclusion of adenosine
deaminase in these incubations does not influence the time-
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course of PAF-primed superoxide anion responses, which
excludes a secondary effect mediated via adenosine release
and autocrine activation of cyclic adenosine monophosphate
(AMP)-dependent protein kinase pathways (Kitchen, Rossi
and Chilvers, unpublished observations, February 1995). Al¬
though homologous receptor desensitization may underlie
the transient nature of the PAF signal, the increased rate of
decay of fMLP-induced superoxide anion release following
UK-74,505 or WEB 2086 addition and the return of a fully
competent PAF priming response after 2 hours suggests that
PAF receptor uncoupling/desensitization is both incomplete
and transient. These data are consistent with previous studies
demonstrating rapid activation-induced uncoupling and in¬
ternalization of PAF receptors followed by subsequent recep¬
tor re-expression.23 The recovery of PAF receptor number
and function is likely to reflect extensive membrane attach¬
ment and metabolism of PAF (approximately 1 pmol/107
neutrophils/min).24'25
From our own comparisons of PAF and TNF-rr and other
published observations, it would appear that neutrophil prim¬
ing in vitro falls into three categories: (1) fully reversible
(eg, that induced by PAF, osmotic swelling, or inositol hexa-
kisphosphate); (2) partially reversible (eg, with IL-17 or IL-
8); or (3) largely irreversible (eg, with GM-CSF19, G-CSF,
or LPS). Further studies would be required to categorize
TNF-a because its effects did not show any signs of recovery
over the 2-hour incubation period used in this study, but have
been reported to decay over 24 hours.7 It is also intriguing to
note that only agents in group (3) are able to modulate the
rate of neutrophil apoptosis, which again testifies to the long
duration of action of this class of agents.26 While it is clear
that neither the efficacy nor extent of the initial priming
signal dictates the reversibility of the primed state (because
PAF. TNF-a [Fig 5], LPS. and GM-CSF [data not shown]
induce equivalent levels of priming), it is possible that the
duration of the priming signal and/or its rate of onset are
key determinants. However, in the absence of any clear
mechanistic basis for neutrophil priming, it is also possible
that the above agents use discrete signalling pathways to
induce their priming effects.
This current observation of reversible priming may allow
the pro-inflammatory, and potentially tissue-damaging, ef¬
fects of neutrophil priming/activation to be counteracted by
a process other than apoptosis or the pharmacological inhibi¬
tion of neutrophil activation. It is unlikely that neutrophils
within an inflammatory focus would be exposed in isolation
to PAF or other "transient" priming agents. However, as
endothelial cell-associated PAF has been shown to play a
central role in neutrophil priming and migration through IL-
1 ^-treated human umbilical vein endothelial cell mono¬
layers in vitro,27 and endogenously formed PAF is involved
in leukocyte extravasation induced by IL-1 in vivo,28 any
delay in cell exit through an activated endothelial surface
may permit cell recovery and the return of unprimed neutro¬
phils to the circulation. Thus, the recognition that neutrophils
have the potential to deprime allows an additional point of
control in the early stages of the acute inflammatory re¬
sponse, whereby cells may return to their former quiescent
state and potentially re-enter the circulating neutrophil pool.
These deprimed neutrophils, once fully recovered, could
again attain their maximal priming potential and mount sub¬
sequent responses, as dictated by ensuing inflammatory chal¬
lenges. In contrast, priming agents with a longer duration of
action would maintain neutrophils in the primed state for a
much longer period of time and may, therefore, play a dis¬
tinct role in vivo, in the wake of a more widespread or
prolonged inflammatory insult.
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